Stiffening the posterior rat sclera to provide neuroprotection in glaucoma by Hannon, Bailey Grace
STIFFENING THE POSTERIOR RAT SCLERA TO PROVIDE 




























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in Bioengineering in the 












COPYRIGHT © 2020 BY BAILEY GRACE HANNON 
 
 STIFFENING THE POSTERIOR RAT SCLERA TO PROVIDE 

























Dr. C. Ross Ethier, Co-Advisor 
Wallace H. Coulter Department of 
Biomedical Engineering 
Georgia Institute of Technology and Emory 
University 
 Dr. J. Brandon Dixon 
George W. Woodruff School of 
Mechanical Engineering 




Dr. Machelle T. Pardue, Co-Advisor 
Wallace H. Coulter Department of 
Biomedical Engineering 
Georgia Institute of Technology and Emory 
University 
 Dr. Brian C. Samuels 
Department of Ophthalmology and 
Visual Sciences 




Dr. Mark R. Prausnitz 
School of Chemical and Biomolecular 
Engineering 
Georgia Institute of Technology 
  
 
   














Without the support, guidance, and mentorship of many individuals, this 
dissertation would not have been possible. I would like to recognize the invaluable 
assistance that you all have provided during my study. 
First, I would like to acknowledge and thank my two thesis advisors, Dr. Ross 
Ethier and Dr. Machelle Pardue. I have grown a lot over these past five years, both as a 
scientist and as a person, much of which is due to my advisors’ outstanding mentorship 
and guidance throughout my Georgia Tech journey. Dr. Ethier has dramatically sharpened 
my maturity as a researcher, not only by guiding me to improved presentation and writing 
skills, but more importantly by pushing me to think critically and in far broader terms. Dr. 
Pardue is both an ocular biology and laboratory technique genius and, at key times, a 
doctoral candidate life coach. I’m thankful for learning essential skills from her while being 
the beneficiary of her upbeat enthusiasm and motivating conversations. Together, my co-
advisors’ wisdom and assistance has been vital to the completion of this project. I cannot 
begin to express how thankful I am for their unwavering and holistic support throughout 
this process, without which this dissertation would not have been possible. 
I am grateful for my other thesis committee members: Dr. Mark Prausnitz, Dr. 
Brian Samuels, and Dr. Brandon Dixon. Dr. Prausnitz’ expertise in chemistry and ocular 
drug delivery provided essential guidance in the development and analysis of the in vivo 
glaucoma study. Dr. Samuels provided important suggestions for improvements in the 
microbead model from a clinical perspective, which was uniquely useful. Dr. Dixon was a 
 v 
pleasure to TA for in Biosolid Mechanics, and his expertise on the subject has been key to 
the analysis of my inflation experiments. 
I would like to thank Dr. Andrew Feola and Dr. Ian Campbell who are both past 
post-doctoral fellows in the Ethier Lab and Career Development Awardees in the Pardue 
Lab. Dr. Feola provided support, knowledge, and mentorship throughout our struggles with 
the microbead model and motivated me to persevere through these difficulties. Dr. 
Campbell provided much of the groundwork necessary to make this thesis possible, 
especially in developing the software and hardware necessary for the supposed ‘turn-key’ 
DIC experimental set-up. 
I would like to give a special thanks to Dr. Brandon Gerberich who has worked 
closely with me throughout my PhD journey. From taking Biology of the Eye together my 
first year at Georgia Tech to our often-absurd glaucoma study schedule, Dr. Gerberich has 
dispensed vast knowledge of statistical analysis and chemistry that were key to this 
dissertation. 
I am blessed to have had the opportunity to work with two undergraduate Petit 
Scholars: Matthew Ritch and R. Kijoon Kim. Matthew’s sharp mind created the machine-
learning axon counting software that was crucial to the completion of Chapters 5-7. As 
much as I love manually counting axons, this automated a very tedious process. Kijoon 
provided essential support in the development of molecular assays and the microbead 
model, while sharing an appreciation with me for both nighttime IOP measurements and 
Northern Ireland.  
 vi 
Additionally, I would like to thank the other past and present Ethier and Pardue Lab 
members who have been generous with their encouragement and experimental ideas 
throughout my time at Georgia Tech. Specifically, I would like to acknowledge Dr. 
Thomas Read, who was instrumental in my early DIC inflation tests, sectioned countless 
optic nerves, and taught me an appreciation for the beauty in histology. Additionally, I 
would like to acknowledge Dr. Stephen Schwaner for helping me navigate through the PhD 
process, providing professional development advice, and for taking the time to create the 
MATLAB GUI used for analysis of our inflation tests.  
I would also like to acknowledge Laura Paige, for her unmatched knack for coming 
up with a solution to every problem (no matter how obscure) and having the compassion 
to drop everything to solve it. Laura has done a wonderful job as an administrator and made 
my time as a BioE student unforgettable.  
Finally, I cannot begin to express my heartfelt gratitude to my family, friends, and 
puppies who supplied endless love and support during my PhD journey. My family, in 
particular, has supported me immensely by providing the enthusiasm, advice, and 
perspective necessary to keep me motivated and emotionally well during this trying quest. 







TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iv 
LIST OF TABLES xii 
LIST OF FIGURES xiii 
LIST OF SYMBOLS AND ABBREVIATIONS xxv 
Summary xxvi 
CHAPTER 1. Introduction 1 
 Glaucoma 1 
 Pathophysiology of Glaucoma 1 
 Regulation of Intraocular Pressure 1 
 Biomechanics in Glaucoma 3 
 Posterior Ocular Anatomy 3 
 Biomechanical Damage in Glaucoma 5 
 Scleral Biomechanics in Glaucoma 6 
 Collagen Crosslinking 7 
 Ocular Use of Collagen Crosslinking Agents 8 
 Rat Model of Glaucoma 10 
 Similarities Between Human and Rat Pathophysiology 10 
 Success of the OHT Model 11 
 Assessing Glaucomatous Damage 16 
 Morphological Outcome Measures 17 
 Functional Assessment of Glaucomatous Damage 19 
CHAPTER 2. Specific Aims 23 
 Aim 1: Evaluate the efficacy of potentially biocompatible non-photoactivated 
collagen crosslinking agents on posterior rat sclera ex vivo. 23 
 Aim 2: Optimize the in vivo delivery technique of a chosen stiffening agent 
selected in Aim 1, and characterize the resulting duration of increased scleral 
stiffness, and potential adverse effects in vivo. 23 
 Aim 3: Determine efficacy of stiffening the posterior sclera as a possible 
neuroprotective therapy in glaucoma. 24 
CHAPTER 3. Quantification of Efficacy of collagen cross-linking agents to 
induce stiffening of rat sclera 26 
 Submission Details 26 
 Abstract 26 
 Introduction 27 
 Methods 29 
 viii 
 Animals 29 
 Tissue Preparation 30 
 Inflation Testing 33 
 Strain Calculation 37 
 Data Analysis 38 
 Results 40 
 DIC System Characterization: 40 
 Average Strain Magnitudes: 41 
 Relative Stiffening: 43 
 Discussion 44 
 Conclusion 50 
CHAPTER 4. Sustained scleral stiffening in rats after a single genipin treatment
    51 
 Submission Details 51 
 Abstract 51 
 Introduction 52 
 Methods 55 
 Overview of Experimental Design 55 
 Animals 56 
 Scleral Stiffening Procedure 56 
 Whole Globe Inflation Testing 58 
 Data Analysis 64 
 Results 67 
 Discussion 69 
 Conclusion 74 
CHAPTER 5. Assessment of visual and retinal function following in vivo 
genipin-induced scleral crosslinking 75 
 Submission Details: 75 
 Abstract 75 
 Introduction 76 
 Methods 78 
 Animals 78 
 Experimental Groups and Crosslinking Procedure 79 
 Tonometry and Eye Exams 81 
 Optomotor Response 81 
 Electroretinogram 82 
 RGC Axon Counting 83 
 RT-PCR 84 
 Proteomics 86 
 Statistical Analysis 88 
 Results 89 
 Discussion 94 
 Conclusion 98 
 ix 
CHAPTER 6. Using retinal function to define ischemic exclusion criteria for 
animal models of glaucoma 99 
 Targeted Submission Details: 99 
 Introduction 99 
 Methods 102 
 Animals 102 
 Microbead Injection Preparation and Procedure 102 
 Tonometry 103 
 Electroretinogram 104 
 RGC Axon Counting 105 
 IOP- and ERG-Based Exclusion Criteria 106 
 Statistical Analysis 107 
 Results 108 
 Discussion 111 
 Conclusion 114 
CHAPTER 7. Genipin-induced scleral stiffening in a rat model of glaucoma 115 
 Introduction 115 
 Methods 117 
 Rationale for Using the Rat Model of Glaucoma 117 
 Decision to Implement an Unpaired Treatment Paradigm 118 
 Animals and Study Design 120 
 Intraocular Pressure Measurements 122 
 Crosslinking Injection Preparation 123 
 HBSS and Genipin Crosslinking Injection Procedures 123 
 Methylene Blue Photocrosslinking Procedure 124 
 Microbead Injection Preparation and Procedure 125 
 Assessment of Retinal Function: Electroretinography 127 
 Ischemic Damage Exclusion Criteria 128 
 Assessment of Visual Function: Optomotor Response 128 
 Assessment of Retinal Morphology: Optical Coherence Tomography  
   129 
 Optic Nerve Sectioning and Axon Counting 130 
 Whole Globe Inflation Testing 131 
 Data Analysis 133 
 Results 135 
 Microbead Injection Successfully Increased IOP 135 
 Mechanical Testing Confirmed That Crosslinking Effectively Increased 
Scleral Stiffness 137 
 Retinal Thickness Measurements Suggested Protective Effects of 
Scleral Stiffening 138 
 Axon Counts are Not Preserved by Scleral Stiffening 141 
 Eye Size Increased with IOP Burden 141 
 Visual Function is Not Preserved by Scleral Stiffening 142 
 RGC Function is Not Preserved by Scleral Stiffening 144 
 Outcome Parameter Correlation Trends Differ by Treatment 144 
 Discussion 145 
 x 
 Toxicity of Crosslinking Treatments May Have Contributed to RGC 
Loss  146 
 Limitations of the Microbead Model Complicate Interpretation of 
Results 147 
 Scleral Stiffening May Protect Against Morphological, but Not 
Functional RGC Damage 148 
 We Were Able to Successfully Stiffen the Posterior Sclera with Both 
Targeted and Non-Targeted Treatments 149 
 Key Differences Exist Between This Study and a Similar Previous 
Study  150 
 Conclusion 151 
CHAPTER 8. Conclusions and Future Directions 152 
 Specific Aim 1: Evaluate the efficacy of potentially biocompatible non-
photoactivated collagen crosslinking agents on posterior rat sclera ex vivo. 152 
 Conclusions 152 
 Limitations 153 
 Future Work 153 
 Specific Aim 2: Optimize the in vivo delivery technique of a chosen stiffening 
agent selected in Aim 1, and characterize the resulting duration of increased 
scleral stiffness, and potential adverse effects in vivo. 155 
 Conclusions 155 
 Limitations 155 
 Future Work 157 
 Specific Aim 3: Determine efficacy of stiffening the posterior sclera as a possible 
neuroprotective therapy in glaucoma. 159 
 Conclusions 159 
 Limitations 162 
 Future Directions 163 
 Final Thoughts 165 
CHAPTER 9. Publications and Conference Presentations Arising from the 
PhD:  167 
APPENDIX A. AxoNet: A deep learning-based tool to count retinal ganglion 
cell axons  170 
 Submission Details 170 
 Abstract 170 
 Introduction 171 
 Methods 175 
Rat Optic Nerve Dataset 175 
NHP Optic Nerve Dataset 181 
AxoNet Development 181 
Model Evaluation 186 
 Results 190 
Rat Model Dataset Results 190 
NHP Dataset Results 193 
 xi 
 Discussion 199 
 Conclusion 204 
 Data Availability 204 
APPENDIX B. Supplemental Information for Chapter 3 205 
APPENDIX C. Supplemental Information for Chapter 5 208 
APPENDIX D. Supplemental Information for Chapter 6 210 
APPENDIX E. Supplemental Information for Chapter 7 211 
REFERENCES 219 
 xii 
Table 1 Concentrations of all stiffening agents tested.  31 
Table 2 Relative stiffening expressed as a percentage. Values are 
mean ± standard deviation. 
44 
Table 3 Comparison of in vivo genipin studies.  57 
Table 4 Number of rats in each group for each outcome measure. 
Columns indicate cohorts of rats within each group. 
Asterisks indicate rats that were used in multiple outcome 
measures. 
80 
Table 5 Relative variance and strengths/weaknesses of various 
treatment designs and statistical comparisons considered for 
our scleral stiffening study design. 
119 
Table 6 Adjusted means and simple comparisons for each parameter 
measured from rat microbead study. Two-way ANCOVAs 
were used to analyze each parameter with IOP burden as the 
covariate. Highly significant (p < 0.0001) p-values are 
bolded.  
140 
Table 7 RT-PCR genes analyzed and corresponding primers.  208 
Table 8 Proteomic expression levels in the sclera, computed as the 
fold change of scleral protein amount in genipin-treated eyes 
compared to contralateral HBSS-treated eyes (n = 3). All q-
values > 0.05. 
208 
Table 9 Tabulated average IOP burden of rats included in each 
outcome parameter group with number of eyes in each 
group. 
211 
Table 10 Table of experimental variables investigated in this study 
compared with those of the Kimball et al. 2014 study which 
investigated effects of scleral crosslinking on 
visual/morphological outcomes in glaucomatous mice. 
213 
Table 11 Two-way ANCOVA outcomes for measured parameters 
including main effects of crosslinking treatment (HBSS, GP, 
MB) and microbead treatment (normotensive, hypertensive) 
accounting for IOP burden as a covariate. Highly significant 




Figure 1 Ocular cross section with anatomical features labelled. Yellow arrows 
denote flow patterns of aqueous humor. Adapted from Martini 2010 
(Martini 2010). 
2 
Figure 2 A) Overview of eye anatomy. Arrows denote IOP. B) OCT image 
showing a cross-section of the optic nerve head region and demonstrating 
the characteristic cupping in glaucoma. The lamina cribrosa and other 
structures are identified. C) 3D representation of a monkey lamina 
cribrosa showing its beautifully intricate structure. RGC axons pass 
through these pores to form the optic nerve (Girard et al. 2013). 
4 
Figure 3 Finite element model of the ONH and peripapillary sclera depicting the 
first principal strains when considering a stiff, normal, and compliant 
sclera. First principal strains in the ONH are lowest with a stiff sclera 
(Eilaghi et al. 2010).  
7 
Figure 4 Classic rat models of OHT. A) Morrison Model: Arrowhead shows 
blanching effect of saline in the episcleral venous plexus and arrow 
indicates a portion of the episcleral venous plexus that has not yet 
blanched (Gossman, Linn, and Linn 2016). B) Episcleral Vein 
Cauterization: Arrow shows tip of the cautery applied on the limbal 
plexus, where the superior portion has already been cauterized (Lani et 
al. 2019). C) Laser Photocoagulation: Schematic of anterior chamber 
which shows laser illumination (Chen et al. 2015). 
13 
Figure 5 Recently Developed Models of OHT: A) Microbead model, showing a 
schematic of the anterior chamber with aqueous humor flow path depicted 
by green arrows with yellow microbeads in the iridocorneal angle (Yang 
et al. 2012). B) Circumlimbal suture model, showing a suture tied firmly 
posterior to the limbus of the rat eye (Liu et al. 2015). 
15 
Figure 6 Optic nerve cross sections with healthy (A) and severely damaged (B) 
RGC axons. Healthy axons have a homogeneous interior surrounded by 
a uniform myelin sheath. Damaged axons have heterogeneous interiors 
and are typically hyper-myelinated. Scalebar is 10µm. 
17 
Figure 7 Paraffin-embedded retinal section (left) and corresponding in vivo OCT 
(right) from rat. Arrows indicate a major blood vessel. Scale bar, 50 μm. 
Adapted from (Nagata et al. 2009). 
19 
Figure 8 Representative ERG waveforms from human (Viswanathan et al. 2001) 
and rat (B) eyes. A) Human ERG intensity series from age-matched 
normotensive eye and glaucomatous eye. B) Rat ERG from normotensive 
control and ocular hypertensive eye 7 days after microbead injection 
(Huang et al. 2018). A, b, and PhNR labels denote the a-wave, b-wave, 
20 
 xiv 
and photopic negative response (PhNR) of each waveform, respectively. 
The decline in the PhNR amplitude is qualitatively more apparent in the 
human case when compared to the rat case. 
 
Figure 9 
Eyes were partially immersed in cross-linking agents, exposing 
approximately half the eye to a stiffening agent overnight by mounting it 
in a trimmed pipette tip (A). Genipin, which is also used as a blue dye, 
provides a visual indicator of its location (B). This is closely localized to 
the treated region and demonstrates little evidence of wicking. Regions 
appearing blueish near the top of panel (B) are actually thin regions of 
translucent sclera where choroid is visible, not regions exposed to 
genipin. Eyes were then incubated overnight while misting the tissue-
draped control half with PBS to keep it moist (C). Dashed line indicates 
limbus. 
31 
Figure 10 Side view of acrylic mounting block. Eyes are placed in the hemisphere 
at top, and a threaded luer fitting mates with the hole in the bottom. 
35 
Figure 11 Digital image correlation was used to spatially resolve the surface strains 
in individual eyes. At left, the speckle pattern on the posterior sclera is 
overlaid with manually-traced masks (made prior to calculating strain) 
denoting the locations treated with cross-linking agent or PBS as a 
control, taking care not to include the optic nerve. At right, we have 
overlaid these same masks on the computed surface strains at an inflation 
pressure of 13 mmHg (normotensive). Regions of comparatively low and 
high strain match closely with the treatment and control zones. 
38 
Figure 12 Representative plot of average 1st principal strain as a function of time 
from a single eye during our inflation experiment. Eyes were maintained 
for 30 minutes at each of 3 pressures representing different ranges of IOP. 
Strains were considerably higher in the control region of eye than in the 
treated region, indicating that the treated region is stiffer. Black overlays 
represent the 95% confidence interval about the mean during the final 10 
minutes of each pressure step, when the eye reached steady state. Error 
bars: standard deviation over the interrogated region. 
42 
Figure 13 Average 1st principal strains for control (horizontal axis) and stiffened 
(vertical axis) regions of eyes treated with (A) genipin, (B) 
glyceraldehyde, or (C) methylglyoxal. Each dot represents the mean 
steady-state strain for one eye, and the surrounding oval represents the 
95% confidence interval of that point from linear fitting. Points falling 
below the unity line (black line) indicate that the treated eye has been 
stiffened relative to the control, and mutatis mutandis. The dotted line 
represents 100% stiffening. Eyes in red lie very close to the unity line, 
suggesting that this low dose has minimal stiffening effect. Higher 
concentrations lie farther from the unity line until reaching a maximum 
effective dose around 7 mM for genipin, 62.5 mM for glyceraldehyde, 
43 
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and 14 mM for methylglyoxal. Higher concentrations do not further 
stiffen the experimental half the eye but do reduce strain in the control 
portion of the eye, possibly as result of diffusion into the internal tissues 
of the eye and crosslinking them. 
Figure 14 Experimental groups: HBSS/Naïve rats received a single (unilateral) 
retrobulbar injection of HBSS, while Genipin/HBSS rats received a 
unilateral retrobulbar injection of genipin and a unilateral retrobulbar 
injection of HBSS contralaterally. 
57 
Figure 15 Whole globe autofluorescence of HBSS (A) and genipin (B) injected 
paired eyes from Genipin/HBSS rat at four weeks post-injection. The 
arrow and corresponding outline indicate the approximate optic nerve 
(ON) location on each eye, while the outer dashed outline indicates the 
approximate size of the eye. Asterisks: vessel locations on posterior 
sclera. Photos taken using Y5 filter cube ((590-650 nm)/(660-740 nm)) 
excitation/emission). The fluorescence induced by genipin-induced 
crosslinks was evident and suggested a relatively even distribution of 
genipin over much of the posterior sclera. Exposure level and gain 
settings were identical in both images. 
58 
Figure 16 Inflation testing schematic. A) Mounting chamber, including rat eye 
mounted cornea-side down. B) Testing apparatus with hydrostatic 
pressure reservoir, flow sensor, pressure transducer, mounting block, and 
DIC cameras. The flow sensor bypass was used to eliminate the lag in 
pressure experienced by the eye (e.g. during preconditioning cycles), as 
described more fully in the text. 
59 
Figure 17 Overview of the reservoir pressure during inflation testing protocol. The 
preconditioning protocol consisted of an acclimatization step where the 
pressure reservoir was set to 15 mmHg, followed by 10 preconditioning 
cycles from 3 to 15 mmHg. The creep testing protocol included three 
pressure steps: 3 to 10 mmHg, 10 to 20 mmHg, and 20 to 30 mmHg. The 
timing of pressure steps varied, with typical step timing shown here. Note 
that this figure represents the set reservoir pressure and not the eye 
pressure as measured by the pressure transducer. It is important to note 
that the actual measured eye pressure was used in data fitting. 
63 
Figure 18 Representative pressure-strain plot for cyclic loading from 3 to 15 mmHg 
during preconditioning. The difference in maximum first principal 
Lagrange strain value between two consecutive cycles reached an 
equilibrium (< 2% change) by 10 cycles. 
63 
Figure 19 Representative flow sensor and strain measurements during a creep test. 
Flow sensor output is shown by the black line (left y-axis), where peaks 
correspond to pressure steps. Mean first principal strain averaged over the 
posterior sclera is shown by the red line (right y-axis). Strain values are 
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referenced to the end of the first pressure step of 3 mmHg. Time shown 
is relative to the start of the creep test. 
Figure 20 Genipin treated eyes yielded visibly stiffer pressure-strain curves. Fit of 
isotropic Fung-type constitutive model to pressure-strain data from each 
eye (all R2 > 0.93). Naïve eyes are shown in dashed black lines, HBSS 
eyes are shown in various shades of purple, and genipin eyes are shown 
in various shades of blue. Dotted red line denotes 22 mmHg, at which the 
difference in strain and percent strain reduction were computed. Letters 
above curves indicate paired eyes from each rat (A-M). For overlapping 
curves, the letter corresponding to the leftmost curve is on top. 
68 
Figure 21 Genipin treatment resulted in greater relative difference in strain. Relative 
difference in strain at 22 mmHg for HBSS/Naïve rats (n = 4) one day 
post-injection and for Genipin/HBSS rats one day (n = 4) and four weeks 
(n = 5) post-injection. The plotted quantity is the difference in average 
first principal scleral strain relative to the contralateral control eye for 
each rat, all evaluated at 22 mmHg, and provides an alternative way of 
presenting the data shown in Figure 8. Relative difference in strain was 
significantly greater at four weeks after injection. Bars show mean ± SD. 




Genipin treatment resulted in reduced scleral strain. Difference in strain 
at an IOP of 22 mmHg for HBSS/Naïve rats (n = 4) one day post-injection 
and for Genipin/HBSS rats one day (n = 4) and four weeks (n = 5) post-
injection. The plotted quantity is the average first principal scleral strain 
in the contralateral control eye minus the strain in the experimental eye 
for each rat, all evaluated at 22 mmHg. There was a greater difference in 
strain in Genipin/HBSS rats compared to HBSS/Naïve rats at one day and 
four weeks. Bars show mean ± SD (* indicates p ≤ 0.05, ** indicates p ≤ 
0.01, both by one-way ANOVA, Holm-Sidak post-hoc). 
69 
Figure 23 Schematic of three groups of rats used in this study: Naïve/Naïve rats (A) 
were completely naïve control rats. HBSS/Naïve rats (B) received a 
single (unilateral) retrobulbar injection of HBSS, and Genipin/HBSS rats 
(C) received a unilateral retrobulbar injection of genipin and a 
contralateral retrobulbar injection of HBSS.  
80 
Figure 24 Ocular examination of eyes immediately and one week after retrobulbar 
injections show mild transient complications. In all eyes receiving a 
retrobulbar injection (HBSS or genipin), a bleb (A) appeared in the nasal 
quadrant immediately after injection. One such bleb is indicated by an 
arrow (OS) and can be compared to the Naïve OD eye (prior to 
retrobulbar injection). Typically, the bleb would resolve one week after 
injection (B). In a few cases, eyes had mild conjunctival chemosis (C) or 
89 
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subconjunctival hemorrhage (D, arrow). All images taken one week after 
injection are oriented such that the nasal portion of the eye is on the left. 
Figure 25 Genipin-induced scleral stiffening did not affect IOP. No significant 
differences in IOP were found in any group at any timepoint up to four 
weeks post-injection. RM ANOVA, F(21,133) = 0.976; p = 0.497. All 
data shown as mean ± SD, all n ≥ 5 
90 
Figure 26 Genipin treatment did not have a sustained effect on spatial frequency or 
contrast sensitivity. Spatial frequency (A) and contrast sensitivity (B) for 
HBSS/Naïve and Genipin/HBSS rats. Spatial frequency was not 
significantly decreased in any of the groups over the course of the 
experiment (RM ANOVA, F(15, 95) = 1.33; p = 0.201). Contrast 
sensitivity was transiently decreased at day 14 in genipin eyes compared 
to Naïve eyes (p = 0.002, denoted by **) and in HBSS eyes (of 
Genipin/HBSS rats) vs. genipin eyes (p = 0.043, denoted by *). All data 
shown as mean ± SD and analyzed by RM ANOVA, Tukey post-hoc used 
when appropriate; all n ≥ 5. 
91 
Figure 27 Retinal function was not altered by HBSS or genipin injections up to four 
weeks post-injection. Electroretinogram Naïve responses for dark-
adapted (A-D) and light-adapted (E-H) testing conditions. Plotted are 
representative waveforms at 1-week (A and E) and 4 weeks (B and F) 
post-injection for Naïve (black dotted) and genipin (black solid) eyes. 
Mean amplitude and implicit time of all genipin (or Naïve) eyes were 
computed at each timepoint and flash intensity to select waveforms that 
most closely matched the means to ensure proper representative 
waveforms. A-wave and B-wave amplitudes from the brightest dark-
adapted flash (2.1 log cd s/m2) are plotted vs. time in (C) and (D) 
respectively. Additionally, B-wave and PhNR amplitudes from the 
brightest single photopic flash (1.4 log cd s/m2) are plotted vs. time in 
(G) and (H). All ERG data was analyzed with a two-way RM ANOVA. 
No significant interactions of time and treatment were found for any flash 
intensity (all p > 0.05). All data shown as mean ± SD, all n ≥ 5. 
92 
Figure 28 Genipin treatment results in a minor, non-statistically significant, loss of 
RGC axons: (A) Whole nerve counts from Naïve (n = 7, randomly 
selected as OD or OS eye), HBSS (n = 9), and genipin (n = 9) eyes. Nerve 
counts were not different in any cohort (One-way ANOVA, F(2, 22) = 
0.733, p = 0.492). (B) Contralateral optic nerve axon count differences 
for Genipin/HBSS rats at four weeks post-injection. Differences are 
computed as whole nerve axon count in genipin eye minus whole nerve 
axon count in contralateral HBSS eye. (One sample t-test, t = 1.276, df = 
8, p = 0.238, black dashed lines represent SD of axon count differences 
from 5 Naïve rats). Data shown as mean ± SD. (C) and (D) show 
representative subregions from the central region of optic nerves from a 
Genipin/HBSS rat, with (C) being the HBSS eye and (D) being the 
93 
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genipin eye. Axons appear to be normal with homogenous interiors 
surrounded by uniform myelin sheaths. 
Figure 29 (A) Representative ERG waveform from a normotensive control eye. 
Green and red lines depict how a-wave and b-wave amplitudes were 
defined, respectively. (B) Peak measured IOP is plotted vs b-wave 
amplitude at day 14 in hypertensive eyes (n = 74 eyes). Blue line denotes 
peak IOP of 60 mmHg, above which rats were excluded based on the IOP 
Exclusion Criterion. Red line denotes the lower 99.5% confidence 
interval of b-wave amplitude at day 14 from contralateral normotensive 
control eyes, below which rats were excluded based on the ERG 
Exclusion Criterion. 
105 
Figure 30 IOP measurements from OHT eyes, showing rats that were included 
(solid) and excluded (hollow symbols) based on the IOP Criterion (A) or 
on the ERG Criterion (B). Excluded eyes had higher IOP values at 3, 5, 
7, 10, and 14 days and 5, 7, and 14 days after microbead injection using 
the IOP Criterion or ERG Criterion, respectively (RM ANOVA, Effect 
of IOP Criterion: F(1, 72) = 23.74, p < 0.0001; Effect of ERG Criterion: 
F(1, 72) = 13.59, p = 0.0004; Sidak post-hoc). IOP burden (C) was larger 
for excluded rats than for included rats for either exclusion criteria (One-
way ANOVA, F (3, 144) = 13.33, p < 0.0001; Sidak post-hoc: IOP 
Criterion p < 0.0001, ERG Criterion p = 0.0002). Data shown as mean ± 
SD (“ns” indicates not significant, * indicates p ≤ 0.05, ** indicates p < 
0.01, *** indicates p < 0.001, **** indicates p < 0.0001). 
108 
Figure 31 Examples of data from rats included (A, B, and C) or excluded (D, E, F) 
by both IOP and ERG exclusion criteria. Plotted are IOP traces vs. time 
(A and D), ERG waveforms (B and E), and central region of optic nerve 
cross sections with the total axon count from the whole optic nerve 
superimposed (C and F). Data shown as mean ± SD, scalebar for optic 
nerve images is 10 µm. 
109 
Figure 32 Data from a rat that was included by ERG Criterion only, (A-C) and from 
two rats that were included by IOP Criterion only (D-I). Shown are IOP 
traces over time (A, D and G), ERG waveforms (B, E, and H), and central 
regions of optic nerve cross sections with the total axon count from the 
whole optic nerve superimposed (C, F, and I). Data shown as mean ± SD, 
scalebar for optic nerve images is 10 µm. 
110 
Figure 33 A) Scleral crosslinked eyes received one of three treatments by 
retrobulbar injection: HBSS (vehicle), Genipin (GP), or Methylene blue 
(MB). Those in the MB group also received 30 minutes of localized red 
light (660nm) to selectively stiffen the peripapillary (but not peripheral) 
sclera. B) Timeline of experiments. Seven days after scleral stiffening 
treatment. the treated (“experimental”) eye received a microbead 
injection to induce ocular hypertension. Ocular hypertension was induced 
121 
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at Day 0. Rats were sacrificed at Day 14. C) Timing of experiments. IOP 
measurements were taken at Days -7, 0, 1, 3, 4, 7, 10 , and 14. OMR 
measurements were taken at Days 0, 7, and 14. ERG measurements were 
taken at Days -7, 7, and 14, and OCT measurements were taken at Days 
-7 and 14. DIC and axon count measurements were necessarily taken post 
mortem after collecting the sclerae and optic nerves on Day 14 
immediately after euthanasia. 
Figure 34 A) Representation of the posterior eye showing the peripapillary sclera, 
here defined as the region enclosed by a 2 mm diameter circle centered at 
the ON. The peripheral sclera was defined as the sclera outside this 
region.  B) Whole globe inflation tests indicated whole sclera stiffening 
with GP and targeted peripapillary sclera stiffening with MB. Mean 
values are plotted. Statistical comparisons were performed using an 
ANCOVA and therefore are comparisons of adjusted means. C) Mean 
IOP burden (pressure x time) did not differ significantly between 
crosslinking treatment groups. D) IOP levels increased after induction of 
ocular hypertension at Day 0 in microbead-injected eyes compared to 
normotensive control eyes. Statistical significance is indicated using the 
following convention: “*” for p < 0.05, “**” for p <0.01, “***” for p < 
0.001, and “****” for p < 0.0001. 
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Figure 35 A) Total retinal thickness measured 0.5 mm from the ONH. Retinal 
thickness in hypertensive GP eyes was not different than in GP 
normotensive controls, while thickness in hypertensive HBSS eyes was 
significantly less than in HBSS normotensive controls. Thickness in 
hypertensive MB eyes was less than in hypertensive GP and HBSS eyes. 
B) Total retinal thickness measured 1.2 mm from the ONH. Thicknesses 
in both GP- and MB-treated hypertensive eyes were not significantly 
different from their respective contralateral eye (normotensive) 
thicknesses, while thickness in hypertensive HBSS-treated eyes was 
significantly less than in HBSS normotensive control eyes. Thickness in 
hypertensive GP eyes was significantly greater than in hypertensive 
HBSS-treated eyes, suggesting a protective effect of GP against retinal 
thinning. C) Axon counts derived from ON cross-sections showed no 
significant protective effects of crosslinking. D) Percent axon loss in 
hypertensive experimental eyes (compared to normotensive control) 
ranked by rat number from least to greatest axon loss suggests that axon 
loss is decreased in GP and MB treated eyes. 
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Figure 36 Functional outcome measurements across crosslinking treatment groups. 
We show OMR measurement outcomes, namely A) spatial frequency and 
B) contrast sensitivity; and ERG outcomes, namely C) pSTR amplitude, 
D) nSTR amplitude, E) b-wave amplitude, and F) oscillatory potential 3 
amplitude. In all cases, a significant deficit was observed for hypertensive 
experimental eyes compared to normotensive control eyes. No significant 
differences were found between hypertensive eye treatment groups. 
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These data indicate crosslinking did not preserve visual acuity or retinal 
function as measured by OMR and ERG. 
Figure 37 Parameters measured in hypertensive rat eyes were cross correlated and 
organized by mechanical, morphological, and functional categories for 
each crosslinking treatment. Stronger correlations were found for HBSS 
than for GP-treated rats, and for GP-treated rats compared to MB-treated 
rats, particularly in the relationship between morphological/functional 
with biomechanical parameters. Mechanical parameters included IOP 
burden, scleral strain, and eye dimensions. Morphological parameters 
include optic nerve size, axon count/density, and retinal thickness. 
Functional parameters include OMR and ERG data. A) HBSS 
hypertensive experimental eye matrix. B) GP hypertensive experimental 
eye matrix. C) MB hypertensive experimental eye matrix. Statistical 
significance was calculated for null hypothesis of zero correlation 
(significance indicated with “*” for the Bonferroni-corrected p<0.05 
level). 
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Figure 38 Rat Dataset Image Variety. A representative set of images from the rat 
optic nerve image dataset is shown. These images include a range of 
nerve health, variations in sample processing quality, and in image 
acquisition contrast and quality. 
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Figure 39 Histogram of Manual Count Variability for Rat Dataset. Variability 
between counters is expressed as the coefficient of variation (standard 
deviation of the manual count divided by the mean of the manual count 
for each image). The median coefficient of variation was 0.12, indicating 
good general agreement between manual counters. 
179 
Figure 40 U-Net Architecture. A visual representation of our adapted U-Net 
convolutional neural network architecture, with the encoding branch on 
the left and the decoding branch on the right. Each box represents the 
output array of one of the convolutional network’s layer operations, 
which are represented by colored arrows. The bold numbers to the left of 
the boxes indicate the row and column sizes of the feature array at those 
layers. The numbers above the boxes indicate the feature depth of each 
layer, which is the third dimension of the feature array at that layer. 
Numbers in the layer operations key indicate the size of that operation’s 
sliding window. Products of feature concatenation are indicated by two 
boxes sharing a border with the concatenated box in grey. The asterisk 
indicates dropout with rate = 0.5 applied after convolution. ReLU is an 
abbreviation for Rectified Linear Unit. Figure adapted from 
Ronnenberger et al. (Ronneberger, Fischer, and Brox 2015). 
183 
 xxi 
Figure 41 AxoNet Training Loss. Average training and validation set loss for each 
epoch vs. epoch number. Training and validation set losses do not 
diverge, indicating that our network did not overfit during training. 
186 
Figure 42 Comparison between automated and manual axon counts for the rat 
validation and testing subsets. Validation subset results are shown for 
AxoNet (a), AxonMaster (b) and AxonJ (c). The regression relationships 
between MC and AC counts were: AxoNet: AC = 0.801*(MC) + 4.8; 
AxonMaster: AC = 0.731*(MC) – 0.633; and AxonJ AC = 0.508*(MC) 
+ 26.2. These relationships were used as correction equations when 
counting axons in the testing subset. Testing subset results are shown for 
AxoNet (d), AxonMaster (e) and AxonJ (f). Testing subset mean absolute 
errors are 4.4, 12.8, and 9.5 axons for AxoNet, AxonMaster, and AxonJ 
respectively. AC values are shown after applying the correction equations 
from the validation subset results. Each data point is obtained from a 
single sub-image from the corresponding subset. 
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Figure 43 Comparison of error distribution for the rat testing subset. Differences 
between rat testing subset MC and corrected AC are plotted against 
manual counts for AxoNet (A), AxonMaster (B) and AxonJ (C) as Bland-
Altman plots. Each data point is a single sub-image from the rat testing 
dataset. Red lines represent the upper and lower bounds for the limits of 
agreement, calculated as mean error ± 1.96*(standard deviation of error). 
Limits of agreement are [-8.3, 12.6], [-14.59, 25.8], and [-27.7, 39.4] 
axons for AxoNet, AxonMaster, and AxonJ, respectively. 
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Figure 44 Visualization of AxoNet Performance. The images from the rat testing 
subset which produced the smallest (top) and greatest (bottom) difference 
between AxoNet predicted and ground truth manual axon count are 
shown in the left column. The corresponding manually annotated ground 
truth axon count density maps are shown in the middle column, and the 
automatically detected axon count density maps are shown in the right 
column. The scale bar on the right shows the map used to visualize axon 
count density as greyscale intensity. 
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Figure 45 Visualization of AxoNet Performance. The images from the rat testing 
subset which produced the smallest (top) and greatest (bottom) difference 
between AxoNet predicted and ground truth manual axon count are 
shown in the left column. The corresponding manually annotated ground 
truth axon count density maps are shown in the middle column, and the 
automatically detected axon count density maps are shown in the right 
column. The scale bar on the right shows the map used to visualize axon 
count density as greyscale intensity. 
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Figure 46 Comparison of error distribution for the NHP testing subset. Differences 
between NHP testing subset semi-automated manual count and corrected 
AC are plotted against semi-automated manual count for AxoNet (A), 
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AxonMaster (B) and AxonJ (C) as Bland-Altman plots. Each data point 
is a single sub-image from the rat testing subset. Red lines represent the 
upper and lower bounds for the limits of agreement, calculated as mean 
error ± 1.96*(standard deviation of error). Limits of agreement are [-43.9, 
42.8], [-48.9, 47.5], and [-91.0, 93.4] axons for AxoNet, AxonMaster, and 
AxonJ respectively.  
Figure 47 AxoNet Plugin Results. After using the AxoNet plugin for ImageJ and 
Fiji on an image of a full rat optic nerve (a), the output axon density map 
(b) and the combination of these two images (c) are displayed. The 
combination of these two images is shown with the input image (a) in 
greyscale and the axon density map (b) overlaid in pink. Axon density 
scale is not provided here because these full images are scaled down 
significantly for inclusion in the manuscript and color scale is 
indistinguishable at this resolution. A grid of dark lines is visible in panel 
a; these lines correspond to tile edges from the microscopy imaging and 
are an artifact of visualization only since counts are carried out on much 
smaller portions of the full image. 
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Figure 48 Training Set Subsampling. The full training data set was sub-sampled to 
produce training data sets of different sizes (N). AxoNet was then trained 
with these sub-sampled sets, and subsequently used to count axons in the 
same data set, i.e. for purposes of generating this figure, the testing and 
training data set were the same for each realization. We computed a mean 
absolute error (MAE) over the data set and repeated this process 3 times 
for each training set size (i.e. 3 replicates) to obtain a mean and standard 
deviation of the MAE. This full analysis was completed for three training 
set conditions: training augmentation without resampling (blue symbols), 
resampling without training augmentation (green symbols), and no 
training augmentation or resampling (red symbols). The respective fitted 
relationships for these three conditions were MAE = 0.1 + 1.8*log(N), 
MAE = -0.4 + 1.5*log(N), and MAE = -0.2 + 1.2*log(N). Note that the 
horizontal axis is logarithmic and that plotted values at the same training 
set size are offset slightly in the horizontal direction for visual clarity.  
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Figure 49 Schematic diagram of quantities used in calculation of relative stiffening 207 
Figure 50 Genipin treatment did not significantly affect message abundance for 
genes involved in extracellular matrix turnover in the sclera, nor for pro-
inflammatory genes in the retina. Plotted is the fold change of message 
for MMPs (A and C) and TIMPs (B and D) at one week (A and B) and 
four weeks (C and D) post-injection in the sclera for HBSS/Naïve and 
Genipin/HBSS rats. In HBSS/Naïve rats, the HBSS-injected eye was 
normalized to the contralateral Naïve eye, and in Genipin/HBSS rats, the 
genipin-treated eye was normalized to the contralateral HBSS-injected 
eye. Values are missing for Mmp3 in (C) and Timp1 in (D) due to lack of 
data after outlier removal. E and F show fold change of message levels 
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for inflammatory cytokines (Cd68, Tnf, and Il1b) at one week (E) and 
four weeks (F) post-injection in the retina for HBSS/Naïve and 
Genipin/HBSS rats. No significant differences were found between 
contralateral eyes in any tissue at any timepoint. (Multiple t-tests using 
Holm-Sidak correction, all p > 0.05, all data shown as mean ± SD). 
Figure 51 Whole nerve axon counts in hypertensive eyes are plotted vs IOP burden 
included (solid) and excluded (hollow) based on IOP Criterion (A) and 
ERG Criterion (B). Axon counts of all hypertensive eyes (black dashed 
in A and B) and hypertensive eyes included based on both IOP Criterion 
(A) and ERG Criterion (B) were significantly correlated with IOP burden 
(all p < 0.0001). C) Axon counts of hypertensive eyes from all rats 
(black), included based on IOP Criterion (blue), and included based on 
ERG Criterion (red) were not different from one another (One-way 
ANOVA, F (2, 175) = 0.5043, p = 0.605). Data shown as mean ± SD 
210 
Figure 52 Chemical crosslinker genipin (left inset) or photocrosslinker methylene 
blue (right inset) were injected by retrobulbar injection to induce scleral 
crosslinking. Genipin induced non-targeted crosslinking. Methylene blue 
was activated with a transpupillary light beam to selectively crosslink 
peripapillary sclera. 
211 
Figure 53 Correlations of baseline control and experimental eye values prior to 
treatments. “Control” indicates eyes designated to be normotensive. 
“Experimental” indicates eyes designated to be normotensive (microbead 
injection). A) pSTR amplitude, B) nSTR amplitude, C) b-wave 
amplitude, D) oscillatory potential 3 amplitude, E) retinal thickness at 0.5 
mm from the ON, F) retinal thickness at 1.2 mm from the ON, G) spatial 
frequency, and H) contrast sensitivity, showed no significant correlation 
at baseline between eyes of the same rat. 
212 
Figure 54 A) Image of BN rat fundus viewed through refraction-negating corneal 
contact lens showing optic nerve head and retinal vasculature. The lens 
created a clear optical path facilitating B) projection of an annular beam 
(measuring 2 mm outer diameter, 1 mm inner diameter) of 660 nm 
incoherent light from a custom-designed microscope to the peripapillary 
sclera following retrobulbar injection of MB. The inset shows an image 
of the beam projected onto a BN rat fundus as viewed using the 
microscope’s camera (inset scale bar = 1 mm). 
212 
Figure 55 A) Peripapillary and B) peripheral strain as a function of IOP burden. 213 
Figure 56 OCT retinal thickness measurements as a function of IOP burden at A) 
0.5 mm from the ONH and B) 1.2 mm from the ONH. 
215 
Figure 57 Representative experimental eye optic nerve/retina OCT images from 
each treatment in specified range of IOP burden. Damage qualitatively 
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increases with increasing IOP burden. “*” indicates choroid, “†” indicates 
optic nerve head. Vertical yellow lines on each image indicate (from left 
to right), -1.2 mm, -0.5 mm, 0 mm, 0.5 mm, 1.2 mm distances from center 
of optic nerve head at which retinal thickness measurements were taken. 
Scale bar = 0.5 mm. Specifically, cupping at the optic nerve head 
increases in all groups. 
Figure 58 A) Axon count, B) axon density, and C) optic nerve cross-sectional area 
as functions of IOP burden. 
 
Figure 59 No qualitative differences were found in optic nerve cross-sections of 
hypertensive eyes between crosslinking treatment groups. Representative 
images from each treatment in specified range of IOP burden are shown. 
Images were taken from the central region of each nerve. Scale bar = 10 
µm. Damage qualitatively increases with increasing IOP burden. 
216 
Figure 60 Eye size parameters vs IOP burden including A) anterior chamber depth, 
B) equatorial width, and C) axial length. 
217 
Figure 61 ERG outcomes vs IOP burden for A) pSTR amplitude, B) nSTR 
amplitude, C) b-wave amplitude, and D) oscillatory potential 3 
amplitude. 
217 
Figure 62 Resolved A) spatial frequency and B) contrast sensitivity of normotensive 
control eyes at Days -7, 0, 7, and 14 with respect to induction of 
hypertension at Day 0. Significant differences were found at Day 7 and 
Day 14 compared to Day -7 (baseline) for spatial frequency and for 
contrast sensitivity in all crosslinking treatment groups. These findings 
suggest the presence of a hyperacuity effect in the normotensive eye after 
induction of hypertension in the contralateral eye C) Spatial frequency 
differed between Day -7 (baseline) and Day 0 (after stiffening treatment) 
for GP (p < 0.01) and MB (p < 0.0001). D) Contrast Sensitivity differed 
between Day -7 (baseline) and Day 0 (after stiffening treatment) for GP 
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Glaucoma is the leading cause of irreversible blindness in the world, affecting 
approximately 80 million people in the year 2020. This degenerative optic neuropathy is 
characterized by retinal ganglion cell (RGC) death, optic nerve damage, and progressive 
vision loss. While the exact etiology remains elusive, elevated intraocular pressure (IOP) 
is a known risk factor and lowering IOP remains the only effective treatment. Elevated IOP 
causes deformation and remodeling of the optic nerve head (ONH) tissues, which in turn 
is thought to promote localized neurodegeneration. Computational and ex vivo studies have 
shown that scleral stiffness strongly influences deformation of the ONH, and that 
increasing the stiffness of the sclera surrounding the ONH (the peripapillary sclera) can 
significantly reduce these excessive strains. We hypothesize that by crosslinking the 
collagenous peripapillary sclera, we will reduce mechanical deformation in the ONH, 
which will in turn mitigate glaucomatous vision loss.  
To investigate this hypothesis, we developed a safe and efficacious scleral 
stiffening treatment using the collagen crosslinking agent genipin, assayed through ex vivo 
and in vivo experiments in healthy rat eyes. We then evaluated our treatment’s efficacy to 
prevent glaucomatous damage in a microbead rat model of ocular hypertension. Our 
results indicate that scleral stiffening protected against retinal thinning but did not 
show protective effects on visual or retinal function, nor preservation of RGC axons. 
Overall, these results demonstrate the feasibility of using genipin for a scleral stiffening 
treatment. The absence of a strong protective effect of genipin-induced scleral stiffening 
on RGC function and structure may be due to limitations in the glaucomatous rat model, 
 xxvii 
in that our model does not mirror the slow progression, nor the moderate IOP elevation 





 Pathophysiology of Glaucoma 
Glaucoma is the leading cause of irreversible blindness and affects roughly 80 
million people worldwide (Cook and Foster 2012; Quigley and Broman 2006). This 
degenerative optic neuropathy is characterized by retinal ganglion cell (RGC) dysfunction 
and death, which leads to progressive and irreversible vision loss. RGC axons transmit 
visual information from the retina to the brain and thus are critical to visual function. 
Although the exact etiology of glaucomatous damage to RGCs is unknown, several risk 
factors have been associated with glaucoma, including: African American descent, family 
history of glaucoma, older age, corticosteroid use, and elevated intraocular pressure (IOP) 
(Weinreb, Aung, and Medeiros 2014; Sommer et al. 1991; Mc, Gordon, and Koteen 1951; 
Tielsch et al. 1994).  
 Regulation of Intraocular Pressure 
The intraocular pressure (IOP) within the globe helps maintain the shape of the eye 
and is determined by the circulation of aqueous humor. Aqueous humor is a transparent 
fluid secreted by the ciliary processes, which flows into the anterior chamber and exits the 
eye through one of two pathways (Figure 1). In the main outflow pathway, known as the 
conventional outflow pathway, aqueous humor flows through the trabecular meshwork, 
into Schlemm’s canal, and then exits the eye through the episcleral vasculature (Goel et al. 
2010; Ashton 1952; Tripathi 1972). The second pathway is known as the unconventional, 
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or uveoscleral, pathway, in which aqueous humor flows out of the eye through the ciliary 
muscle into the suprachoroidal space, and then exits through the sclera, among other routes 
(Tripathi 1977). 
 
Since IOP is major risk factor for glaucoma, a great deal of glaucoma research is 
focused on development of IOP-lowering techniques that utilize pharmacology or surgery. 
Commonly used pharmaceuticals aim to lower IOP by increasing unconventional 
(prostaglandin analogs) or conventional (cholinergic agonists or rho kinase inhibitors) 
aqueous humor outflow, or by reducing aqueous humor production (beta-adrenergic 
blockers and carbonic anhydrase inhibitors, and alpha-adrenergic agonists) (Weinreb, 
Aung, and Medeiros 2014; Tanna and Johnson 2018; Goh et al. 1988; Kerstetter et al. 1988; 
Elliot, Cullen, and Phillips 1975; Becker 1955). IOP-lowering drugs have been shown to 
slow or prevent the progression of vision loss in glaucoma patients (Bron 2002; Becker 
Figure 1: Ocular cross section with anatomical features labelled. Yellow arrows denote flow 
patterns of aqueous humor. Adapted from Martini 2010 (Martini 2010). 
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1954). Unfortunately, IOP-lowering drugs have notably poor patient compliance and in 
some cases do not lower IOP sufficiently (Robin and Grover 2011). In such cases, 
surgically-based methods of lowering IOP are required. These include laser 
trabeculoplasty, shunts, trabeculotomy, and more recently, minimally-invasive glaucoma 
surgical techniques (Mori et al. 2020; Bovee and Pasquale 2017; Hu, Ang, and Yip 2020), 
which all aim to increase aqueous humor outflow without the need for daily patient 
intervention. While these approaches are useful, studies have shown that as many as 45% 
of patients continue to progress even with use of IOP-lowering therapies (Heijl et al. 2002). 
Thus, there is a significant need to develop a treatment for glaucoma that is not solely 
aimed at lowering IOP.  
 Biomechanics in Glaucoma 
With the goal of developing other treatments for glaucoma, research has focused 
on understanding the relationship between ocular biomechanics and glaucomatous damage. 
To better understand this relationship, I will first describe the anatomical features of the 
posterior eye (Figure 2) that are thought to be important in glaucoma.  
 Posterior Ocular Anatomy 
RGCs are retinal neurons which transmit visual information from the retina to the 
brain via axons which make up the optic nerve. The sclera is the opaque, collagenous, 
connective tissue that comprises five-sixths of the outer layer of the eye and provides 
structural support for the globe (Figure 2A). The optic nerve head (ONH) is a region within 
the posterior sclera where RGC axons converge and exit the eye through a canal known as 
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the scleral canal (Figure 2B). The posterior scleral region immediately surrounding the 
ONH is known as the peripapillary sclera.  
 
1.2.1.1 Scleral Structure 
The sclera consists of lamellar layers containing mainly crosslinked type I collagen 
fibers (90% by weight) and elastin surrounded by a proteoglycan-rich matrix (Rada, 
Shelton, and Norton 2006). These collagen lamellae are oriented in a heterogeneous 
manner; for example, in the peripapillary sclera the collagen preferentially aligns in a 
circumferential orientation to resist expansion of the scleral canal (Coudrillier et al. 2013; 
Pijanka et al. 2012; Gogola et al. 2018). In contrast, collagen lamellae are less aligned in 
the peripheral sclera, but have a preferred radial orientation (Gogola et al. 2018; Pijanka et 
al. 2012).  
Figure 2: A) Overview of eye anatomy. Arrows denote IOP. B) OCT image showing a cross-section 
of the optic nerve head region and demonstrating the characteristic cupping in glaucoma. The 
lamina cribrosa and other structures are identified. C) 3D representation of a monkey lamina 
cribrosa showing its beautifully intricate structure. RGC axons pass through these pores to form 
the optic nerve (Girard et al. 2013). 
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1.2.1.2 Optic Nerve Head and Lamina Cribrosa Structure 
Along with RGC axons, the ONH contains support cells (astrocytes and glial cells) 
and, in humans, a collagenous, sieve-like structure called the lamina cribrosa (Figure 2C). 
The lamina cribrosa is composed of types I and III collagen, elastin, and proteoglycans 
(Hernandez et al. 1987) and provides the main structural and functional support to the RGC 
axon bundles that pass through its pores (Girard et al. 2013; Burgoyne et al. 2005).  
 Biomechanical Damage in Glaucoma 
It is well accepted that elevated IOP leads to biomechanical insult to the ONH, which 
in turn likely contributes to RGC loss (Burgoyne 2011) via several different mechanisms. 
In glaucoma, elevated IOP causes the ONH to undergo a significant amount of tissue 
remodeling, including posterior bowing of the lamina cribrosa. One of the hallmarks of 
glaucoma is an early thickening of the lamina followed by a thinning and posterior bowing, 
which contributes to the phenomenon observed clinically as ‘cupping’ (Figure 2B) 
(Agoumi et al. 2011; Girard et al. 2013; Yang, Downs, and Burgoyne 2009). Since the 
lamina cribrosa provides structural and functional support for RGC axons, this remodeling 
of the lamina is believed to contribute to RGC axonal death in glaucoma (Sigal et al. 2007; 
Coudrillier et al. 2012; Quigley et al. 1985). Additionally, mechanosensitive astrocytes 
become reactive and form glial scars, which promotes RGC apoptosis (Alqawlaq, 
Flanagan, and Sivak 2019; Nickells 1996; Hayreh 1976; Hernandez 2000; Pena et al. 
2001).  RGC death can also in part be attributed to ischemia caused by mechanically 
obstructed blood flow in ONH capillaries (Burgoyne 2011; Hamard et al. 1994). Together, 
these mechanisms of RGC damage can each be linked back to excessive ONH strains. 
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Thus, if there was a way to mitigate such strains, we could presumably decrease RGC 
dysfunction, and thereby preserve vision in patients with glaucoma.  
 Scleral Biomechanics in Glaucoma 
Motivated by a desire to understand the causes of excessive ONH strain in eyes 
with elevated IOP, a computational study determined which biomechanical properties of 
posterior eye tissues most influenced ONH strain (Sigal, Flanagan, and Ethier 2005). This 
study revealed that the stiffness of the peripapillary sclera had a major influence on strain 
in the ONH. Several other computational studies have further demonstrated similar 
conclusions, i.e. that these excessive strains could be alleviated by increasing the 
peripapillary scleral stiffness (Figure 3) (Eilaghi et al. 2010; Sigal et al. 2004). Therefore, 
it is hypothesized that scleral stiffening may confer protection against IOP-induced 
glaucomatous damage (Campbell, Coudrillier, and Ethier 2014). 
This hypothesis was further evaluated in an ex vivo study which showed that 
increasing peripapillary scleral stiffness by approximately 100%, i.e. a doubling in scleral 
stiffness, provided a significant reduction in ONH strain (Coudrillier, Campbell, et al. 
2016) Additionally, preliminary in vivo data has revealed a neuroprotective effect in rats 
with ocular hypertension (OHT) when increasing the scleral stiffness by 75% via 
overexpression of bone morphogenetic protein 2 using a viral vector delivered to the 
posterior eye (Ethier 2015).  
Currently, one study has considered the effect of scleral stiffening in an animal model 
of glaucoma, specifically analyzing the effect of glyceraldehyde in vivo in mice (Kimball 
et al. 2014). Contrary to our hypothesis, this study reported that stiffening the posterior 
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sclera caused increased, rather than decreased, RGC damage in an OHT model of 
glaucoma, rather than acting as a neuroprotectant. I will discuss this in more detail in 
section 1.3.1.2 and Chapter 7.  
 
 Collagen Crosslinking  
A large body of research exists on various collagen crosslinking agents for a myriad 
of applications, e.g. increasing the rigidity of tissue grafts to recipient heart valves (Sung 
et al. 2000; Yoo et al. 2011), stem cell scaffolds (Rowland et al. 2013), acellular plug 
treatment for osteochondral defects (Hrabchak et al. 2010), and hydrogels used for drug 
delivery (Hennink and van Nostrum 2002). In many of these applications, collagen 
crosslinking agents are applied ex vivo before being used in vivo, because one of the major 
drawbacks of using collagen crosslinking agents is the high level of toxicity. For instance, 
one of the most commonly used collagen crosslinkers, glutaraldehyde, is highly toxic and 
thus unacceptable for in vivo use (Coudrillier, Campbell, et al. 2016; Gough, Scotchford, 
and Downes 2002). For applications in which collagen crosslinking agents are applied in 
vivo, more research needs to be performed on other less-toxic, natural, collagen 
crosslinking agents.  
Figure 3: Finite element model of the ONH and peripapillary sclera depicting the first principal 
strains when considering a stiff, normal, and compliant sclera. First principal strains in the ONH 
are lowest with a stiff sclera (Eilaghi et al. 2010). 
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 Ocular Use of Collagen Crosslinking Agents 
Ocular collagen crosslinking has been proposed as a potential therapeutic treatment 
for not only glaucoma, but also for keratoconus and myopia. Keratoconus is a disease in 
which the cornea becomes thinner, weaker, and misshapen, thus distorting vision (Chunyu 
et al. 2014). Collagen crosslinking with riboflavin, photoactivated by Ultraviolet-A light, 
was proposed as a therapy for keratoconus (Spoerl, Huhle, and Seiler 1998; Wollensak, 
Spoerl, and Seiler 2003). This treatment, which increases corneal stiffness, has been 
recently clinically approved and is currently used worldwide (Hersh et al. 2017; Chunyu et 
al. 2014). In myopia, or nearsightedness, scleral remodeling leads to axial ocular elongation 
which contributes to increased refractive error (Harper and Summers 2015; Rada, Shelton, 
and Norton 2006). Collagen crosslinking of the sclera has been hypothesized as a treatment 
to slow or reverse scleral remodeling that leads to increased axial length and thus refractive 
error in myopia (Levy, Fazio, and Grytz 2018; Liu and Wang 2017). Unfortunately, the 
riboflavin + Ultraviolet-A collagen crosslinking method used to treat keratoconus is toxic 
to the retina, and cannot be used for scleral crosslinking (Glickman 2011; Wollensak et al. 
2005). For this reason, development of alternative collagen crosslinking approaches is 
necessary to safely stiffen the posterior sclera for potential treatment of myopia and 
glaucoma. 
1.3.1.1 Biocompatible Collagen Crosslinking Agents 
Through an extensive literature search evaluating potential biocompatible, non-
photoactivated, collagen crosslinking agents, genipin has emerged as a viable option for 
scleral crosslinking (Avila and Navia 2010; Hrabchak et al. 2010; Hwang et al. 2011; Liu, 
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Luo, et al. 2014; Liu and Wang 2013; Wang and Corpuz 2015; Wong et al. 2012; Xu, 
Chow, and Zhang 2011). As such, the vast majority of scleral crosslinking research has 
been focused on genipin crosslinking (Avila and Navia 2010; Hwang et al. 2011; Liu, Luo, 
et al. 2014; Liu and Wang 2013; Wang and Corpuz 2015; Wong et al. 2012; Xu, Chow, 
and Zhang 2011; Levy, Fazio, and Grytz 2018; Dias et al. 2015; Liu and Wang 2017). 
Genipin has been shown to have anti-inflammatory and anti-angiogenic properties (Koo et 
al. 2004), can induce stable crosslinks in biological tissue (Sung et al. 2001), and is 
significantly less cytotoxic than glutaraldehyde (Sung et al. 1999; Chang et al. 2002) and 
riboflavin (Song et al. 2017; Avila, Gerena, and Navia 2012).  
Of several studies that have evaluated genipin-induced scleral crosslinking, only 
two have evaluated both the efficacy and safety of genipin-induced scleral crosslinking in 
vivo (Liu and Wang 2017; Wang and Corpuz 2015). These studies examined the 
biomechanical properties of genipin-stiffened scleral strips, gross ocular anatomy via slit-
lamp exams after treatment, and histological and immuno-histological sections of ocular 
tissues in rabbits (Liu and Wang 2017) and guinea pigs (Wang and Corpuz 2015). These 
studies found that genipin successfully stiffened the sclera and did not cause any gross 
changes in ocular structures. However, to date no study has evaluated whether genipin-
induced scleral collagen crosslinking affects visual and retinal function in vivo. Therefore, 
Chapter 4 and Chapter 5 will thoroughly evaluate the stiffening duration and functional 
effects of genipin-induced scleral stiffening, respectively. These experiments will lay the 
groundwork for studying the efficacy of scleral stiffening as a treatment for glaucoma 
(Chapter 7). 
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1.3.1.2 Previous Scleral Crosslinking Studies 
There are several differences between the previously published collagen 
crosslinking study by Kimball et al. and our proposed study (Kimball et al. 2014). These 
include differences in the animal model, injection procedure, volume, agent, and 
concentration (described in detail in Chapter 7). In addition to these differences, several 
studies have confirmed the toxicity of glyceraldehyde (Kitahara et al. 2008; Usui et al. 
2004; Koriyama et al. 2015). We thus hypothesize that scleral stiffening with a proven 
nontoxic agent will provide neuroprotection in glaucoma. 
 Rat Model of Glaucoma 
 Similarities Between Human and Rat Pathophysiology 
For our study, we have chosen to use a rat model of glaucoma, one of several 
available. Rats are a very widely used animal model for glaucoma because of many 
parallels to glaucoma in humans. Ocular hypertensive rat models of glaucoma involve 
restricting the outflow of aqueous humor to elevate the animal’s IOP. These models have 
been shown to yield ONH tissue deformations and demonstrate the ONH ‘cupping’ 
clinically present in humans (Morrison, Cepurna Ying Guo, and Johnson 2011; Quigley 
and Green 1979; Johnson et al. 2000). They also present similar features, including: RGC 
apoptosis (Guo et al. 2005), remodeling of extracellular matrix components in the ONH 
(Johnson et al. 2000), and the ONH being a main and early site of damage (Morrison, 
Cepurna Ying Guo, and Johnson 2011). Rat and human optic nerves also possess several 
anatomical similarities including: unmyelinated axonal fiber bundles within the anterior 
nerve, astrocytes aligned transversely to these axons, and a similar RGC damage pattern 
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(Morrison, Cepurna Ying Guo, and Johnson 2011; Johnson et al. 2000). Further, rodents 
are more cost effective and desirable from an ethical viewpoint when compared to non-
human primates. The rat eye is twice the size of the mouse eye, and rats are therefore easier 
to work with than mice when delivering ocular injections and carrying out mechanical 
testing (Remtulla and Hallett 1985). IOP measurements in mice are typically performed 
under anesthesia, which leads to underestimating the IOP (Jia et al. 2000a). The Brown 
Norway rat that we have chosen is notably more docile than other strains, and therefore we 
can measure IOP in awake rats. Together, these reasons make the Brown Norway rat a 
good animal model of glaucoma for our purposes. 
 Success of the OHT Model 
There are several rat models currently used in glaucoma research, the majority of 
which aim to induce OHT. The general methodology behind these models is to increase 
outflow resistance of aqueous humor, thus leading to an increase in IOP. Although 
hindering aqueous humor outflow seems simple in theory, in practice there are several 
complications due to the dynamic flow patterns within the trabecular meshwork, limited 
access to the outflow pathway, and the small size of the rat eye (Goel et al. 2010; Bouhenni 
et al. 2012). Once the outflow pathway has been restricted, the resultant IOP is extremely 
variable, with fluctuations over time within a single animal and within a cohort of animals 
(Levkovitch-Verbin et al. 2002; Chen and Zhang 2015; Feola et al. 2019; Kwong et al. 
2013), which can result in extremely high IOPs, e.g. more than twice the baseline pressure 
(Foxton et al. 2013; Samsel et al. 2011; Dai et al. 2012; Bunker et al. 2015). This IOP 
history differs from the clinical presentation and such elevated pressures can even cause 
ischemic damage to the ONH and other retinal layers (as discussed in 0), adding difficulty 
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to determining the effect of a treatment (Bunker et al. 2015; Bui et al. 2013). Because of 
these complexities, there is unfortunately no ideal rat model of OHT. Here, I will briefly 
describe the currently used rat models of OHT and each of their potential limitations. It 
should be noted that there are other models of OHT which elevate IOP for acute periods, 
but these will not be described below (Levkovitch-Verbin et al. 2002; Lani et al. 2019). 
1.4.2.1 Classic Models of OHT 
1.4.2.1.1 Hypertonic Saline/Morrison Model 
An early rat model of OHT is known as the Morrison model (Figure 4A), or 
hypertonic saline model of OHT (Morrison et al. 1997). In this method, hypertonic saline 
is injected into the episcleral limbal veins to induce sclerosis in the outflow tract and 
consequently elevate IOP. The resultant IOP elevation has been shown to last 4 to 8 weeks 
and RGC axonal damage patterns are similar to the clinical presentation (Morrison et al. 
1997; Feola et al. 2019). The Morrison model is a difficult surgical procedure to perform 
because the episcleral veins are incredibly small, and thus requires extensive training 
(Morrison et al. 1995). This model of OHT also has a large amount of variability in IOP 
elevation for individual rats (Jia et al. 2000b) and it is difficult for labs to obtain similar 
IOP elevations to published results (Levkovitch-Verbin et al. 2002). 
 
1.4.2.1.2 Episcleral Vein Cauterization 
At a similar time as the development of the Morrison model, Shareef et al. 
developed a model of OHT involving cauterization of 2 to 3 episcleral veins (Figure 
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4B)(Shareef et al. 1995). Application of this method showed sustained IOP elevation for 
up to 6 months with approximately 40% RGC loss (Sawada and Neufeld 1999). However, 
an invasive surgery is necessary to access the episcleral veins and there is a risk of burning 
the sclera which leads to necrosis. Also, the resulting IOP is extremely high, reaching up 
to 60 mmHg under anesthesia; thus the unanesthetized IOP is even higher, since anesthesia 
depresses IOP by as much as 50% (Mittag et al. 2000; Jia et al. 2000a; Shareef et al. 1995). 
More recent research on this model has shown that OHT is induced by restricting blood 
flow and not aqueous outflow, which leads to a uniform RGC damage pattern instead of 
an initial superior RGC axon loss seen in other models of OHT (Mittag et al. 2000; 
Morrison 2005; Morrison, Cepurna Ying Guo, and Johnson 2011).  
 
1.4.2.1.3 Laser Photocoagulation 
Other investigators have taken an approach which utilized a laser to burn either the 
trabecular meshwork, the episcleral veins, or both (Figure 4C) to restrict aqueous humor 
outflow (Levkovitch-Verbin et al. 2002; Ueda et al. 1998). This method is more attractive 
Figure 4: Classic rat models of OHT. A) Morrison Model: Arrowhead shows blanching effect of 
saline in the episcleral venous plexus and arrow indicates a portion of the episcleral venous plexus 
that has not yet blanched (Gossman, Linn, and Linn 2016). B) Episcleral Vein Cauterization: Arrow 
shows tip of the cautery applied on the limbal plexus, where the superior portion has already been 
cauterized (Lani et al. 2019). C) Laser Photocoagulation: Schematic of anterior chamber which 
shows laser illumination (Chen et al. 2015).  
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that the Morrison or cauterization methods because it is less surgically invasive, requires 
only use of a slit lamp, and takes just 3 minutes per rat to perform. Levkovitch-Verbin et 
al. also used this method after failing to obtain sufficient IOP elevation to produce RGC 
loss using these two previous methods (Levkovitch-Verbin et al. 2002). Consequently, 
using laser translimbal photocoagulation showed IOP elevation lasting 6 weeks and 
resulted in approximately 50-60% RGC axon loss. However, some of the limitations of this 
method are the need for an expensive diode or continuous wave laser, the fact that IOPs 
can reach up to 50 mmHg under anesthesia (which introduces the same issues stated in the 
previous paragraph), and the need for multiple lasering sessions to achieve significant RGC 
loss (Ueda et al. 1998; Levkovitch-Verbin et al. 2002). 
1.4.2.2 Recently Developed Models of OHT 
1.4.2.2.1 Microbead Model of OHT 
Currently, the most widely used rat model of glaucoma in rodents is the microbead 
model (Figure 5A) in which microbeads (ranging from 1 to 15µm) are injected into the 
anterior chamber to increase resistance to aqueous humor outflow (Morgan and Tribble 
2015). This method was first developed for non-human primates (Weber and Zelenak 
2001) and was first adapted in use in rats by Urcola et al. (Urcola, Hernandez, and Vecino 
2006). Variations in microbead sizes, injection volumes, and injection media have been 
explored by various labs (Dai et al. 2012; Smedowski et al. 2014). One of the main 
limitations of this method is that microbeads tend to obstruct the visual axis. Samsel et al. 
improved the method to use magnetic microbeads instead of polystyrene (non-magnetic) 
beads (Samsel et al. 2011). In this modified method, a handheld magnet is placed around 
the limbus of the eye so that the magnetic microbeads are pulled tightly into the angle, 
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thereby preserving clarity of the visual axis. Microbead model studies have reported 
successful IOP elevation lasting between 2 and 6 weeks (Sappington et al. 2010; Dai et al. 
2012; Bunker et al. 2015; Matsumoto et al. 2014; Morgan and Tribble 2015; Samsel et al. 
2011; Foxton et al. 2013), and those that have performed multiple injections have reported 
elevation of up to 27 weeks (Urcola, Hernandez, and Vecino 2006). Limitations of this 
model include the variations in IOP elevation and duration, anterior chamber inflammation, 
obstruction of the visual axis, and high IOP spikes which can cause corneal edema or 
ischemia (Urcola, Hernandez, and Vecino 2006; Morgan and Tribble 2015; Smedowski et 
al. 2014). 
 
1.4.2.2.2 Circumlimbal Suture Model of OHT 
More recently, investigators have developed a circumlimbal suture technique 
(Figure 5B) in which a suture is applied to the conjunctiva behind the limbus of the eye, 
which results in OHT for 8-15 weeks (He et al. 2018; Liu et al. 2015). Studies utilizing this 
Figure 5: Recently Developed Models of OHT: A) Microbead model, showing a schematic of the 
anterior chamber with aqueous humor flow path depicted by green arrows with yellow microbeads 
in the iridocorneal angle (Yang et al. 2012). B) Circumlimbal suture model, showing a suture tied 
firmly posterior to the limbus of the rat eye (Liu et al. 2015). 
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method see a mild loss of RGC function after 8 weeks of elevated IOP as well as retinal 
nerve fiber layer thinning and minor RGC density loss after 15 weeks of elevated IOP (Liu 
et al. 2015). There are several limitations of using the circumlimbal suture model of 
hypertension, including: 1) the need for a trained surgeon to properly implement the model, 
2) a high IOP spike of up to 81 mmHg immediately after suture application, 3) uncertainty 
about the exact method of IOP elevation, and, most importantly, 4) only transient RGC 
functional loss, i.e. RGC function has been shown to recover to baseline levels after 
removing the circumlimbal suture at 8 weeks after initial application (Liu et al. 2017).  
Upon close evaluation of each of these models and evaluation of preliminary data, 
we have chosen to implement the magnetic microbead model of OHT. We have adapted 
the procedures used by Foxton et al. and Bunker et al. (Foxton et al. 2013; Bunker et al. 
2015). 
 Assessing Glaucomatous Damage 
Typically, when evaluating a treatment for glaucoma, rodent models rely on 
molecular assays and RGC quantification instead of evaluating visual or retinal function 
(Chen et al. 2011; Wareham et al. 2019; Yang et al. 2012; Foxton et al. 2013). These 
include measurement of anterograde axonal transport (Lambert et al. 2011), 
immunohistochemical analysis of protein levels (Inman et al. 2013), and/or qualitative 
fundus and histological examinations (Levkovitch-Verbin et al. 2002). Visual and retinal 
function are rarely assessed in glaucoma studies (Ishikawa et al. 2015). Here we review 
several possible outcome measures to assess glaucomatous damage. 
 Morphological Outcome Measures 
 17 
1.5.1.1 RGC Axon Counts 
Quantification of RGC axons is currently the gold standard for analyzing 
glaucomatous damage in animal models, since studies suggest that up to 25-35% RGC loss 
can occur before a significant decrease in visual function outcomes can be detected 
(Medeiros et al. 2013) using tests such as electroretinography (ERG) and optomotor 
response (OMR) (see below). Healthy axons present a homogeneous texture and light 
interior color surrounded by a thin myelin sheath and relatively simple shapes resembling 
ellipses or circles (Figure 6A). Degenerating axons present darker and irregular interior 
color and texture and are surrounded by much thicker myelin sheaths and/or show highly 
irregular shapes (Figure 6B)(Read and Govind 1997). 
Currently, manual counting performed by an expert is considered the most reliable 
method for quantification of optic nerve axons. However, as rat optic nerves contain tens 
of thousands of axons (Templeton et al. 2014), manual counts are extremely time- and 
labor-intensive. Indeed, it is possible to count only part of the full nerve cross section, and 
thus investigators extrapolate such limited counts to estimate the full count. This approach 
Figure 6: Optic nerve cross sections with healthy (A) and severely damaged (B) RGC axons. 
Healthy axons have a homogeneous interior surrounded by a uniform myelin sheath. Damaged 
axons have heterogeneous interiors and are typically hyper-myelinated. Scalebar is 10µm. 
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saves time but suffers from inevitable counting variability within and between experts. 
Another method, the semi-automated approach, combines human selection of regions of 
homogeneous damage and computer-assisted counting within those regions (Marina, Bull, 
and Martin 2010b). Although more desirable than full or partial manual counts, a fully 
automated technique remains preferable to a semi-automated approach. 
Fully automated counting methods attempt to provide counts with higher 
repeatability in a shorter time than manual or semi-automated counting. Existing automated 
counting software such as AxonMaster (Reynaud et al. 2012) involve thresholding and 
edge-finding algorithms targeting myelin sheaths, as they are darker and easily 
distinguishable from the optic nerve extracellular matrix. AxonMaster has been validated 
for use in healthy and glaucomatous non-human primate ONs, but not in rodents.  
Therefore, for this work, we developed a machine learning-based algorithm to 
automatically count normal RGC axons in rodents and non-human primates (described in 
Appendix A). 
1.5.1.2 Optical Coherence Tomography 
Optical Coherence Tomography (OCT) is an interferometric imaging technique 
used to visualize, among other tissues, the retinal layers and ONH in vivo (Szigeti et al. 
2014; Schuman, Hee, Arya, et al. 1995). Glaucoma can be clinically diagnosed using OCT 
imaging to visualize structural changes at the ONH and retinal thinning (Quigley and 
Sommer 1987; Schuman, Hee, Puliafito, et al. 1995). Although it is difficult to accurately 
measure rat retinal thickness using OCT, studies have been able to resolve changes in 
retinal thickness measurements using OCT in glaucomatous rats (Feola et al. 2019; Nagata 
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et al. 2009). Thickness measurements using OCT also have been correlated to thickness 
measurements in paraffin-embedded sections (Figure 7), adding to the reliability of this 
metric (Nagata et al. 2009). 
 
 Functional Assessment of Glaucomatous Damage 
Functional assessments are incredibly important when evaluating a potential 
treatment for glaucoma, since one must ensure that a proposed treatment has in fact 
preserved some visual function. The optomotor response (Prusky et al. 2004; Douglas et 
al. 2005) evaluates visual acuity and contrast sensitivity and is important to evaluate retinal 
toxicity (Redfern et al. 2011). This technique has recently been applied to assess 
glaucomatous damage in rats (Sapienza et al. 2016; Feola et al. 2019). Sapienza et al. 
induced OHT using episcleral vein cauterization and found a significant decrease in spatial 
frequency threshold at 7 days after induction (Sapienza et al. 2016). Feola et al. used the 
hypertonic saline/Morrison model of glaucoma to induce OHT and obtained significant 
deficits in both spatial frequency and contrast sensitivity at 4 weeks after induction (Feola 
et al. 2019). 
Figure 7: Paraffin-embedded retinal section (left) and corresponding in vivo OCT (right) from rat. 
Arrows indicate a major blood vessel. Scale bar, 50 μm. Adapted from (Nagata et al. 2009). 
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The electroretinogram (ERG) is a tool to evaluate function of specific retinal 
neuronal layers using flash stimuli of varying intensities. Extensive research on ERG 
parameters by Porciatti, Bui, Fortune, et al. have led to several different procedures that 
can be used to selectively stimulate RGCs. These include analysis of the photopic negative 
response (PhNR), scotopic threshold (STR), and a variation of the ERG called the pattern 
ERG (Porciatti et al. 1996; Bui and Fortune 2004). Although the pattern ERG is widely 
used to assess RGC damage, we did not have access to an in-house validated pattern ERG 
experimental set-up. Therefore, I will explain the two former assessment techniques which 
use a full-field ERG. 
 
The PhNR is the negative potential that follows the b-wave in light-adapted 
(photopic) ERGs (Viswanathan et al. 1999). Clinical studies have shown significant 
reduction in the PhNR amplitude in glaucoma patients (Figure 8A), even when visual 
sensitivity losses are minimal (Viswanathan et al. 2001). However, is debate about whether 
the PhNR of rodents is affected after induction of OHT (Bui and Fortune 2004; Porciatti 
Figure 8: Representative ERG waveforms from human (Viswanathan et al. 2001) and rat (B) eyes. 
A) Human ERG intensity series from age-matched normotensive eye and glaucomatous eye. B) Rat 
ERG from normotensive control and ocular hypertensive eye 7 days after microbead injection 
(Huang et al. 2018). A, b, and PhNR labels denote the a-wave, b-wave, and photopic negative 
response (PhNR) of each waveform, respectively. The decline in the PhNR amplitude is 
qualitatively more apparent in the human case when compared to the rat case. 
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2015). Huang et al. have evaluated changes in the PhNR after inducing OHT using the 
microbead model of glaucoma and found a significant decrease (Figure 8B)(Huang et al. 
2018). In contrast, Liu et al. did not find any significant changes after using an optic nerve 
crush model in mice (Liu, McDowell, et al. 2014). We have also measured the PhNR in 
OHT eyes after using the microbead model of glaucoma. We failed to find any significant 
differences in PhNR amplitude, even when there was significant loss of visual function 
measured via OMR (data not shown). Therefore, we hypothesize that changes in a rat’s 
PhNR after OHT may be more difficult to quantify than in humans, as we can qualitatively 
see in Figure 8.  
Another outcome measure used to assess RGC function is the STR (Bui and Fortune 
2004). The dark-adapted full-field ERG response at very dim flash intensities, also known 
as the scotopic threshold, has been shown to be due to RGCs in several different animals, 
including rats (Bui and Fortune 2004). Within the STR, there exists positive and negative 
potentials, known as the pSTR and nSTR, respectively. Bui et al. have also shown that the 
pSTR appears to be more sensitive to OHT damage than the nSTR (Bui and Fortune 2004). 
In our preliminary studies, we have found similar results, i.e. the pSTR appears to be 
affected before the nSTR when inducing OHT using the microbead model of glaucoma 
(data not shown).  
From these literature studies, we have identified an ERG protocol to assess RGC 
function (STR), as well as two OMR outcome measures to assess visual function (spatial 
frequency and contrast sensitivity). These functional outcome measures, along with 
morphological outcome measures (RGC axon counts and retinal thickness) will be used to 




 Aim 1: Evaluate the efficacy of potentially biocompatible non-
photoactivated collagen crosslinking agents on posterior rat sclera ex 
vivo. 
Various natural collagen crosslinkers have been used to stiffen collagenous ocular 
tissues ex vivo. However, the dose-response relationship for these agents has not been 
explored nor evaluated for use in rat sclera. Approach: Rat eyes will be partially incubated 
overnight in one of three different crosslinking agents at varying concentrations ex vivo. 
We will use whole globe inflation tests to determine the relative stiffness between treated 
and untreated regions of the eyes. We will use these data to develop dose-response curves 
for each agent and select which candidate crosslinking agent provides the most viable and 
efficacious results for our in vivo studies. Impact: The mechanical results will: i) 
demonstrate the first use of collagen crosslinking agents to stiffen the rat sclera ex vivo, 
and ii) provide information on the effective dosage required to stiffen the posterior sclera 
by a desired amount.  
 Aim 2: Optimize the in vivo delivery technique of a chosen stiffening 
agent selected in Aim 1, and characterize the resulting duration of 
increased scleral stiffness, and potential adverse effects in vivo. 
Although considered biocompatible, there have been no studies to evaluate the 
potential toxicity of our candidate crosslinking agents, nor of the longevity of the resultant 
increased scleral stiffness. Approach: After selecting a crosslinking agent based on data 
from Aim 1, we will determine the injection approach, volume, and concentration that 
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optimize the effects of the stiffening agent on the posterior globe. Animals will be 
sacrificed at 1 day and 4 weeks post-injection and we will perform whole globe inflation 
tests on enucleated eyes to determine stiffening effects in the posterior sclera relative to the 
contralateral sham-treated control eye. Evaluation of adverse effects will be determined by 
visual acuity assays including electroretinography (ERG) and optomotor response (OMR) 
at 0, 1, 2, and 4 weeks post-injection. We will assess damage RGC damage by creating 
machine-learning based software to automatically count normal RGC axons in optic nerve 
sections. Impact: We will determine an optimal delivery technique, the resulting longevity 
of scleral stiffening, and any cytotoxic effects due to the stiffening agent. This will inform 
any future studies utilizing this agent in the eye, as well as Aim 3.  
 Aim 3: Determine efficacy of stiffening the posterior sclera as a possible 
neuroprotective therapy in glaucoma. 
In a rat model of glaucoma, we will stiffen the sclera, induce ocular hypertension and 
evaluate retinal and visual acuity throughout a two-week study, assess retinal ganglion cell 
morphology, and confirm scleral stiffening. Approach: We will inject our chosen 
stiffening agent using the methodology determined in Aim 2 and then induce ocular 
hypertension using a rat model of glaucoma. Over the course of the 14 day study, we will 
measure intraocular pressure regularly, evaluate retinal and visual function using ERG and 
OMR weekly, and assess retinal morphology through optical coherence tomography 
(OCT) imaging. After sacrifice, we will conduct RGC axon counts from optic nerve cross 
sections and perform whole globe inflation testing to verify the success of scleral stiffening. 
Impact: These assays will allow us to determine whether delivery of a stiffening agent to 
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the posterior sclera provides neuroprotection in glaucomatous eyes; if successful, this work 
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 Abstract 
The concept of scleral stiffening therapies has emerged as a novel theoretical 
approach for treating the ocular disorders glaucoma and myopia. Deformation of specific 
regions of the posterior eye is innately involved in the pathophysiology of these diseases, 
and thus targeted scleral stiffening could resist these changes and slow or prevent 
progression of these diseases. Here, we present the first systematic screen and direct 
comparison of the stiffening effect of small molecule collagen cross-linking agents in the 
posterior globe, namely using glyceraldehyde, genipin, and methylglyoxal (also called 
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pyruvaldehyde). To establish a dose-response relationship, we used inflation testing to 
simulate the effects of increasing intraocular pressure in freshly harvested rat eyes stiffened 
with multiple concentrations of each agent. We used digital image correlation to compute 
the mechanical strain in the tissue as a metric of stiffness, using a novel treatment paradigm 
for screening relative stiffening by incubating half of each eye in cross-linker and using the 
opposite half as an internal control. We identified the doses necessary to increase stiffness 
by approximately 100%, namely 30 mM for glyceraldehyde, 1 mM for genipin, and 7 mM 
for methylglyoxal, and we also identified the range of stiffening possible to achieve with 
such agents. Such findings will inform development of in vivo studies of scleral stiffening 
to treat glaucoma and myopia.  
 Introduction 
Vision loss has been ranked in patient surveys as the worst possible type of health 
outcome, equivalent to a diagnosis of cancer, HIV/AIDS, and losing a limb (Scott et al. 
2016). It is therefore unfortunate that there is no known cure for either glaucoma, the 
second leading cause of blindness (Tham et al. 2014), or myopia, the most common vision 
disorder (Foster and Jiang 2014) with incidence rates approaching 90% in some countries 
(Morgan, Ohno-Matsui, and Saw 2012). Although both diseases can be treated, these 
treatments are not successful in all patients and are not a true cure. In glaucoma, for 
example, 25-45% of patients continue to lose vision even with treatment (Anderson et al. 
2001; Heijl et al. 2002; Noecker 2006). At present, all therapies for glaucoma are based 
upon the notion of reducing intraocular pressure (IOP); when these approaches fail, there 
is no alternative treatment paradigm. Thus, there is significant clinical need for novel 
treatments for vision loss from glaucoma and myopia. 
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Some evidence suggests that stiffening the sclera may be a beneficial treatment for 
these diseases (reviewed extensively in (Campbell, Coudrillier, and Ethier 2014)). In 
glaucoma, the elastic modulus of the peripapillary sclera (the region immediately 
surrounding the optic nerve) has been shown in computer models and physical tests to 
strongly influence deformation of the lamina cribrosa, the region where axonal damage 
first starts (Campbell, Coudrillier, and Ethier 2014; Sigal, Flanagan, and Ethier 2005; 
Anderson and Hendrickson 1974; Quigley and Anderson 1976; Coudrillier, Campbell, et 
al. 2016; Coudrillier, Geraldes, et al. 2016). In myopia, the stiffness of the sclera may play 
a role as well, although conflicting data exists, warranting further study (Grytz and 
Siegwart 2015; Phillips and McBrien 2004). Finally, corneal stiffening is currently used as 
a clinical treatment for keratoconus (Goldich et al. 2012), suggesting that the eye can 
tolerate local modulation of the stiffness of its collagenous tissues. 
Pursuant from this evidence, in vivo testing of scleral stiffening therapies for 
disorders of the posterior eye is indicated. This requires dose-response relationships for 
suitable such agents to be well understood. Collagen crosslinking agents have been used in 
the orthopedic and ophthalmic literature to modulate stiffness, and based upon this 
evidence, three agents have emerged with potential for posterior eye scleral stiffening: 
glyceraldehyde (Danilov et al. 2008; Hwang et al. 2013; Kimball et al. 2014; Spoerl, 
Boehm, and Pillunat 2005; Wollensak and Iomdina 2008a, 2008b; Wollensak and Spoerl 
2004; Mattson et al. 2010), genipin (Avila and Navia 2010; Hrabchak et al. 2010; Hwang 
et al. 2011; Liu, Luo, et al. 2014; Liu and Wang 2013; Wang and Corpuz 2015; Wong et 
al. 2012; Xu, Chow, and Zhang 2011), and methylglyoxal (Spoerl, Boehm, and Pillunat 
2005; Stewart et al. 2009; Wong et al. 2012) (also called pyruvaldehyde). Glutaraldehyde 
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is known to increase scleral stiffness (Coudrillier, Campbell, et al. 2016; Kimball et al. 
2014) but is toxic in vivo (Ballantyne and Myers 2001), and riboflavin, used in treatment 
of keratoconus, requires ultraviolet light to induce crosslinking (Goldich et al. 2012), which 
adds complications for posterior eye delivery in a clinical setting. 
Although these agents have been identified and studied in an ocular context, no 
studies to date have directly compared the dose-stiffening relationship of all these agents 
for sclera. A few studies have examined multiple agents (Spoerl, Boehm, and Pillunat 
2005; Wong et al. 2012) or more than two concentrations of a single agent (Avila and Navia 
2010; Liu and Wang 2013; Stewart et al. 2009) side by side, but the paucity of agents 
interrogated with identical testing methodologies limits the ability to widely compare the 
dose-stiffening relationship of scleral collagen crosslinking agents. Given the prevalence 
and acceptance of rodent models in pre-clinical studies of treatments for vision disorders, 
there is also significant need for a well-characterized dose of scleral stiffening agents to be 
used in animal trials. Here, we hypothesize that incubation in collagen cross-linking agents 
will locally reduce the strain in the sclera resulting from elevated IOP in a dose-dependent 
manner. In this study, our specific objective is to determine the dose-response of each 
agent’s effect on scleral stiffness with a goal of approximately doubling scleral stiffness 
(roughly the magnitude observed in prior trials (Kimball et al. 2014)) for future use in vivo. 
 Methods 
 Animals 
Eyes were freshly harvested from a total of 67 euthanized male, retired breeder 
(approximately 9–12 months old) Brown Norway rats (Charles River Laboratories, Inc., 
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Wilmington, MA) that were otherwise experimentally naïve. All procedures were approved 
by the Institutional Animal Care and Use Committee at the Georgia Institute of 
Technology, and all experiments were performed in compliance with the ARVO Statement 
for the Use of Animals in Ophthalmic and Vision Research. Female retired breeders were 
not used in this initial study, as estrogen is known to modulate collagen density and 
turnover with mechanical consequences (Wei et al. 2012), and female rats that have had 
numerous litters (such as retired breeders) may have atypical estrogen levels. Further work 
will consider animals of both genders. 
Based upon the results of preliminary studies performed during methods 
development, we used an a priori power analysis to estimate that we needed 3 
rats/concentration/agent (nested 2-factor ANOVA [agent and concentration]; α=0.05; ratio 
of treatment effect to error effect size = 1.2; 95% power). To be conservative, we harvested 
5 eyes per group and used all that were not excluded due to methodological problems (e.g. 
puncture while cleaning or air bubble when inflating) except for two groups where we 
harvested 8 eyes (62.5 mM and 125 mM glyceraldehyde). Eyes were randomized. 
 Tissue Preparation 
1.12.2.1 Stiffening Agents 
Stiffening agents and administered concentrations were chosen based on published 
studies (Avila and Navia 2010; Danilov et al. 2008; Hrabchak et al. 2010; Hwang et al. 
2013; Hwang et al. 2011; Kimball et al. 2014; Liu, Luo, et al. 2014; Liu and Wang 2013; 
Mattson et al. 2010; Spoerl, Boehm, and Pillunat 2005; Stewart et al. 2009; Wang and 
Corpuz 2015; Wollensak and Iomdina 2008a, 2008b; Wollensak and Spoerl 2004; Wong 
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et al. 2012; Xu, Chow, and Zhang 2011). We used three agents: Genipin (078-03021, Wako 
Pure Chemical Industries, Ltd., Richmond, VA), Glyceraldehyde (G5001-5G, Sigma-
Aldrich Corp., St. Louis, MO), and Methylglyoxal (W296902-100G, Sigma-Aldrich Corp., 
St. Louis, MO). Several concentrations (Table 1) of each agent were used to establish a 
dose-response curve of concentration and relative stiffness. All dilutions were made in 
phosphate-buffered saline (PBS) except for glyceraldehyde, which was made at stock 
concentration (500 mM) in deionized water to obtain an osmolality similar to extracellular 
fluid, then diluted further with PBS. 
 
 
Stiffening Agent Concentration (mM) Concentration (% w/v in PBS) 
Genipin 0.25, 0.50, 1.0, 7.5, 15, 30 0.006, 0.011, 0.023, 0.170, 0.339, 0.679 
Glyceraldehyde 10.0, 30.0, 62.5, 125 0.090, 0.270, 0.563, 1.126 
Methylglyoxal 3.5, 7.0, 14 0.025, 0.050, 0.101 
Table 1: Concentrations of all stiffening agents tested. 
 
Figure 9: Eyes were partially immersed in cross-linking agents, exposing approximately half the 
eye to a stiffening agent overnight by mounting it in a trimmed pipette tip (A). Genipin, which is 
also used as a blue dye, provides a visual indicator of its location (B). This is closely localized to 
the treated region and demonstrates little evidence of wicking. Regions appearing blueish near the 
top of panel (B) are actually thin regions of translucent sclera where choroid is visible, not regions 
exposed to genipin. Eyes were then incubated overnight while misting the tissue-draped control 
half with PBS to keep it moist (C). Dashed line indicates limbus. 
 32 
1.12.2.2 Partial Incubation Technique 
Intact eyes were incubated in stiffening agents overnight, such that half the sclera 
was immersed in the stiffening solution (treated) and the other half (control) was moistened 
by PBS. Freshly harvested rat eyes were cleaned under a dissecting microscope by 
carefully removing excess fat, connective tissue, and musculature from the posterior sclera. 
A 3 ml polypropylene transfer pipette (225, Samco Thermo Scientific, Waltham, MA) was 
then trimmed to yield a cone approximately the diameter of the eye (approximately 6.5 
mm). The eye was then gently placed into the cut pipette with the anterior-posterior axis 
(identified by the position of the optic nerve) parallel to the cut 
Figure 9A) with the ophthalmic blood vessels aligned with the cut and serving as 
natural landmarks to aid in identifying the scleral region exposed to stiffening agent. Two 
small (approximately 1 mm diameter) droplets of glue (Loctite Super Glue Ultragel 
Control, Henkel Corporation, Westlake, OH) were applied to the cornea with a toothpick, 
attaching the cornea to the pipette, and a third droplet was carefully applied to the face of 
the distal optic nerve so that no glue touched the sclera. Drops of PBS were applied to keep 
the eye moist during handling. Stiffening agent (Table 1) was injected slowly into the 
pipette tip with a hypodermic needle until all air was evacuated. 
Once the pipette was filled with the agent, a small rectangle (4 x 8 mm) of paraffin 
film was tightly wrapped around the opening at the bottom of the pipette to prevent any 
stiffening agent from leaking out. A Kimwipe was cut into a 5 x 5 cm cross shape, wetted 
with PBS, draped over the top of the eye, and then wetted with PBS to maintain moisture 
in the region not immersed in stiffening solution. The entire assembly (pipette, eye, and 
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Kimwipe) was then placed into a PBS-filled 1.5 ml microtube with the dangling strips of 
the Kimwipe allowing PBS to wick up to keep the control portion of the eye moist. To 
further maintain physiological conditions overnight, the microtube was placed in a floating 
rack in a 37°C water bath (Precision Shallow Chamber Water Bath 280, Thermo Scientific, 
Waltham, MA) and misted from above (Monsoon RS400, EXO TERRA, Mansfield, MA) 
every 3 minutes with PBS (Figure 9C). Eyes were carefully removed from the tube the next 
day (approximately 16 hours incubation time) and mounted for inflation testing. 
 Inflation Testing 
Stiffening agents were evaluated by comparing mechanical strain measurements 
(stiffened vs. control regions) during whole globe inflation tests. We modulated the 
intraocular pressure of each eye while submerged in a PBS bath at physiological 
temperature. Calibrated stereo cameras (including compensation for refraction through 
PBS) imaged a speckle pattern on the surface of the eye throughout the inflation test, and 
3D digital image correlation (DIC) was used to quantify surface strain (Q-400 DIC, Dantec 
Dynamics, Holtsville, NY). 
1.12.3.1 Testing Chamber Construction 
The eye was submerged in a temperature controlled, PBS-filled plastic chamber 
(Kritter Keeper, Lee’s Aquarium & Pets, San Marcos, CA) during experimentation. To 
model physiological conditions ex vivo, the temperature of the PBS in the chamber was 
maintained at 37°C ± 2°C throughout the experiment by pumping saline through a 
thermoelectric heater assembly (LA-045-24-02-00-00, Laird Technologies, London, UK; 
temperature controller TC-XX-PR-59; measured by thermistor TC-NTC-1 immersed next 
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to the eye) using a peristaltic pump (BT300L, Golander LLC, Duluth, GA; pump head 
DT15-44; tubing #25 [ID 4.8 mm, OD 8 mm]) at 60 ml/min. This low flow rate was 
selected so as not to produce any turbulence and resultant optical distortion in the PBS 
around the eye. 
To avoid evaporation of PBS during experimentation, a 1/8” thick borosilicate glass 
sheet was placed over the chamber and warmed to 70°C to prevent condensation (3682K25, 
McMaster Carr, Douglasville, GA; PID controller 36815K71). The mounted eye was then 
illuminated from above with dual gooseneck lighting (Mi-LED-US-DG, Dolan-Jenner 
Industries, Boxborough, MA). 
An adjustable-height pressure reservoir (Sherwood et al. 2016) was connected to 
the base of the chamber through silicone tubing connected to a bulkhead fitting. This 
presented a female luer connection on the inside surface of the chamber where we could 
attach mounted eyes and modulate their IOP using hydrostatic pressure. 
1.12.3.2 Mounting Procedure 
Prior to experimentation, custom-made mounting blocks (Figure 10) were 
manufactured from acrylic sheets (8560K369, McMaster Carr, Douglasville, GA). A 1/4” 
diameter ball end mill created a hemispherical cradle for rat eyes, and a thin channel was 
drilled through the block with a 1/16” drill bit. This hole was widened opposite the 
indentation for the eye using a 3/16” drill bit that could accept a luer fitting adaptor 
Following overnight (16 hours) incubation, the orientation of the eye relative to the 
solution was recorded. The cornea was blotted dry with a Kimwipe, and a small, continuous 
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bead of gel superglue was applied along the inner rim of the mounting block hemisphere. 
The eye was then placed onto the hemisphere, cornea-side down, with the optic nerve 
centered upwards, and excess glue was scraped away. The mounting block was marked 
with a waterproof marker to record the region of the eye that was incubated in stiffening 
solution. 
 
In order for DIC to evaluate displacements, a speckle pattern must be applied to the 
tissue. For this study, the speckle pattern was applied to the posterior sclera with graphite 
powder (#970 PG, General Pencil Company, Inc., Redwood City, CA). Graphite was 
poured onto a fine mesh sieve (Tensile bolting cloth #60, Amazon) and an airbrush was 
used to blow the powder through the sieve onto the external surface of the eye and allowed 
to dry briefly. This method was repeated until the graphite powder formed a speckle pattern 
that did not detach from the surface of the eye when submerged in PBS. Eyes were 
immersed in ice-cold PBS until testing began. 
Figure 10: Side view of acrylic mounting block. Eyes are placed in the hemisphere at top, and a 
threaded luer fitting mates with the hole in the bottom. 
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1.12.3.3 Experimental Procedure 
Prior to testing each day, the PBS chamber was filled and heated to temperature, 
and the intrinsic stereo calibration parameters of the cameras were determined using a 
standardized checkerboard calibration target. To inflate the eye, the cornea was punctured 
by inserting a 1 mm biopsy punch through the 3/16” hole in the mounting block and 
twisting gently until slight collapse of the eye was observed. Care was taken to ensure the 
eye not detach from the mounting block, nor the biopsy punch deeply penetrate the eye. A 
threaded male luer fitting (EW-45505-84, Cole-Parmer, Vernon Hills, IL) was then glued 
into the 3/16” hole. 
The pressure reservoir was set to the height corresponding to the baseline IOP of 3 
mmHg (approximately the minimum necessary to prevent the eye globe from buckling 
under its own weight). PBS was injected through polyethylene tubing into the lumen of the 
mounting block to purge all air bubbles. The eye was then submerged in the PBS chamber 
25 mm below the surface, imparting an external pressure of approximately 2 mmHg to the 
eye, and attached to the luer fitting at the base of the chamber connected to the pressure 
reservoir. Extrinsic camera calibration parameters were then determined after the eye was 
mounted to account for refraction through the borosilicate glass sheet and PBS (Kunz and 
Singh 2008). 
Effective IOP was calculated by subtracting the external pressure on the eyes (2 
mmHg from the tissue bath) from the internal hydrostatic pressure from the reservoir. 
Images were captured every 30 seconds at an exposure time of 20 milliseconds for 30 
minutes (see DIC system characterization results) at each of 3 pressures: 3 
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(low/hypotensive IOP), 13 (normal/normotensive IOP), and 28 mmHg (high/hypertensive 
IOP). The pressure reservoir was raised after each set of 60 images to the next height via 
stepper motor at a speed of 5 mm/second. Eyes were not preconditioned prior to inflation 
testing. 
 Strain Calculation 
Dantec’s Istra 4D software (v4.4.1) was used to compute displacement and 
resulting principal strains from the image dataset using DIC. Correlation settings were: 99 
pixel facets, 45-pixel grid spacing, maximum permissible start points accuracy 0.2 pixels, 
residuum of 30 gray values, and 3D residuum of 1.1 pixels. All strain calculations were 
performed from smoothed displacement data using a 2D bicubic spline function to the data 
set. The grid reduction factor (minimizes the difference between the data point and the 
spline function) was set to 3 for displacement and 2 for contours, and the smoothness factor 
(straightens the filtered data) was set to 0 for both items. 
Strain was computed relative to the reference state (3 mmHg after 30 minutes). 
Exported strain data for each image was then segmented (Figure 11) in custom MATLAB 
software (R2016a, MathWorks, Natick, MA) by manually tracing the experimental and 
control regions of the posterior sclera (excluding the optic nerve) based upon the markings 
made on the mounting block prior to testing. Relative stiffness as a percent change between 
Eexp (elastic modulus in the experimental region) and Econ (elastic modulus in the control 
region, see Appendix B for derivation) was defined as: 
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× 100% (1) 
where εcon represents strain in the control region and εexp represents strain in the stiffened 
region. The calculation was performed following outlier removal, as described in Data 
Analysis 
 
 Data Analysis 
DIC data is noisy, particularly when dealing with small strains, as tiny errors in 
displacements become amplified in strain computations. Although smoothing 
displacements helps minimize this type of error, we required outlier detection to remove 
spurious data points. Having verified that the data was normally distributed within both the 
experimental and control regions of each eye at each time point (Anderson-Darling 
Figure 11: Digital image correlation was used to spatially resolve the surface strains in individual 
eyes. At left, the speckle pattern on the posterior sclera is overlaid with manually-traced masks 
(made prior to calculating strain) denoting the locations treated with cross-linking agent or PBS 
as a control, taking care not to include the optic nerve. At right, we have overlaid these same masks 
on the computed surface strains at an inflation pressure of 13 mmHg (normotensive). Regions of 
comparatively low and high strain match closely with the treatment and control zones. 
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normality test, p>0.05), the median absolute deviation (MAD) was calculated according to 
1.4826 times the median of the absolute values of the difference between each data point 
and the median (Leys et al. 2013). Any values that were more than 2 MADs away from the 
median were considered to be outliers and removed from the data set. 
We then computed the mean and standard deviation of the 1st principal Lagrange 
strain, as this metric is sensitive to deformation in the direction of local stretching were 
then calculated for a given control or experimental region at each time point. The primary 
deformation mode of a spherical eye is expected to be a hoop deformation, which would 
result in in-plane extension of the sclera; thus, the principal Lagrange strains should capture 
this effect. Following outlier removal, we used a weighted linear fit of this strain metric 
(weighted by 1/σ2) using Matlab’s lmfit function using strains from the final 10 minutes 
at normotensive and hypertensive IOPs each. If the slope of this fit was above 0.5 
millistrain (mStrain) per minute, we assumed the eye was creeping and had not reached its 
steady state, and thus the eye was discarded from further analysis (2 of 73 total inflation 
tests were excluded under this criterion). We then recorded the intercept of fits that were 
not excluded as well as the 95% confidence interval of the intercept of this fit as an 
indication of the uncertainty of the test. 
Finally, we used equation 1 to compute the relative stiffness at normotensive and 
hypertensive IOPs for both the control and experimental halves of the eye. Using a nested 
2-factor ANOVA (relative stiffening as a function of pressure nested within concentration; 
R 3.3.1), we compared the relative stiffness of each ocular region as a function of treatment 
and inflation pressure. 
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 Results 
 DIC System Characterization: 
We characterized two aspects of our inflation testing system. First, to estimate the 
baseline correlation noise of the system, we speckled a glass sphere approximately the 
same radius as a rat eye (3.25mm radius, 8996K25, McMaster-Carr), immersed it in our 
PBS bath, and imaged it for 8 hours. Noise was < 2 mStrain, indicating this level as the 
minimum resolvable strain magnitude.  
To study the viscoelastic relaxation of pressurized rat eyes, we also imaged an 
untreated pair of rat eyes at pressure levels corresponding to baseline/hypotensive, 
normotensive, and hypertensive IOPs (3, 13, and 28 mmHg) for 2 hours per pressure level. 
We fit a standard Kelvin-Voigt model of viscoelastic relaxation 
 
𝜖(𝑡) = 𝐴 (1 − 𝑒−
1
𝜏
𝑡) + 𝐶 (2) 
to this strain ε as a function of time t in Matlab with fitting constants A, C, and τ, and we 
found that the time constant τ was approximately 1 minute. Out of abundance of caution, 
specifically to avoid confounding our stiffness findings with biomechanical creep of the 
scleral shell, we thus maintained our treated eyes for 30 minutes at these same three 
pressure levels and only analyzed data from the final 10 minutes of each pressure step. 
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1.13.1.1 Partial Immersion of Eyes in Collagen Crosslinking Agents: 
Eyes were partially immersed in various stiffening agents overnight such that 
approximately half the eye was exposed to the collagen cross-linking agent and the other 
half to PBS as a control. Genipin, which is also used as a blue dye, acted as a visual reporter 
of its presence, confirming that the agent stayed constrained to the incubation region and 
did not diffuse or wick into the control region (Figure 9B). We also visually confirmed that 
agents did not adversely affect the structure of the eye. In preliminary experiments (not 
shown), we incubated eyes overnight in 500 mM glyceraldehyde, as has been done 
previously (Kimball et al. 2014; Spoerl, Boehm, and Pillunat 2005; Wollensak and Iomdina 
2008a). However, the eyes were visibly dehydrated the following day. We calculated that 
the osmolarity of 500 mM glyceraldehyde is approximately 800 mOsm, whereas the 
osmolarity of aqueous humor and PBS is about 300 mOsm (Agarwal, Agarwal, and Apple 
2002). Thus, we diluted the glyceraldehyde and only used lower concentrations in these 
experiments. 
 Average Strain Magnitudes: 
In almost all eyes, the mean 1st and 2nd principal strains (representing stretch in the 
direction of greatest local deformation and the stretch orthogonal to this direction, both 
tangent to the surface of the eye) in the control half the eye were on the order of 40-150 
mStrain at 13 and 28 mmHg, respectively, relative to the reference configuration at 3 
mmHg. These strain values are well above the noise floor of our system. In the stiffened 
half of the eye, strains were lower, generally 10-50 mStrain, again above the noise floor. 
Strains stabilized within minutes of a change in pressure in all but 2 cases, and the 
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difference in strain between baseline/hypotensive and normotensive pressures was always 
considerably larger than between the normotensive and hypertensive pressures (Figure 12). 
2nd principal strains in the posterior sclera were approximately half the magnitude of 1st 
principal strains, consistent with current understanding that there is a direction of 
preferential collagen fiber alignment but that the posterior sclera is quasi-transversely 
isotropic tangent to the scleral surface (Baumann et al. 2014). The distribution of strains 
within each region at any given timepoint followed a normal distribution (Anderson-
Darling test; p>0.05). 
 
Figure 12: Representative plot of average 1st principal strain as a function of time from a single 
eye during our inflation experiment. Eyes were maintained for 30 minutes at each of 3 pressures 
representing different ranges of IOP. Strains were considerably higher in the control region of eye 
than in the treated region, indicating that the treated region is stiffer. Black overlays represent the 
95% confidence interval about the mean during the final 10 minutes of each pressure step, when 
the eye reached steady state. Error bars: standard deviation over the interrogated region. 
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 Relative Stiffening:  
We observed a significant (p = 1.03×10-9) stiffening effect (relative stiffening as a 
function of pressure nested within concentration; Table 2) pooled over all agents. All three 
agents demonstrated a dose-dependent stiffening effect where increasing the concentration 
of the solution increased the relative stiffness of the treated region. However, at very high 
concentrations (for genipin, above 7.5 mM; for glyceraldehyde, above 62.5 mM), 
increasing concentration did not increase stiffness. For genipin (Figure 13A), we observed 
stiffness increases between 14.7% and 1320%. For glyceraldehyde (Figure 13B), stiffness 
increased between 21.8% and 273%, and for methylglyoxal (Figure 13C), stiffness 
increased between 11.9% and 310% at the concentrations included in these studies. In order 
to achieve a target increase in stiffness of approximately 100% (Coudrillier, Geraldes, et 
Figure 13: Average 1st principal strains for control (horizontal axis) and stiffened (vertical axis) 
regions of eyes treated with (A) genipin, (B) glyceraldehyde, or (C) methylglyoxal. Each dot 
represents the mean steady-state strain for one eye, and the surrounding oval represents the 95% 
confidence interval of that point from linear fitting. Points falling below the unity line (black line) 
indicate that the treated eye has been stiffened relative to the control, and mutatis mutandis. The 
dotted line represents 100% stiffening. Eyes in red lie very close to the unity line, suggesting that 
this low dose has minimal stiffening effect. Higher concentrations lie farther from the unity line 
until reaching a maximum effective dose around 7 mM for genipin, 62.5 mM for glyceraldehyde, 
and 14 mM for methylglyoxal. Higher concentrations do not further stiffen the experimental half 
the eye but do reduce strain in the control portion of the eye, possibly as result of diffusion into the 
internal tissues of the eye and crosslinking them. 
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al. 2016), the appropriate dose for a rat eye overnight is therefore approximately 1 mM for 
genipin, 30 mM for glyceraldehyde, and 7 mM for methylglyoxal. 
 Discussion 
This study offers the first quantification of the efficacy of scleral stiffening agents 
in the rat eye, a common and important animal model of experimental glaucoma. It also 
offers the first demonstration of the efficacy of genipin and methylglyoxal in the rodent 
eye, an important milestone for use in mice, whose eyes have similar collagen composition 
to rats and are widely used in glaucoma and myopia research. We found that each agent is 
capable of stiffening the sclera by several hundred percent but that there exists an upper 
bound to this stiffening effect. This quantification sets a range on the magnitude one might 
be able to achieve using collagen crosslinking approaches to scleral stiffening. Researchers 
investigating the physiological consequences of scleral stiffening using these agents should 
not expect to increase stiffness by more than several hundred percent. 





(%) at 13 mmHg 
 Relative 






0.25 15 ± 14 19 ± 17 6 
0.5 64 ± 23 54 ± 23 4 
1 108 ± 28 86 ± 16 4 
7.5 1,321 ± 703 577 ± 220 5 
15 503 ± 252 253 ± 130 4 
30 576 ± 164 348 ± 137 5 
Glyceraldehyde 
10 22 ± 26 20 ± 20 4 
30 73 ± 64 55 ± 40 6 
62.5 273 ± 143 165 ± 75 8 
125 192 ± 214 131 ± 120 7 
Methylglyoxal 
3.5 12 ± 20 11 ± 19 4 
7 108 ± 52 81 ± 38 5 
14 310 ± 222 160 ± 119 5 
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While we cannot determine the mechanism causing genipin to achieve its highest 
stiffness around 7 mM and glyceraldehyde around 30 mM from the data at hand, we 
hypothesize that the collagen crosslinking sites have become fully saturated at these higher 
concentrations. Thus, the presence of additional crosslinker may have no further effect. 
Although we did observe a drop in relative stiffness at the highest concentrations of genipin 
and glyceraldehyde in this study, this resulted from a decrease in strain in the control 
portion of the eye without change in the treated portion. Thus, this phenomenon should not 
be interpreted as a drop in efficacy at the highest concentrations. Instead, it is likely that 
the agents at these very high concentrations diffused through the eye into the internal 
tissues or even into the control portions, potentially crosslinking them and reducing strain, 
thereby decreasing the relative stiffness of the eye. 
Our novel approach to treating approximately half an eye with stiffening agent 
overnight while using the other half as a control provides a powerful tool for studying the 
efficacy of small molecule collagen crosslinking agents. Although these agents may diffuse 
outside the desired region of the eye at very high concentrations, we do not believe this is 
a problem at the more moderate concentrations examined in this study. Genipin yields a 
visible blue dye at sites where it is present (Figure 9B), and this color change has previously 
been shown to correlate with scleral stiffness (Liu, Luo, et al. 2014), suggesting its 
relevance as a visual reporter of cross-linking. Glyceraldehyde and methylglyoxal have 
approximately half the molecular weight of genipin, and thus they may diffuse slightly 
faster but are not expected to considerably enter the control half of the eye. Strain maps for 
these eyes similar to Figure 11 show a relatively sharp line of demarcation between the two 
halves. To avoid confounding our analysis with any diffusion effects, however minor, we 
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also avoided including regions closest to the line of demarcation when computing average 
strain. As seen in Figure 11, the perimeters of the regions of interest do not overlap 
perfectly where they come closest to intersecting (there are no points included that are 
underneath the visible perimeters) in order to exclude strain measurements in the transition 
zone. Additionally, it is important to remember that the relatively higher strains in the 
stiffened region close to its boundary with the control region result from cross-linker not 
fully diffusing into this region, so we err on the side of under-diffusion, not cross-linker 
bleed-over. We also used outlier removal to eliminate any data points that deviated 
considerably from the median, such as those resulting from edge effects, and by computing 
the mean relative stiffness from several hundred data points per region after outlier 
removal, the effect of any small bleed-over should be small. 
Our method of using half of each eye as experimental and control groups to 
compute relative stiffening is especially powerful when we consider the inter-eye 
variability in strains in naïve regions of eyes (and confirmed in fully untreated eyes, data 
not shown). Even in two eyes from a single rat, strains in PBS-treated regions can vary by 
a factor of approximately three (see dispersion of data points along X-axis in Figure 11). 
Thus, by using the two halves of each eye as an internal comparison, we can minimize the 
effects of inter-eye variability. While it is certainly true that strains are somewhat 
heterogeneous even within regions of a single eye (as in Figure 11) our technique for 
computing relative strain allows us to only introduce intra-eye variability without adding 
the effect of inter-eye variability to each relative strain calculation. 
An additional benefit of using half the eye as an internal control and making a 
relative comparison is that the need for preconditioning is greatly reduced. Prior work such 
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as that of Wong et al. (Wong et al. 2012) used up to 10 cycles of preconditioning before 
the eye converged to a stable relation between inflation and strain. With our testing 
methodology, we are comparing the relative stiffness of two halves of a single eye such 
that preconditioning effects, or lack thereof, should be approximately uniform between the 
two halves. Thus, the strain magnitudes quantified in this study may not exactly equal 
ocular strains in the rat eye at various magnitudes of IOP, but the relative stiffening effect 
should still be relevant to future in vivo studies in the rat. 
This study focused exclusively on eyes ex vivo, although we took care to freshly 
harvest eyes and maintain them at physiological temperatures during testing. We treated 
eyes overnight in order to simulate the stiffening effect that might result if such agents were 
delivered to the posterior eye within the Tenon’s capsule. However, because this is a 
relatively un-explored frontier of ophthalmology, it is unclear what the body’s clearance 
of such agents would be in vivo. Recently, Kimball et al. investigated the efficacy of 
glyceraldehyde scleral stiffening in vivo in a mouse model of glaucoma and found that its 
use was detrimental to visual function (Kimball et al. 2014). In an attempt to recreate the 
conditions of their study, we first attempted to study eyes incubated in 500 mM 
glyceraldehyde, identical to the Kimball et al. paper. However, eyes became significantly 
dehydrated and collapsed with this treatment, presumably from a significant osmolarity 
mismatch. Such an effect would clearly be problematic in vivo and could explain the 
negative findings of the Kimball study, but active transport of fluids in a living mouse also 
might be able to compensate for any osmolar mismatch. Further investigation is certainly 
warranted. 
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Eyes were freshly harvested from rats daily and randomized to a treatment agent 
and concentration. However, in an effort to ensure that our stiffening solutions were 
freshly-mixed from a stock solution, all eyes studied in a single day (usually 2-3 pairs) 
were incubated in a single agent, although often at different concentrations of that agent. 
Thus, one limitation of the present work is that some treatments were from both eyes of a 
single rat. Although Brown Norway rats are an inbred strain and thus should have low 
genetic variability, as previously mentioned, in initial testing prior to this study using naïve 
eyes (not shown), variability in average strain between two eyes from a single rat were 
high enough that, for this study, we assumed that each eye was an independent sample 
regardless of which rat it came from. 
Although the eyes in this study were all studied within 24 hours of harvest, another 
unknown factor for scleral stiffening therapies is the temporal efficacy of such agents. 
Previously, Wollensak et al. showed that glyceraldehyde increases scleral stiffness for at 
least 8 months in rabbits (Wollensak and Iomdina 2008b), a promising finding. However, 
further work is necessary to characterize the temporal profile of the stiffening agents in this 
study, both in terms of how long the eye must be incubated in order to derive a stiffening 
effect as well as in terms of how long the eye maintains its increased stiffness before 
collagen turnover and remodeling negates the effects of treatment. 
Eyes were incubated in agents for approximately 16 hours each, with an 
unavoidable variability of several hours as result of practical aspects of the eye mounting 
procedure, tissue cleaning, etc. Per Fick’s law, the rate of diffusion into the tissue should 
drop as the concentration of cross-linker equalizes between the solution and the tissue. 
Additionally, we can approximately estimate an upper bound on the effects of different 
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incubation times using the fact that the diffusion distance is proportional to the square root 
of elapsed time, so a deviation of two hours less than our approximated 16 hours would 
lead to a variation in the extent of cross-linking of roughly 8-9% (√14 16⁄ ), considerably 
smaller than the stiffening effects of 100% or more observed in this study. Further study is 
certainly warranted to better characterize the dynamics of cross-linking treatments to ocular 
tissues, but in the present study, we attempted to characterize the role of collagen cross-
linking at various starting concentrations with the understood limitation that some modest 
variability in stiffening may result from variations in tissue preparation. 
Having characterized these three collagen crosslinking agents ex vivo, our next step 
will be to deliver them to rats in vivo to answer the questions raised by this and other 
studies. Future work will need to characterize how well-tolerated these agents are by 
delicate neural tissues of the retina and optic nerve head, as well as by the scleral fibroblasts 
providing collagen turnover in the eye. If the stiffening agents have any sort of toxic effect 
to these components of the eye, it may be necessary to take care to use highly targeted 
delivery of such agents using novel drug delivery techniques. Such approaches might 
involve delivering agents with an activatable reservoir of cross-linker or by flushing away 
agents from undesired locations, but such techniques will need to be evaluated after 
determining whether scleral stiffening offers any benefit for glaucoma or myopia as well 
as which agents are the safest for in vivo use. It will also be important to quantify whether 
the same magnitude of relative stiffening for the concentrations of the agents measured 
here exists in vivo and how long the stiffening is maintained. Most importantly, future 
studies should build upon this foundation in order to evaluate the efficacy of various scleral 
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stiffening approaches for ocular diseases such as glaucoma and myopia in order to improve 
our clinical ability to preserve vision. 
 Conclusion 
Here, we have reported the first direct comparison of the dose-response relationship 
of three stiffening agents in sclera. All three collagen cross-linking agents examined in this 
study, genipin, glyceraldehyde, and methylglyoxal, exhibited dose-dependent stiffening 
behavior, with maximum relative stiffening of several hundred percent at higher 
concentrations. Thus, all 3 agents can be titered to achieve a desired magnitude of 
stiffening. Future studies will examine the efficacy of these agents in vivo to ensure the 
stiffening effect is maintained in longitudinal studies and, more importantly, to assess 
whether scleral stiffening agents protect against vision loss in diseases like glaucoma and 
myopia. 
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 Abstract 
Scleral stiffening has been proposed as a therapy for glaucoma and myopia. 
Previous in vivo studies have evaluated the efficacy of scleral stiffening after multiple 
treatments with a natural collagen crosslinker, genipin. However, multiple injections limit 
clinical translatability. Here, we examined whether scleral stiffening was maintained after 
four weeks following a single genipin treatment. Eyes from Brown Norway rats were 
treated in vivo with a single 15 mM genipin retrobulbar injection, sham retrobulbar 
injection, or were left naïve. Eyes were enucleated either one day or four weeks post-
injection and underwent whole globe inflation testing. We assessed first principal Lagrange 
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strain of the posterior sclera using digital image correlation as a proxy for scleral stiffness. 
Four weeks post-injection, genipin treatment resulted in a 58% reduction in scleral strain 
as compared to controls (p = 0.005). We conclude that a single in vivo injection of genipin 
effectively stiffened rat sclera for at least four weeks which motivates further functional 
studies and possible clinical translation of genipin-induced scleral stiffening. 
 Introduction 
Scleral biomechanical properties are thought to play a role in two major ocular 
pathologies: glaucoma and myopia (Levy, Fazio, and Grytz 2018; Campbell, Coudrillier, 
and Ross Ethier 2014). Glaucoma, the leading cause of irreversible blindness worldwide 
(Cook and Foster 2012), is characterized by the loss of retinal ganglion cells (RGCs) at the 
optic nerve head (ONH). Although the exact etiology remains unknown, a major risk factor 
for glaucoma is elevated intraocular pressure (IOP) (Bengtsson and Heijl 2005). Elevated 
IOP leads to deformation of the ONH, which may negatively affect RGCs via several 
mechanisms, including changes in blood flow and chronic cellular mechanostimulation 
(Burgoyne 2011; Hernandez 2000). Previous work has shown that chemical crosslinking 
of the peripapillary sclera decreased IOP-induced ONH deformation (Coudrillier, 
Campbell, et al. 2016), making scleral crosslinking a potential therapeutic strategy for 
glaucoma patients.  
Scleral crosslinking has also been proposed as a treatment for patients suffering 
from myopia (nearsightedness). Myopia is the most common refractive error and is 
expected to affect nearly half of the world’s population by the year 2050 (Holden et al. 
2016). In myopia, the eye elongates and the sclera becomes weaker and thinner due to 
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active remodeling of collagen (Rada, Shelton, and Norton 2006). Therefore, it is 
hypothesized that scleral crosslinking could slow or reverse the effects of the scleral 
remodeling to prevent late stage complications, more common in cases of high myopia 
(Saw et al. 2005). 
Chemical crosslinking has been widely used to stiffen hydrogels and biological 
tissues (Sung et al. 2000; Yoo et al. 2011; Rowland et al. 2013). Recently, photochemical 
crosslinking of corneal collagen has been approved as an effective clinical treatment for 
keratoconus, in which the cornea becomes weaker and misshapen, resulting in impaired 
visual acuity (Hersh et al. 2017). This treatment uses Ultraviolet-A (UVA) irradiated 
riboflavin to induce crosslinking; however, this method has been shown to be cytotoxic to 
the retina when applied to stiffen the sclera (Glickman 2011; Wollensak et al. 2005). 
Therefore, alternative biocompatible treatments that avoid retinal UVA exposure are better 
suited for scleral stiffening (Backhouse and Gentle 2018).  
Previous research in our lab has investigated the efficacy of three crosslinkers 
(methylglyoxal, glyceraldehyde, and genipin) to stiffen the rat sclera ex vivo (Campbell et 
al. 2017). Of these agents, genipin demonstrated effective stiffening at low concentrations 
and has been reported to be a biocompatible collagen crosslinker (Song et al. 2017; Sung 
et al. 2001). Further, Avila et. al (Avila, Gerena, and Navia 2012) evaluated genipin and 
riboflavin/UVA crosslinking in porcine corneas and found that both treatments yielded 
similar amounts of stiffening and minimal toxicity. Genipin has also been used to 
effectively stiffen tree shrew (Levy, Fazio, and Grytz 2018) and porcine (Wong et al. 2012; 
Liu, Luo, et al. 2014) sclera ex vivo, as well as rabbit (Liu and Wang 2017) and guinea pig 
(Wang and Corpuz 2015) sclera in vivo. A widely demonstrated scleral stiffening effect 
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and high biocompatibility of make genipin an excellent candidate for eventual clinical 
translation.  
The current study presents new support for the use of genipin as a scleral crosslinker 
by demonstrating the ability of a single in vivo genipin injection to produce sustained 
stiffening in the rat (a useful model of ocular disease), with improved mechanical testing 
methods. All previously published in vivo studies have implemented multiple injections of 
genipin over time to stiffen the sclera (Liu and Wang 2017; Wang and Corpuz 2015). To 
assess translational potential, we tested whether scleral stiffness modifications were 
sustained for four weeks after a single injection of genipin. Additionally, these previous 
tests of in vivo genipin treatment have been evaluated by uniaxial strip testing. While these 
biomechanical tests measure intrinsic scleral stiffness, they are known to have significant 
limitations (Lari et al. 2012), including the inability to test the sclera under physiological 
modes of deformation. Thus, we utilized whole globe inflation testing, which more closely 
mimics in vivo scleral loading conditions (Campbell et al. 2017). Since glaucoma is a 
disease that progresses over decades, we were primarily interested in assessing the effects 
of our crosslinking treatment on the mechanical stiffness of the sclera at steady state than 
on assessing scleral viscoelastic properties, although the viscoelastic properties of the 
sclera may also be important in glaucoma due to fluctuations in IOP (Coleman and Trokel 
1969).To focus on steady state properties, we chose a creep test rather than a ramp-hold 
test to assess the effects of our treatment on the sclera. Further, there were technical 
advantages to using a creep test (see Discussion). Finally, no previously published in vivo 
scleral stiffening studies have been conducted using rat eyes. The rat is a widely used model 
for vision research, and has several advantages for use as a glaucoma therapy test bed 
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(Morrison, Cepurna Ying Guo, and Johnson 2011), including the fact that there are 
established methods for inducing rat ocular hypertension that result in glaucomatous 
damage (Bunker et al. 2015; Bouhenni et al. 2012). Furthermore, evidence indicates that 
the rat sclera is structurally similar to that of the human, being composed mainly of collagen 
fibers (Cone-Kimball et al. 2013; Coudrillier et al. 2015) that are organized in a 
circumferential pattern near the optic nerve head and are less organized further from optic 
nerve head (Girard et al. 2011). In addition, the rat affords advantages over other glaucoma 
models. Namely, rat eyes are larger and much easier to test biomechanically than mouse 
eyes, and rats are more amenable for high subject studies compared to monkeys, due to 
their low cost, ease of animal husbandry, and low genetic variability between individuals. 
Rat models of myopia have also been reported (Shinohara et al. 2018; Zhang et al. 2013). 
Therefore, this study represents the successful development of methods to investigate 
genipin-induced scleral stiffening as a therapy for common ocular pathologies in an 
affordable animal model. 
 Methods 
 Overview of Experimental Design  
In brief, rat eyes were treated in vivo with either a genipin or sham retrobulbar 
injection or were left naïve (Figure 14). Eyes were enucleated one day or four weeks post-
injection and prepared for whole globe inflation testing to determine scleral stiffness. 
Whole globes were attached cornea-side down to a mounting block and IOP was controlled 
by raising and lowering a hydrostatic pressure reservoir in fluidic connection with the eye. 
Images were taken of the posterior sclera throughout the inflation test and analyzed by 
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digital image correlation (DIC) software to compute scleral surface displacement and 
strains. Pressure-strain data were fit with a constitutive equation that was then used to 
quantify scleral stiffening. 
 Animals 
This study used twenty-eight retired breeder (male, 6–13 months old) Brown 
Norway rats (Charles River Laboratories, Inc., Wilmington, MA). All procedures were 
approved by the Institutional Animal Care and Use Committee at the Georgia Institute of 
Technology. Some rats from the starting cohort were removed from this study according 
to exclusion criteria, as described below. 
 Scleral Stiffening Procedure 
Rats were anesthetized systemically with ketamine (60 mg/kg) and xylazine (7.5 
mg/kg), and a drop of topical tetracaine (1%) was applied to the eye. Rats were randomly 
assigned to one of two groups for stiffening treatment (Figure 14). The first group 
(HBSS/Naïve) received a single (unilateral) retrobulbar injection of Hank’s Balanced Salt 
Solution (HBSS; 150 µl), while the contralateral eye was left as a naïve control. The second 
group (Genipin/HBSS) received a single retrobulbar injection of genipin (Wako Pure 
Chemical Industries, Ltd., Richmond, VA) mixed in HBSS (15 mM, 150 µl), while the 
contralateral eye received a single retrobulbar injection of HBSS (150 µl). This genipin 
concentration was motivated by our previous ex vivo study (Campbell et al. 2017) and 
recent in vivo work (Table 3) (Liu and Wang 2017; Wang and Corpuz 2015). Eyes were 
randomized to each treatment. After injections, rats were given topical antibiotic (Certi-
sporyn, Kansas City, MO) to prevent infection and antisedan (1 mg/kg) to reverse 
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anesthesia (Turner and Albassam 2005). Genipin/HBSS rats were divided into two 
subgroups and euthanized (via CO2 overdose) either one day or four weeks post-injection. 
enucleated and refrigerated until testing, which always occurred within 6 hours of 
euthanasia. All Naïve/HBSS rats were euthanized one day post-injection. Eyes were 
immediately after euthanasia. 
 
Figure 14: Experimental groups: HBSS/Naïve rats received a single (unilateral) retrobulbar 
injection of HBSS, while Genipin/HBSS rats received a unilateral retrobulbar injection of genipin 
and a unilateral retrobulbar injection of HBSS contralaterally. 
















































 Whole Globe Inflation Testing 
1.19.4.1 Eye Mounting Procedure 
Eyes were carefully cleaned under a dissecting microscope with micro-scissors to 
remove all fat, episclera, and extraocular muscles from the sclera. Since genipin-induced 
collagen crosslinks are known to autofluoresce (Hwang et al. 2011), we then imaged whole 
globes using an epifluorescent scope (Leica DM6 B, Leica Microsystems, Wetzlar, 
Germany) to confirm posterior scleral coverage of genipin crosslinks (Figure 15). 
 
 
Figure 15: Whole globe autofluorescence of HBSS (A) and genipin (B) injected paired eyes from 
Genipin/HBSS rat at four weeks post-injection. The arrow and corresponding outline indicate the 
approximate optic nerve (ON) location on each eye, while the outer dashed outline indicates the 
approximate size of the eye. Asterisks: vessel locations on posterior sclera. Photos taken using Y5 
filter cube ((590-650 nm)/(660-740 nm)) excitation/emission). The fluorescence induced by 
genipin-induced crosslinks was evident and suggested a relatively even distribution of genipin over 
much of the posterior sclera. Exposure level and gain settings were identical in both images. 
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 After imaging, a hole, approximately 4 mm in diameter, was cut in the cornea using 
micro-scissors. A thin ring of ethyl 2-cyanoacrylate adhesive (CAS#7085-85-0, Henkel, 
Rocky Hill, CT) was applied around the interior edge of a hemispherical well on an 
aluminum mounting plate (Figure 16A) and the eye was glued cornea-side down into the 
well. Care was taken to ensure that the limbus of the eye was in full contact with the glue 
and the ONH was centered upwards. The glue was cured with phosphate-buffered saline 
(PBS) to create a seal between the plate and limbus. After the eye was securely attached, 
the lens and vitreous humor were removed through the 4 mm hole in the cornea by gently 
pressing on the posterior sclera, as previously described (Bianco 2018). The mounting plate 
was then attached with screws to the base of the empty mounting chamber (Figure 16A) 
and securely fastened to create a watertight seal. The sealed chamber was flooded with 
PBS and purged of air bubbles using two ports on opposite sides of the chamber which 
were re-sealed once all air bubbles had been cleared. Throughout the cleaning and 
mounting process, the eye was kept hydrated by frequent applications of PBS.  
Figure 16: Inflation testing schematic. A) Mounting chamber, including rat eye mounted cornea-
side down. B) Testing apparatus with hydrostatic pressure reservoir, flow sensor, pressure 
transducer, mounting block, and DIC cameras. The flow sensor bypass was used to eliminate the 
lag in pressure experienced by the eye (e.g. during preconditioning cycles), as described more fully 
in the text. 
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To provide a high-contrast pattern for DIC analysis, a uniform speckle pattern was 
applied to the posterior scleral surface using graphite powder (#970 PG, General Pencil 
Company, Inc., Redwood City, CA). Finally, a 3D printed oil reservoir (Figure 16A) was 
attached to the top of the mounting block and filled with mineral oil (CAS# 8042-47-5, 
McMaster-Carr, Douglasville, GA) to prevent the eye from dehydrating during testing 
while allowing camera visibility to the posterior sclera. 
1.19.4.2 Inflation Testing Experimental Hardware: 
The experimental setup used for inflation testing is shown in Figure 16B. IOP was 
elevated by increasing the height of a hydrostatic pressure reservoir attached to a stepper 
motor. Flow rates into the eye were measured with an in-line flow sensor (SLG64-0075; 
Sensiron, Stafa, Switzerland), and IOP was measured downstream of the flow sensor with 
a gage pressure transducer (142PC01G; Honeywell, Charlotte, NC). The flow sensor, 
pressure transducer, and eye mounting block were connected to a fluid manifold to enable 
modifications to the flow path as needed during calibration and inflation testing. While 
flow measurements were useful (e.g., to facilitate leak detection), the inclusion of a flow 
sensor in the system also introduced a high fluidic resistance between the pressure reservoir 
and eye. This resistance to flow, together with the compliance of the eye, led to a delay 
during pressurization/filling of the eye, as well as the ocular pressure being less than the 
reservoir pressure. Thus, we included tubing to bypass the flow sensor when rapid 
pressurization of the eye was desired (Figure 16B). iPerfusion software was used to record 
pressure and flow data, and to initiate pressure stepping protocols (Sherwood et al. 2016). 
Throughout inflation tests, scleral deformation was recorded with two stereo cameras 
(Dantec Dynamics, Holtsville, NY).  
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The measurement hardware was calibrated regularly before testing. The pressure 
transducer was zeroed to atmospheric pressure at the free surface of the mineral oil by 
using a custom-built chamber filled with PBS to simulate the hydrostatic pressure of 
mineral oil on the eye, which accounted for the difference in specific gravity between PBS 
and mineral oil. The pressure transducer was calibrated by setting the reservoir to a series 
of pressure (height) steps to correlate sensor voltage with known pressure steps. Weekly 
intrinsic and daily extrinsic calibrations of the stereo cameras were performed with a 
calibration target according to manufacturer protocols. For extrinsic calibrations, the 
calibration target was submerged in mineral oil in the custom calibration chamber to ensure 
compensation for the refractive index of mineral oil. The surface of the eye was imaged 
throughout the inflation test with a 100 ms exposure time. 
1.19.4.3 Preconditioning and Creep Procedure: 
After attaching the mounting chamber to the system hardware, the flow sensor was 
bypassed, and the pressure was set to 2 mmHg. With the flow sensor in-line, image 
recording was initiated (1 image per minute), and the pressure reservoir was set to 15 
mmHg to check for leaks. Based on preliminary testing, an eye was considered leak-free if 
the flow rate dropped below 600 nl/min and the eye pressure reached 11 mmHg in less than 
20 minutes. If a leak was present at this step, the eye (and fellow contralateral eye) was 
excluded from the study. The non-zero steady state flow rate was likely due to several 
possible outflow passages from the eye, including remnants of the trabecular meshwork in 
the anterior eye, vortex veins exposed by removal of the vitreous, and micro-leaks in the 
glue. In certain instances, outflow from the vortex veins created a fluid bubble in the oil 
that distorted the cameras’ view of the speckle pattern, resulting in a large fraction of the 
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scleral surface that could not be tracked by the DIC algorithm. Eyes (and fellow 
contralateral eyes) affected by either exclusion criteria: 1) a leak in the eye, or 2) a fluid 
bubble impeding sufficient DIC analysis, were excluded from the study (13 of 28 rats).  
The flow sensor bypass was then opened, causing the pressure to immediately 
increase from the approximately 11 mmHg reached during the leak check to the 15 mmHg 
set pressure. The eye was then held at 15 mmHg for 5 minutes as an acclimatization step. 
The eye was subsequently subjected to 10 load-unload cycles from 3 to 15 mmHg at a rate 
of 0.5 mmHg/second and images were taken every 4 seconds (Figure 17). We determined 
empirically that 10 cycles were sufficient to ensure that variation in the mean peak scleral 
strain was no greater than 2% between cycles (Figure 18). In preliminary testing, we found 
that the acclimatization step was very important to reach a preconditioned state within the 
10 cycles. When the eye was subjected to load-unload cycles only, the number of cycles 
required was variable. After preconditioning, eye pressure was lowered to 3 mmHg, and 
the flow sensor bypass was closed, which added the flow sensor back into the flow path.  
The eye was then subjected to a creep testing protocol comprising three pressure 
steps of 10, 20, and 30 mmHg (Figure 17). Pressure steps were initiated only after the flow 
reading reached a designated stability criterion based on measured flow rate of ± 2 nl/min/s 
of variation over a 10-minute window. This flow stability criterion ensured that posterior 
ocular tissues had sufficient time to creep under the applied pressure, resulting in stabilized 
strain readings for each pressure step (Figure 19). Note that since the flow sensor had a 
high fluid resistance, there was a small pressure drop, usually 0.5 to 2 mmHg, between the 
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pressure applied to the system and IOP. Throughout the creep testing, images were 
captured every 30 seconds.  
 
 
Figure 17: Overview of the reservoir pressure during inflation testing protocol. The 
preconditioning protocol consisted of an acclimatization step where the pressure reservoir was set 
to 15 mmHg, followed by 10 preconditioning cycles from 3 to 15 mmHg. The creep testing protocol 
included three pressure steps: 3 to 10 mmHg, 10 to 20 mmHg, and 20 to 30 mmHg. The timing of 
pressure steps varied, with typical step timing shown here. Note that this figure represents the set 
reservoir pressure and not the eye pressure as measured by the pressure transducer. It is important 
to note that the actual measured eye pressure was used in data fitting. 
Figure 18: Representative pressure-strain plot for cyclic loading from 3 to 15 mmHg during 
preconditioning. The difference in maximum first principal Lagrange strain value between two 
consecutive cycles reached an equilibrium (< 2% change) by 10 cycles. 
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 Data Analysis 
Dantec’s Istra 4D software (v4.4.1, Dantec Dynamics, Holtsville, NY) was used for 
image analyses. The reference configuration for local surface strain calculations was 
chosen as the frame one minute before the first pressure step, at which point the eye was 
exposed to a pressure of approximately 3 mmHg. The following correlation settings were 
used: facet size of 45 pixels, grid spacing of 28 pixels, maximum permissible start point 
accuracy of 0.2 pixels, residuum of 30 grey values, and 3D residuum of 1.1 pixels. In 3D 
space, the resulting grid spacing between facets was approximately 150 µm. Displacement 
data was smoothed prior to strain calculations using parameters recommended by Dantec 
Dynamics: a grid reduction factor (minimizing the difference between the data point and 
the spline function) of 2 for displacement and contours, and a smoothness factor 
(straightens filtered data) of -0.5 for displacement and 0 for contours. 
Figure 19: Representative flow sensor and strain measurements during a creep test. Flow sensor 
output is shown by the black line (left y-axis), where peaks correspond to pressure steps. Mean first 
principal strain averaged over the posterior sclera is shown by the red line (right y-axis). Strain 
values are referenced to the end of the first pressure step of 3 mmHg. Time shown is relative to the 
start of the creep test. 
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A custom Matlab code (2018b; MathWorks, Natick, MA) was used for further 
analysis. First, facets that were correlated in fewer than 75% of the images were removed. 
Further, facets from each image whose first principal strain values were in the top and 
bottom 5th percentile ranges were excluded from that image as outliers. The mean first 
principal strain averaged over the entire posterior sclera, excluding the ONH region and 
the excluded facets, was then calculated in each frame by averaging the x, y, and xy 
components of Lagrange strain from all facets, populating a 2x2 matrix with these 
averages, and calculating the two eigenvalues. The more positive eigenvalue was taken as 
the average first principal strain magnitude. The mean strain for each pressure step was 
computed by averaging the first principal strain over the five frames prior to the increase 
in pressure. The mean pressure for each step was computed by averaging the recorded 
pressure values for the last 5 minutes of the step. Pressure-strain data from each eye was 
fit to an isotropic Fung-type model, similar to the approaches used in (Wong et al. 2012) 





(𝑒𝐵𝜀 − 1) + 𝐶 (3) 
where 𝜀 represents the first principal Lagrange strain, 𝐶 represents the intraocular pressure 
reached at the reference pressure step (reservoir pressure of 3 mmHg), and 𝐴 and 𝐵 are 
fitting coefficients. An R-squared value was computed for the Fung model fit to the 
experimental data, and if either R-squared value for a pair of eyes was lower than 0.9, that 
pair was excluded from the study according to this exclusion criteria (2 of 28 rats). This fit 
was then used to compute the strain at 22 mmHg, which is the physiological IOP of awake 
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normotensive Brown Norway rats recorded in our lab, which is similar to that reported in 
other labs (Jia et al. 2000b). This procedure allowed us to compare scleral deformations in 
all eyes at an equal IOP. 
We computed the difference in strain at 22 mmHg by subtracting control strain 
from experimental strain. In the genipin/HBSS group, the experimental eye was the 
genipin-treated eye, and in the HBSS/naïve group, the HBSS eye was the experimental eye. 
Negative values indicated that the experimental eye was stiffer. Relative difference in strain 
for each rat was computed using the equation:  
 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑠𝑡𝑟𝑎𝑖𝑛 =
𝜀𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − 𝜀𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝜀𝑐𝑜𝑛𝑡𝑟𝑜𝑙
∙ 100 (4) 
where 𝜀𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 and 𝜀𝑐𝑜𝑛𝑡𝑟𝑜𝑙 are the strains at 22 mmHg in the experimental eye and 
control eye, respectively.  
1.19.5.1 Statistical Analysis 
Fifteen rats were removed from the study due to the exclusion criteria described 
above. Thus, thirteen rats were used for statistical analysis, broken down as follows: 
Naïve/HBSS rats one day post-injection (n = 4), Genipin/HBSS rats one day post-injection 
(n = 4), and Genipin/HBSS rats four weeks post-injection (n = 5). 
Difference in strain for each group was compared using one-way ANOVA with a 
Holm-Sidak post-hoc test, and percent strain reduction for each group was compared using 
Kruskal-Wallis with a Dunn’s post-hoc test (GraphPad Software v8, San Diego, CA). 
Results are presented as mean ± standard deviation, unless otherwise noted. 
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 Results 
The Fung model provided an excellent fit to each set of pressure vs. strain data, 
with an average R-squared value of 0.99 ± 0.015 as seen in Figure 20. All curves for 
genipin-treated eyes were clustered towards the left side of the graph, indicating a stiffer 
sclera in these eyes. In contrast, the curves for all HBSS and naïve eyes were dispersed 
throughout the middle and right portions of the graph, indicating a softer sclera and higher 
variability in these eyes.  
As expected, the mean difference in strain in the HBSS/Naïve rats was 
approximately zero (0.0002 ± 0.00022 strain), indicating that HBSS (sham) injection did 
not affect scleral stiffness one day post-injection. Genipin/HBSS rats showed a reduction 
in strain at both one day (-0.0098 ± 0.0052 strain) and four weeks (-0.0154 ± 0.006strain) 
post-injection (Figure 21), i.e. there was less scleral strain in the genipin-treated eyes. There 
was a significant scleral stiffening effect due to genipin treatment [one way ANOVA: F(2, 
10) = 11.25, p = 0.0028] as evidenced by the greater difference in strain in the 
Genipin/HBSS groups compared with the HBSS/Naïve group (Holm-Sidak post-hoc: one 
day, p = 0.016; four weeks, p = 0.002). Relative difference in strain (Figure 22) in 
Genipin/HBSS rats one day (-41.2 ± 14.1%) and four weeks (-58.3 ± 15.6%) post-injection 
were greater in magnitude than Naïve/HBSS rats (1.6 ± 6.5%); however, this result was 
only significant at four weeks post-injection (Kruskal-Wallis, p < 0.001; Dunn’s post-hoc, 
HBSS/Naïve vs Genipin/HBSS at one day: p = 0.170 and HBSS/Naïve vs Genipin/HBSS 






Figure 20: Genipin treated eyes yielded visibly stiffer pressure-strain curves. Fit of isotropic Fung-
type constitutive model to pressure-strain data from each eye (all R2 > 0.93). Naïve eyes are shown 
in dashed black lines, HBSS eyes are shown in various shades of purple, and genipin eyes are 
shown in various shades of blue. Dotted red line denotes 22 mmHg, at which the difference in strain 
and percent strain reduction were computed. Letters above curves indicate paired eyes from each 
rat (A-M). For overlapping curves, the letter corresponding to the leftmost curve is on top. 
Figure 21: Genipin treatment resulted in greater relative difference in strain. Relative difference 
in strain at 22 mmHg for HBSS/Naïve rats (n = 4) one day post-injection and for Genipin/HBSS 
rats one day (n = 4) and four weeks (n = 5) post-injection. The plotted quantity is the difference in 
average first principal scleral strain relative to the contralateral control eye for each rat, all 
evaluated at 22 mmHg, and provides an alternative way of presenting the data shown in Figure 8. 
Relative difference in strain was significantly greater at four weeks after injection. Bars show mean 
± SD. (** indicates p ≤ 0.01 by Kruskal-Wallis test, Dunn’s post-hoc). 
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 Discussion 
In this study, we show that a single retrobulbar in vivo injection of 15 mM genipin 
can effectively stiffen rat sclera and that the effect is sustained for at least four weeks post 
injection. This finding is significant because it justifies the use of a single injection in future 
studies evaluating the effects of scleral stiffness, whereas previous protocols utilized 
multiple injections (Table 3). We expect that this improvement will greatly simplify future 
studies, since each injection introduces risk and variability, and may eventually increase 
the potential for translation of genipin stiffening treatments in the eye.  
The degree of scleral stiffening that is required to provide an effective treatment for 
glaucoma is not known. However, we can predict minimum efficacious stiffening levels 
based on the stiffening magnitude needed to significantly reduce strains in the ONH. 
Coudrillier et al. evaluated the effects of posterior scleral stiffening via glutaraldehyde on 
 
Figure 22: Genipin treatment resulted in reduced scleral strain. Difference in strain at an IOP of 
22 mmHg for HBSS/Naïve rats (n = 4) one day post-injection and for Genipin/HBSS rats one day 
(n = 4) and four weeks (n = 5) post-injection. The plotted quantity is the average first principal 
scleral strain in the contralateral control eye minus the strain in the experimental eye for each rat, 
all evaluated at 22 mmHg. There was a greater difference in strain in Genipin/HBSS rats compared 
to HBSS/Naïve rats at one day and four weeks. Bars show mean ± SD (* indicates p ≤ 0.05, ** 
indicates p ≤ 0.01, both by one-way ANOVA, Holm-Sidak post-hoc). 
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ONH strain in ex vivo porcine eyes (Coudrillier, Campbell, et al. 2016). Specifically, a -
40% relative difference in scleral strain (at an IOP of 22 mmHg) led to a relative difference 
in ONH strain of -47% and -39% at 15 mmHg and 30 mmHg, respectively. In this study, 
we reduced scleral strain at 22 mmHg by a similar amount at one day (-41.2%) and four 
weeks (-58.3%) post-injection, suggesting that our genipin treatment is likely to markedly 
reduce ONH strains in the rat eye. In the context of myopia, Wang et al. demonstrated a 
significant decrease in refractive error after genipin treatment (Wang and Corpuz 2015). 
However, it is challenging to directly compare our stiffening results due to differences in 
uniaxial loading regime (Wang and Corpuz 2015).  
More broadly, we note that the ultimate clinical benefits of scleral stiffening in 
glaucoma remain to be determined. A preliminary study suggested that increasing scleral 
stiffness provides neuroprotection in glaucoma (Ethier 2015), yet a larger study by Kimball 
et al. (Kimball et al. 2014) reported that stiffening the posterior mouse scleral increased 
(rather than decreased, as hypothesized in this study) glaucomatous damage. While these 
results are important, the stiffening technique described in this study has significant 
differences compared to Kimball et al.’s study, including: animal type, number of 
injections, type of injection, volume of crosslinker, concentration of crosslinker, and type 
of crosslinker. There are also the observations that the sclera becomes stiffer in glaucoma, 
and that African descent is associated with a higher peripapillary scleral stiffness and a 
higher incidence of glaucoma. These data could suggest that a stiffer sclera increases 
glaucoma risk, or alternatively they could mean that scleral stiffening is a beneficial 
adaptive response to mitigate glaucomatous damage/risk. Considering all of the above, the 
reality is that we do not know whether scleral stiffening will provide neuroprotection in 
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glaucoma, and we expect that research such as described in this work will help to answer 
this fundamental question. We have confirmed a successful genipin retrobulbar injection 
by visualizing autofluorescent genipin-induced collagen crosslinks (Figure 15), observing 
a relatively uniform autofluorescence distribution posteriorly, with reduced 
autofluorescence as the limbus was approached. This reduced cross-linking in the more 
anterior portions of the sclera was expected, since the conjunctiva acts as an anatomical 
barrier for fluid transport from the retrobulbar space. Importantly, when considering the 
posterior sclera, there was no obvious correlation between the local variations in 
autofluorescence and local variations in strains as measured by DIC (data not shown). This 
is likely because the stiffness and thickness of the sclera naturally vary by location even 
before genipin treatment. Therefore, regional differences in strain magnitude as shown by 
DIC could be due to natural variations in structural stiffness that existed before genipin 
injection, to a localized effect of the stiffening agent, or both. 
This study introduces several methodological improvements as compared to our 
previously published inflation testing procedure (Campbell et al. 2017). First, we included 
a preconditioning protocol to reduce variability between samples. Preconditioning was not 
required in our previous study because we utilized a partial incubation protocol that 
allowed us to determine a treatment effect using only a single eye. Since the present study 
compared strains between treated and contralateral eyes, reducing the testing variability 
increased the power of the study. Second, we incorporated a flow sensor into the testing 
setup to determine when the eye reached equilibrium at each pressure step. The time to 
reach equilibrium is expected to vary with viscoelastic properties and outflow rates, both 
of which are variable in normal populations and may be altered with genipin treatment. Yet 
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without a flow sensor, pressure steps could only be initiated at fixed time intervals, since 
the DIC software was unable to provide information about sample deformation while a test 
was in progress. The flow sensor also enabled accurate identification and exclusion of eyes 
with unstable leaking or creeping phenomena that would have biased the results. Finally, 
we developed an improved mounting procedure similar to that described by Bianco et al. 
(Bianco 2018). Specifically, we removed the lens from each eye to prevent it from 
occluding the flow of PBS into the eye. We also used an eye bath of mineral oil rather than 
PBS to prevent evaporation of fluid during the test while maintaining tissue hydration.  
These changes have also introduced some minor but notable limitations, were 
outweighed by their benefits, as follows. First, the addition of a flow sensor (with its 
inherent flow resistance) makes it difficult to precisely set the pressure in the eye. Since 
the flow rate entering each eye can differ, an eye-specific pressure drop occurs across the 
flow sensor and this difference becomes more significant as the IOP changes. However, 
eye pressure throughout the duration of the test is directly measured in the described set 
up. This allows for all test data to be referenced to a common IOP through use of a Fung-
type constitutive model which permits comparisons across eyes with different starting 
pressures. Also, by specifying a creep test rather than a ramp-hold test, we were able to 
minimize the potential importance of this effect. Second, since the eye was pressurized 
with PBS but was tested in a bath of mineral oil, leaking PBS from the eye, even at very 
low flow rates, occasionally resulted in a bubble of PBS that distorted the image of the 
underlying speckle pattern seen by the cameras. Finally, we chose to implement a 
preconditioning procedure which used cyclic loads between 3 and 15 mmHg, whereas our 
creep pressure steps were higher than this range (20 mmHg and 30 mmHg). Because of 
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this, our results could potentially be affected by the Mullins effect, in which a material’s 
softening effect is dependent on the maximum load the tissue is subjected to during its 
preconditioning loading history. We chose our preconditioning pressures to minimize 
leakage from eyes, which occurred more often when eyes were dynamically loaded to 
higher pressures during preconditioning. Additionally, while preconditioning is extremely 
important in uniaxial and biaxial strip testing, it has been shown that the sclera exhibits 
only modest preconditioning effects during inflation tests in other species (Tonge et al. 
2013; Coudrillier et al. 2012; Myers et al. 2010). These results are encouraging and 
motivate further testing with genipin.  
Although this study did not explicitly evaluate any potential toxicity of genipin, 
animals were monitored after retrobulbar injections with either genipin or HBSS. In all 
rats, there was a small bleb of fluid visible in the inferior and nasal regions of the 
conjunctiva which resolved within one to five days post-injection. Adverse effects from 
the retrobulbar injections included a few eyes in which there was a small amount of 
bleeding from the periocular space immediately following the injection, presumably due 
to a blood vessel being accidentally damaged during the injection. Further, we do not 
expect genipin treatments to be cytotoxic, since Liu et al. demonstrated no cytotoxicity due 
to genipin treatment in rabbits (Liu and Wang 2017). However, Liu et al. used a lower 
concentration than that used in the present study (Table 3), and future work must assess 
potential genipin-induced cytotoxicity. We are currently evaluating the safety of genipin 
injections and plan to describe this in a separate publication in due course. Future work 
should also determine the maximum duration of this stiffening effect. 
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 Conclusion 
We have demonstrated stiffening of rat sclerae after a single in vivo injection of 
genipin in rats. The stiffening effect was sustained for at least four weeks, longer than 
previously demonstrated. This is important for simplifying research studies and facilitating 
possible future clinical translation, where frequent injections are undesirable. These 
findings were enabled by development of an improved inflation testing protocol for 
measuring strain in genipin-treated eyes. Altogether, these results will be used to guide 
future in vivo studies aimed at evaluating the efficacy of scleral stiffening via genipin 
injection as a treatment for glaucoma, myopia or other applications. 
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 Abstract 
Purpose: Genipin has been proposed as a possible neuroprotective therapy in myopia and 
glaucoma. Here, we aim to determine the effects of prolonged genipin-induced scleral 
stiffening on visual function.  
Methods: Eyes from Brown Norway rats were treated in vivo with either a single 15 mM 
genipin retrobulbar injection or sham retrobulbar injection and were compared to naïve 
eyes. Intraocular pressure, optomotor response, and electroretinograms were repeatedly 
measured over four weeks following retrobulbar injections to determine visual and retinal 
function. At four weeks we quantified retinal ganglion cell axon counts. Finally, molecular 
changes in gene and protein expression were analyzed via RT-PCR and proteomics. 
Results: Retrobulbar injection of genipin did not affect IOP or retinal function, not did it 
have a sustained impact on visual function. While genipin-treated eyes had a small decrease 
in retinal ganglion cell axon counts compared to sham-treated eyes (-8,800 ± 20,698, mean 
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± SD), this decrease was not statistically significant (p = 0.238, n = 9). Lastly, we did not 
observe any changes in gene or protein expression due to genipin treatment. 
Conclusions: Posterior scleral stiffening with a single retrobulbar injection of 15 mM 
genipin causes no sustained deficits in visual or retinal function or at the molecular level 
in the retina and sclera. Retinal ganglion cell axon morphology appeared normal. 
Translational significance: These results support future in vivo studies to determine the 
efficacy of genipin-induced posterior scleral stiffening to help treat ocular diseases like 
myopia and glaucoma. 
 Introduction 
Scleral collagen crosslinking has been proposed as a therapeutic treatment for 
myopia and glaucoma. In myopia, refractive error is largely caused by scleral remodeling 
which leads to axial elongation (Harper and Summers 2015; Rada, Shelton, and Norton 
2006), and crosslinking the posterior sclera has been hypothesized as a treatment to slow 
or reverse this process (Levy, Fazio, and Grytz 2018; Liu and Wang 2017). In glaucoma, 
intraocular pressure (IOP) causes excessive biomechanical strains on the optic nerve head, 
which is the main and early site of retinal ganglion cell (RGC) damage. It is hypothesized 
that reducing such excessive strains by crosslinking the posterior sclera surrounding the 
optic nerve may protect against RGC loss in glaucoma (Sigal, Flanagan, and Ethier 2005; 
Campbell, Coudrillier, and Ross Ethier 2014).  
Ocular collagen crosslinking has recently been clinically approved for the treatment 
of keratoconus, where the cornea becomes weak and misshapen (Hersh et al. 2017). This 
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treatment uses a collagen crosslinker, riboflavin, that is photoactivated by Ultraviolet-A 
(UVA) light to strengthen the cornea. Unfortunately, scleral crosslinking using riboflavin 
and UVA light is known to be toxic to the retina (Glickman 2011; Wollensak et al. 2005). 
Thus, alternative collagen crosslinking approaches have been evaluated to stiffen the 
posterior sclera for myopia and glaucoma treatment.  
Genipin, a naturally occurring, non-photoactivated, collagen crosslinking agent 
extracted from the Gardenia fruit, has been previously investigated as a collagen 
crosslinker for ocular use (Avila and Navia 2010; Liu, Luo, et al. 2014; Wang and Corpuz 
2015; Levy, Fazio, and Grytz 2018; Dias et al. 2015; Liu and Wang 2017). Genipin acts as 
an anti-inflammatory and anti-angiogenic agent (Koo et al. 2004) and can induce stable 
crosslinks in biological tissue (Sung et al. 2001). Genipin-induced crosslinking increases 
tissue stiffness by similar magnitudes as do glutaraldehyde (Huang et al. 1998) and 
riboflavin (Song et al. 2017; Avila, Gerena, and Navia 2012), yet is significantly less 
cytotoxic than are glutaraldehyde (Sung et al. 1999; Chang et al. 2002) and riboflavin 
(Song et al. 2017; Avila, Gerena, and Navia 2012).  
Of several studies that have evaluated genipin-induced scleral crosslinking, only 
two have evaluated both the efficacy and safety of genipin-induced scleral crosslinking in 
vivo (Liu and Wang 2017; Wang and Corpuz 2015). These studies examined the 
biomechanical properties of genipin-stiffened scleral strips, gross ocular anatomy via slit-
lamp exams after treatment, and histological and immuno-histological sections of ocular 
tissues in rabbits (Liu and Wang 2017) and guinea pigs (Wang and Corpuz 2015). These 
studies found that genipin successfully stiffened the sclera and did not cause any gross 
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changes in ocular structures. However, to date no study has evaluated whether genipin-
induced scleral collagen crosslinking affects visual and retinal function in vivo. 
We have previously shown the efficacy of genipin (15 mM) to induce sustained 
scleral stiffening for up to four weeks after retrobulbar injection in Brown Norway rat eyes 
(Hannon et al. 2019). However, it is important to ensure that long-term scleral stiffening is 
safe and has negligible adverse effects on visual function. Here, we aim to evaluate the 
potential use of genipin-induced collagen crosslinking in the sclera on visual and retinal 
function over four weeks. 
 Methods 
 Animals 
This study used 37 retired breeder (7-13 months old) Brown Norway rats (Charles 
River Laboratories, Inc., Wilmington, MA). Most rats used in this study (n = 34 rats) were 
male, while a small group of female rats (n = 3) were used in a preliminary proteomics 
study. All rats were housed on a 12-hour light (fluorescent 25-200 lux)/12-hour dark cycle 
and were provided with food and water ad libitum. All procedures were approved by the 
Institutional Animal Care and Use Committee at the Georgia Institute of Technology, Duke 
University, and the Atlanta VA Healthcare System. All procedures adhered to the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research. The numbers of rats 
used for each outcome parameter are listed in Table 4. 
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 Experimental Groups and Crosslinking Procedure 
Rats were randomly assigned to one of three groups for this study, as displayed in 
Figure 14. The first group of rats (Naïve/Naïve, n = 7 animals) were from a previous study 
in our lab in which both eyes were left completely naïve. Optic nerves were removed from 
these eyes and used for RGC axon count comparisons (Schwaner et al. 2020). Rats in the 
second group (HBSS/Naïve, n = 10) received a single (unilateral) retrobulbar injection of 
Hank’s Balanced Salt Solution (HBSS; 150 µl) unilaterally, while the contralateral eye was 
left as a Naïve control. Rats in the third group (Genipin/HBSS, n = 20) received a single 
retrobulbar injection of genipin (Wako Pure Chemical Industries, Ltd., Richmond, VA) 
mixed in HBSS (15 mM, 150 µl) unilaterally, while the contralateral eye received a single 
retrobulbar injection of HBSS (150 µl). For all retrobulbar injections, rats in the remaining 
two groups were anesthetized with a cocktail of ketamine (60 mg/kg) and xylazine (7.5 
mg/kg) and a drop of topical tetracaine (0.5%, Alcon, Geneva, Switzerland) was applied 
as a local anesthetic to both eyes. All retrobulbar injections were performed using a sterile 
31G insulin syringe needle (BD 300 µl Insulin Syringe Ultra-Fine™ needle, Becton, 
Dickinson and Company, Franklin Lakes, New Jersey) inserted into the inferior quadrant. 
A genipin concentration of 15mM was previously used in our in vivo stiffening study 
(Hannon et al. 2019), and successfully stiffened the posterior rat sclera for four weeks. Rats 
received a topical antibiotic (Certi-sporyn, Kansas City, MO) to avoid infection and 
antisedan (1 mg/kg) to reverse anesthesia (Turner and Albassam 2005). All rats were 
euthanized (via CO2 overdose) either one day, one week, or four weeks post-injection, 






Table 4: Number of rats in each group for each outcome measure. Columns indicate cohorts of 
rats within each group. Asterisks indicate rats that were used in multiple outcome measures.  
Figure 23: Schematic of three groups of rats used in this study: Naïve/Naïve rats (A) were 
completely naïve control rats. HBSS/Naïve rats (B) received a single (unilateral) retrobulbar 
injection of HBSS, and Genipin/HBSS rats (C) received a unilateral retrobulbar injection of 
genipin and a contralateral retrobulbar injection of HBSS. 
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 Tonometry and Eye Exams 
IOP measurements were taken between 9:00am and 11:00am using a Tonolab 
rebound tonometer (Icare Finland Oy, Vantaa, Finland) in HBSS/Naïve (n = 5) and 
Genipin/HBSS (n = 6) rats. The tonometer was previously calibrated on a cannulated eye, 
in which we externally set IOP ranging from 5 to 50 mmHg using an external reservoir 
(data not shown). Awake rats were gently restrained by hand while eight tonometer 
readings were recorded on each eye. We removed the lowest and highest IOP values and 
averaged the remaining six measurements to represent IOP from that eye. IOP 
measurements were recorded at 0 (baseline, just before injection), 3, 7, 10, 14, 21, and 28 
days relative to the time of retrobulbar injection. At each of these timepoints, rat eyes were 
also grossly observed for any abnormalities arising from the retrobular injections. 
 Optomotor Response 
The optomotor response (OMR) was used to assess visual function (OptoMotry®; 
Cerebral-Mechanics, Lethbridge, AB, Canada (Douglas et al. 2005)) at 0 (baseline), 1, 7, 
14, and 28 days after retrobulbar injection. We evaluated the OMR in HBSS/Naïve (n = 5) 
and Genipin/HBSS (n = 6) rats. In brief, awake rats were placed on a platform in the center 
of a chamber consisting of four flat screen computer monitors. Each monitor displayed 
vertical black and white gratings which produced a virtual drum rotating at a speed of 12 
degrees/second (deg/s). A video camera above the platform was used by a trained observer 
to visualize the rat’s reflexive head movements during the experiment. Gratings rotated in 
a clockwise or counter clockwise direction to separately stimulate the responses of the left 
and right eyes, respectively (Douglas et al. 2005). To determine a rat’s spatial frequency 
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threshold, the vertical bands were displayed at 100% contrast starting at 0.042 
cycles/degree and the spatial frequency of the bands was adjusted until the rat no longer 
demonstrated an OMR, as determined by a lack of reflexive head movement. Contrast 
sensitivity was measured at baseline, week two, and week four. To determine contrast 
sensitivity, spatial frequency was set to 0.064 cycles/degree, while the contrast was 
adjusted from 100% following a staircase paradigm until the animal no longer displayed a 
reflexive response. Contrast sensitivity is reported as the reciprocal of the Michelson 
contrast from the screen’s luminance, as previously described (Prusky et al. 2004). 
 Electroretinogram 
To assess inner and outer retinal function we performed electroretinograms 
(ERGs). ERG measurements on HBSS/Naïve (n = 5) and Genipin/HBSS (n = 6) rats were 
taken at baseline, 1, 2, and 4 weeks post-injection. For each timepoint, rats were dark-
adapted for 30 minutes and anesthetized using a cocktail of ketamine (60 mg/kg) and 
xylazine (7.5 mg/kg), after which drops of tetracaine (0.5%) and tropicamide (1%) were 
applied topically to anesthetize corneas and dilate pupils, respectively. Reference needle 
electrodes were carefully inserted subcutaneously in each cheek and a ground electrode 
was placed in the tail. Custom gold-loop corneal electrodes were placed on the cornea of 
each eye under a layer of carboxymethylcellulose (Celluvisc, Allergan, Dublin, Ireland) to 
ensure electrical conductivity and prevent the eye from drying. Electrical responses to 
various full-field flash stimuli in a Ganzfield dome were recorded and differentially 
amplified (1-1500 Hz) using a signal-averaging ERG system (UTAS BigShot; LKC 
Technologies, Gaithersburg, MD) that was calibrated according to manufacturer’s 
specifications. Under dark-adapted conditions, a five-step series of increasing flash 
 83 
intensities (-3.0 to 2.1 log cd s/m2) was used to selectively isolate rod and mixed rod/cone 
dominated photoreceptor responses. Interstimulus intervals increased from 2 to 70 seconds 
at each stimulus level to provide full recovery of the retina before the next flash. 3 to 10 
flashes were averaged to generate a waveform for each scotopic flash. Rats were then light-
adapted for 10 minutes (30 cd/m2) before being presented with a three-step series of 
increasing light stimuli (0.4 to 1.4 log cd s/m2) followed by a flickering light stimulus (1.9 
log cd s/m2 at 6 Hz) to isolate cone photoreceptor responses. Each photopic waveform was 
averaged from 25 flashes. Oscillatory potentials (OPs) were filtered with a 65-275 Hz 
bandpass fifth order Butterworth filter and then measured on the leading edge of the b-
wave starting with the first trough. Amplitudes and implicit times were measured as 
follows: baseline to trough (a-waves and photopic negative responses (PhNR)) and trough 
to peak (OPs, b-waves, and flicker response).  
 RGC Axon Counting 
RGC axon numbers were quantified in Genipin/HBSS (n = 9) and Naïve/Naïve (n 
= 7) rats at four weeks post-injection. Immediately after euthanasia, optic nerves were 
dissected from the enucleated eye and fixed in isotonic PBS (Sorensen’s buffer) containing 
2.5% glutaraldehyde and 2% paraformaldehyde (PFA, EMS, Hatfield, PA). The tissue was 
then post-fixed in 1% osmium tetroxide, dehydrated through an ethanol series, embedded 
in Araldite 502/Embed 812 resin (EMS, Hatfield, PA) and cured in a 60 °C oven for 24 h. 
Semi-thin cross sections (0.5 µm thick) were then cut approximately 1.0 mm posterior to 
the sclera, using a Leica EM UC7 ultramicrotome (Leica Microsystems, Buffalo Grove, 
IL) with a diamond or glass knife. Cross-sections were then dried and stained with 1% 
toluidine blue on a 70 °C hotplate for 15 seconds and imaged with a Leica DM6 microscope 
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(Leica Microsystems) at an objective power of X100. Tiled images were collected and 
merged together to produce a montage of the entire optic nerve cross-section. From this 
image, normal-appearing axons were then automatically counted using the AxoNet fully 
convolutional neural-network software, as described previously (Ritch et al. 2019) as well 
as in APPENDIX A. 
 RT-PCR 
A preliminary study was performed to assess genipin treatment’s effect on 
abundance of extracellular matrix (ECM) proteases in the sclera and inflammatory markers 
in the retina. RT-PCR was performed on HBSS/Naïve (n = 6) and Genipin/HBSS (n = 6) 
rats at one week and four weeks (n = 3/group) post injection. Whole globes were enucleated 
immediately after euthanasia and stored in RNA later (ThermoFisher Scientific, Waltham, 
MA) until processing. Sclerae were cleaned of fat, tissue, and muscle, cut along the limbus, 
and opened to create four quadrants. Retinas were separated and put in a biomasher tube 
(Kimble, Tokyo, Japan) with trizol (Thermo Fisher Scientific). RPE was gently peeled and 
then scraped off from the sclera with a blade and the sclera was washed in PBS, cut into 
small pieces and then put into a biomasher tube with trizol. Retina and sclera tissues were 
then homogenized, mixed with chloroform (200 µl per ml of trizol) and centrifuged at 4oC 
for 15 minutes at 12,000g. The upper phase containing RNA was collected, cleaned, and 
concentrated using RNeasy MiniElute Cleanup Kit (Qiagen, Germantown, MD) according 
to the manufacturer’s instructions.  
Once RNA was acquired, strand cDNA was synthesized from total RNA (700 ng) 
by reverse transcription using oligodT and Superscript III reverse transcriptase (Thermo 
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Fisher Scientific, Waltham, MA) according to manufacturer’s instructions. Q-PCR 
reactions were performed in 20µl mixture containing 1µl of the cDNA preparation, 1X iQ 
SYBR Green Supermix (Biorad, Hercules, CA) and 10µM primers, using the following 
PCR parameters: 95oC for 5 minutes followed by 40 cycles of 95oC for 15 seconds, 55oC 
for 15 seconds and 72oC for 15 seconds. β-Actin and GADPH were used as internal 
standards of mRNA expression. The absence of nonspecific products was confirmed by the 
analysis of the melt curves. The primers used for Q-PCR amplification are shown in table 
S1. During this processing, one globe from a four week HBSS/Naïve rat was damaged and 





1.26.8.1 Sample Preparation 
Proteomics analysis was performed on sclerae from Genipin/HBSS (n = 3) rats at 
four weeks post injection to determine the effect of genipin treatment on the abundance of 
various proteins involved in various functions, including protein binding, cell motility, and 
ECM structural support. Eyes were enucleated immediately after euthanasia and kept in 
cold PBS until processing. The sclera was first cleaned of conjunctiva, retina, muscle, and 
fat, and the RPE was gently peeled and scraped off from the sclera with a blade. The sclera 
was then washed in PBS, cut into smaller pieces, transferred to an Eppendorf tube, and 
frozen in liquid nitrogen. Frozen scleral pieces were ground using a CryoGrinder kit (OPS 
Diagnostics, Lebanon, NJ) and then suspended in 300µl of lysis buffer (10 mM HEPES, 
42 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT (all from Sigma-Aldrich, St. 
Louis, MO), 1× protease inhibitor (Thermo-Fisher Scientific)) and homogenized in a 
biomasher tube. Samples were sonicated on ice three times for 10 seconds and SDS was 
added for a final concentration of 2% (w/v). Samples were incubated at room temperature 
for 10 minutes to lyse the cells and extract the proteins, then spun for 45 minutes at 14 000 
× g, at room temperature. SDS-soluble proteins were kept on ice, while SDS-insoluble 
proteins were processed further by adding 10 volumes of urea buffer (8M urea; 4% SDS, 
60 mM Tris-HCl, (Sigma-Aldrich) 12.5 EDTA in deionized water) to samples, incubating 
30 minutes at room temperature, and then centrifuging at 16,000g for 5 minutes. 
Supernatant was precipitated using methanol/chloroform, resuspended on 2% SDS, and 
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combined with SDS-soluble protein. Samples were reduced with DTT (10mM) at 60 °C 
for 20 minutes, alkylated with iodoacetamide (IAA, 25mM, Sigma-Aldrich) for 30 minutes 
at room temperature in the dark. The IAA was then quenched with DTT. Samples were 
precipitated using methanol/chloroform, and resuspended in digestion buffer (8M urea, 
0.1M Tris pH 8.0) containing trypsin-Lys-C mix (Promega) and incubated overnight at 37 
°C. The following morning, 50mM ammonium bicarbonate (Sigma-Aldrich) was added 
containing 1:40 trypsin/Lys-C and samples were incubated for 3 more hours with 10% 
trifluoroacetic acid (Sigma-Aldrich). Peptides were cleaned up using C18 tips (Nest Group, 
Southborough, MA), following manufacturer’s instructions and dried by Speed Vac. 
1.26.8.2 Mass Spectrometry Analysis and Protein Quantification 
Tryptic peptides eluted from the beads were dried under vacuum and dissolved in 
2% acetonitrile and 0.25% formic acid. Peptides (typically 0.5-1µg) were analyzed using 
a NanoAcquity UPLC system coupled to a Synapt G2 HDMS mass spectrometer (Waters 
Inc., Milford, MA) employing a LC-MS/MS experiment in a data-independent acquisition 
mode complemented with ion mobility separation (HDMSE). Samples were analyzed in 
duplicate on a 1.7 mm 75 mm x 150 mm C18 130 A BEH column (Waters Inc.) using a 90 
minute, 5% to 30% gradient of acetonitrile in 0.1% formic acid at a flow rate of 0.3 ml/min 
at 35oC. Eluting peptides were sprayed into the ion source of the Synapt G2 using the 10 
μm PicoTip emitter (Waters Inc.) at a voltage of 2.5 kV.  
Duplicate data-independent analyses (HDMSE) for each sample were conducted 
with similar LC settings for simultaneous peptide identification and quantification. For 
robust peak detection and alignment of individual peptides across all HDMSE runs, we 
 88 
performed automatic alignment of ion chromatography peaks representing the same 
mass/retention time features using Progenesis QI software. To perform peptide assignment 
to the features, PLGS 2.5.1 (Waters Inc.) was used to generate searchable files that were 
submitted to the IdentityE search engine incorporated into Progenesis QI for Proteomics. 
For peptide identification, we searched against the UniProt rat protein database (July 2016 
release) using Cys carbamidomethyl as constant modification and Met oxidation as 
variable modification. Protein abundances in control and treated samples were calculated 
from the sum of all unique peptide ion intensities for each protein normalized to the same 
total ion current intensity of all peptides in all experimental samples. Conflicting peptides 
for different proteins and their isoforms were excluded from the calculations. All identified 
proteins were ranked based on their abundance ratios between control (HBSS) and treated 
(Genipin) samples.  
 Statistical Analysis 
All data were analyzed using one of the following approaches, depending on the 
number of groups and independent variables: two-way repeated measures (RM) ANOVA 
with Tukey post-hoc, two-way ANOVA with Sidak post-hoc, one-way ANOVA with 
Tukey post hoc, multiple t-tests with Holm-Sidak correction, or one sample t-test 
(GraphPad Software v8, San Diego, CA). For two-way RM ANOVA, the reported F 
statistic is the interaction effect unless otherwise stated. All statistical tests used for each 
assay are reported in figure legends and results. 
For RT-PCR results, fold change was computed as the increase in expression of the 
experimental eye normalized to the control eye. In HBSS/Naïve rats, the experimental eye 
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was the HBSS eye and for Genipin/HBSS rats the experimental eye was the genipin-treated 
eye. Outliers were detected and removed based on Graphpad’s ROUT method with a 
threshold of 0.1% to remove definitive outliers (Motulsky and Brown 2006). Proteomic 
results were analyzed using Progenesis QI for Proteomics software (Waters Inc., Durham, 
NC) which was used to compute q- and p-values for each protein. Significant changes in 
protein expression were defined as any q < 0.05 (Liu et al. 2019). All results are presented 
as mean ± SD.  
 
 Results 
Throughout the experiments, animals were carefully observed to determine whether 
complications occurred from the retrobulbar injection itself (HBSS eyes) or from genipin 
Figure 24: Ocular examination of eyes immediately and one week after retrobulbar injections show 
mild transient complications. In all eyes receiving a retrobulbar injection (HBSS or genipin), a 
bleb (A) appeared in the nasal quadrant immediately after injection. One such bleb is indicated by 
an arrow (OS) and can be compared to the Naïve OD eye (prior to retrobulbar injection). Typically, 
the bleb would resolve one week after injection (B). In a few cases, eyes had mild conjunctival 
chemosis (C) or subconjunctival hemorrhage (D, arrow). All images taken one week after injection 
are oriented such that the nasal portion of the eye is on the left. 
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retrobulbar injections (Genipin eyes). A bleb was visible in the nasal/inferior region of the 
conjunctiva immediately after retrobulbar injection in all eyes, regardless of injection fluid 
(Figure 24A). All blebs resolved within one to three days post-injection. In approximately 
5% of genipin-treated eyes, we saw chemosis which lasted approximately one week after 
injection (Figure 24C); compared to a normal-appearing genipin-treated eye one week after 
injection, (Figure 24B). Additionally, we observed a small amount of conjunctival bleeding 
upon removal of the needle after the a retrobulbar injection, likely due to damaging small 
conjunctival blood vessels when inserting the needle. After blotting with gauze, bleeding 
quickly subsided and, in a few cases, caused a subconjunctival hemorrhage that was visible 
one week post-injection (Figure 24D). 
 
Genipin treatment of the posterior sclera did not affect IOP for up to four weeks 
following injection (Figure 25; RM ANOVA, interaction of time and treatment: F(21,133) 
= 0.976; p = 0.497), although there was a mild transient decrease in IOP in all injected 
Figure 25: Genipin-induced scleral stiffening did not affect IOP. No significant differences in IOP 
were found in any group at any timepoint up to four weeks post-injection. RM ANOVA, F(21,133) 
= 0.976; p = 0.497. All data shown as mean ± SD, all n ≥ 5 
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eyes. OMR assessment of visual function did not reveal any changes in spatial frequency 
(Figure 26A; RM ANOVA, interaction of time and treatment: F(15, 95) = 1.33; p = 0.201), 
but did show mild transient changes in contrast sensitivity (Figure 26B, RM ANOVA, F(3, 
38) = 3.099; p = 0.014). Specifically, at two weeks post injection, the contrast sensitivity 
of genipin treated eyes was lower than in Naïve eyes (Tukey post-hoc, p = 0.002) and in 
HBSS eyes from Genipin/HBSS rats (Tukey post-hoc, p = 0.043). This deficit recovered 
by four weeks post injection (all p > 0.05). 
 
Retinal function assessment via full-field ERGs showed no differences between 
treatment groups in implicit time or amplitude over time at any flash intensity for both dark 
adapted and light adapted ERGs (Figure 27; RM ANOVA, all p > 0.05). Representative 
waveforms from genipin and Naïve eyes at one- and four-weeks post-injection from the 
brightest flash in dark adapted (2.1 log cd s/m2, Figure 27A and B) and light adapted (1.4 
log cd s/m2, Figure 27E and F) protocols are plotted for qualitative analysis.  
Figure 26: Genipin treatment did not have a sustained effect on spatial frequency or contrast 
sensitivity. Spatial frequency (A) and contrast sensitivity (B) for HBSS/Naïve and Genipin/HBSS 
rats. Spatial frequency was not significantly decreased in any of the groups over the course of the 
experiment (RM ANOVA, F(15, 95) = 1.33; p = 0.201). Contrast sensitivity was transiently 
decreased at day 14 in genipin eyes compared to Naïve eyes (p = 0.002, denoted by **) and in 
HBSS eyes (of Genipin/HBSS rats) vs. genipin eyes (p = 0.043, denoted by *). All data shown as 




RGC axon counts from Naïve, HBSS, and genipin eyes were not significantly 
different from one another (Figure 28A; One-way ANOVA, F(2, 22) = 0.733, p = 0.492). 
However, the mean axon counts of genipin treated eyes (70,523 ± 19,668, mean ± SD) 
showed a trend towards being lower than that of HBSS (79,323 ± 18,215) and Naïve 
(79,328 ± 12,581) eyes. We further analyzed the axon counts in a paired manner by 
computing the difference in axon count between genipin and HBSS eyes (Figure 28B), 
with a negative value indicating the genipin-treated eye had fewer axons than the 
contralateral HBSS injected eye. The difference in axon count was not significantly 
different than zero (one sample t-test, t = 1.276, df = 8, p = 0.238), although the mean value 
was negative (-8,800 ± 20,698 axons). These differences translate to an 8.1% ± 29.8% 
Figure 27: Retinal function was not altered by HBSS or genipin injections up to four weeks post-
injection. Electroretinogram Naïve responses for dark-adapted (A-D) and light-adapted (E-H) 
testing conditions. Plotted are representative waveforms at 1-week (A and E) and 4 weeks (B and 
F) post-injection for Naïve (black dotted) and genipin (black solid) eyes. Mean amplitude and 
implicit time of all genipin (or Naïve) eyes were computed at each timepoint and flash intensity to 
select waveforms that most closely matched the means to ensure proper representative waveforms. 
A-wave and B-wave amplitudes from the brightest dark-adapted flash (2.1 log cd s/m2) are plotted 
vs. time in (C) and (D) respectively. Additionally, B-wave and PhNR amplitudes from the brightest 
single photopic flash (1.4 log cd s/m2) are plotted vs. time in (G) and (H). All ERG data was 
analyzed with a two-way RM ANOVA. No significant interactions of time and treatment were found 
for any flash intensity (all p > 0.05). All data shown as mean ± SD, all n ≥ 5. 
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axonal loss in genipin-injected eyes compared to fellow HBSS-injected eyes and were also 
not statistically significant (one sample t-test, t = 0.82, df = 8, p = 0.4366, data not shown). 
Qualitative evaluation of a genipin/HBSS rat shows healthy axon morphology with 
uniform myelin sheath surrounding homogenous axonal interior in both HBSS (Figure 
28C) and genipin (Figure 28D) eyes.  
 
 
Figure 28: Genipin treatment results in a minor, non-statistically significant, loss of RGC axons: 
(A) Whole nerve counts from Naïve (n = 7, randomly selected as OD or OS eye), HBSS (n = 9), 
and genipin (n = 9) eyes. Nerve counts were not different in any cohort (One-way ANOVA, F(2, 
22) = 0.733, p = 0.492). (B) Contralateral optic nerve axon count differences for Genipin/HBSS 
rats at four weeks post-injection. Differences are computed as whole nerve axon count in genipin 
eye minus whole nerve axon count in contralateral HBSS eye. (One sample t-test, t = 1.276, df = 
8, p = 0.238, black dashed lines represent SD of axon count differences from 5 Naïve rats). Data 
shown as mean ± SD. (C) and (D) show representative subregions from the central region of optic 
nerves from a Genipin/HBSS rat, with (C) being the HBSS eye and (D) being the genipin eye. Axons 
appear to be normal with homogenous interiors surrounded by uniform myelin sheaths. 
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RT-PCR was used to evaluate message abundance for ECM proteases in the sclera 
and inflammatory markers in the retina (Appendix C: Table 7) at one and four weeks after 
injection. No significant changes in message for ECM proteases in the sclera or pro-
inflammatory cytokines in the retina were found at one week or four weeks after injection 
(Appendix C: Figure 50, multiple t-test, all p > 0.05). We also used proteomic analysis to 
determine the amount of various scleral proteins involved in protein binding, cell motility, 
and ECM structural support at four weeks post-injection (Appendix C: Table 8). Protein 
levels were not significantly different in genipin-injected eyes compared to their 
contralateral HBSS-injected eyes (all q > 0.05). 
 Discussion 
Previous work from our lab demonstrated successful stiffening of the posterior rat 
sclera for four weeks after a single retrobulbar injection of genipin (Hannon et al. 2019) as 
a possible therapy to mitigate axial elongation in myopia or optic neuropathy in glaucoma. 
In the present study, we have used the same genipin injection procedure to evaluate 
potential adverse effects of genipin-induced scleral crosslinking at the molecular and 
functional levels in the eye. We conclude that genipin-induced scleral crosslinking had no 
sustained effect on visual and retinal function over a 4 week period, although there was a 
trend towards a slight (non-statistically significant) loss of retinal ganglion cell axons. 
These results are the first to assess functional outcomes of genipin stiffening, required for 
eventual clinical translation of a potential therapy for myopia or glaucoma. 
Although no change in steady-state IOP was found in this study, it is important to 
note that fluctuations in IOP are a risk factor for glaucomatous damage (Asrani et al. 2000). 
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Clayson et al. (2017) found that scleral stiffening with glutaraldehyde increased the 
magnitude of IOP spikes in ex vivo porcine eyes, although to a much lesser extent than 
corneal crosslinking (Clayson et al. 2017). Future research with genipin-induced scleral 
crosslinking should evaluate the potential effects on the magnitude of IOP fluctuations. 
A slight decrease in visual acuity (spatial frequency) was measured at one day post 
injection in all eyes receiving a retrobulbar injection with any fluid (HBSS or genipin). 
This initial deficit was most likely due to the retrobulbar injection itself, which seemed to 
cause a nonsignificant, recoverable, deficit. Also, at two weeks post injection, genipin-
treated eyes had significantly lower contrast sensitivity compared to Naïve and HBSS (of 
Genipin/HBSS rats) eyes; however, this deficit recovered by week four. Because contrast 
sensitivity was only evaluated at baseline, week two, and week four, no conclusions can be 
made about whether genipin affected contrast sensitivity within the first two weeks after 
injection. However, there appears to be no sustained deficit in spatial frequency or contrast 
sensitivity due to a single retrobulbar injection of genipin. 
A robust ERG protocol was implemented in this study to selectively stimulate 
retinal layers and cell types. Amplitude and implicit time of each wave were analyzed to 
evaluate retinal function and kinetics. In all parameters evaluated, no significant effects of 
treatment over time were found. Therefore, genipin-induced scleral stiffening does not 
appear to affect retinal function in any retinal layer as detectable by ERGs. 
Even though no sustained visual or retinal functional deficits were found, it was 
important to assess RGC axon counts at four weeks after injection. Genipin/HBSS rats did 
not have a statistically significant loss in RGC axons in the genipin-treated eye, but these 
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eyes showed on average a loss of approximately 8,800 axons, or 8.1% of total axons (using 
paired analysis). The mean difference between axon counts in genipin and contralateral 
HBSS eyes was within one standard deviation of axon count differences from contralateral 
eyes of naïve rats. This amount of axonal loss appears not to have been functionally 
significant, but is nonetheless a potential concern. Clinical studies have estimated that 
patients with glaucoma with the earliest detectable vision loss may already have on average 
around 30% RGC loss (Medeiros et al. 2013; Kerrigan-Baumrind et al. 2000). If one 
extrapolates from human clinical data to the rat, one could state that the amount of RGC 
axon loss that we observed is roughly three times smaller than the threshold for visual 
deficits; however, any RGC axonal loss is worrisome, especially if genipin is to be 
considered as a treatment for glaucomatous optic neuropathy. Therefore, if genipin 
treatment is used to treat glaucoma or myopia in the future, RGC axonal loss due to minor 
genipin toxicity should be carefully evaluated. Additionally, a lower dose of genipin 
(volume or concentration or combination of the two) could be considered to potentially 
mitigate the slight loss of RGC axons that we observed, although we note that the dose and 
concentration that we used was selected since it was the lowest dose that achieved a desired 
level of scleral stiffening (Hannon et al. 2019). 
Several studies have found that genipin is cytotoxic at low concentrations (0.02 – 
0.50 mM) when cultured with various cell types (Kim et al. 2005; Kreiter et al. 2019; Kim 
et al. 2014; Wang et al. 2011). These concentrations of genipin are much lower than the 15 
mM concentration used in this study. It is important to note that 15 mM was the 
concentration that was injected into the periocular space, and therefore the exact 
concentration of genipin that scleral fibroblasts or retinal cells were exposed to is unknown. 
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In our pilot study evaluating molecular changes in gene expression and protein levels, we 
also did not find any significant changes in scleral gene expression related to ECM 
turnover, or in retinal gene expression for inflammatory cytokines. Since these molecular 
analyses were based upon a small number of animals, this data should be considered as a 
pilot study to identify large effects of genipin treatment on transcript and protein levels. 
We did not identify any such effects, but further studies are warranted. 
Retrobulbar injections are used clinically to anesthetize the globe and extraocular 
muscles for cataract and retinal surgery (Alhassan, Kyari, and Ejere 2015). Some of the 
major complications of retrobulbar injections include: inadvertent globe perforation, 
retrobulbar hemorrhage, central retinal artery occlusion, and even death (Patel et al. 1996; 
Vasavada, Baskaran, and Ramakrishnan 2017). None of these serious complications 
occurred in any of the injected rats in this study. Other minor complications of retrobulbar 
injections include chemosis and subconjunctival hemorrhage (Jacobi, Dietlein, and Jacobi 
2000; Patel et al. 1996). Here, we did observe a few eyes with chemosis that persisted for 
approximately one week after injection, but which spontaneously resolved by two weeks 
after injection. Since no signs of chemosis were seen in HBSS injections, we infer that the 
genipin treatment itself could have caused minor transient conjunctival inflammation. On 
the other hand, subconjunctival hemorrhage was seen in both HBSS- and genipin-injected 
eyes, and thus we conclude that subconjunctival hemorrhage was a complication from the 
injection rather than from the genipin per se. 
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 Conclusion 
Previous research has shown that retrobulbar injection of 15 mM genipin produces 
sustained posterior scleral stiffening. Here, we find that the same injection protocol does 
not cause prolonged decrease in visual or retinal function. However, we did observe some 
possible signs of toxicity when evaluating RGC axons and gross anatomy of eyes after 
injection. This work lays the groundwork for future in vivo studies to evaluate genipin-
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 Introduction 
Glaucoma is the most common cause of irreversible blindness worldwide (Quigley 
and Broman 2006). While glaucoma can occur at any level of intraocular pressure (IOP), 
elevated IOP remains a major causal risk factor for developing glaucoma. Ocular 
hypertension (OHT) is commonly used in animal models to study the mechanisms, 
progression, and potential treatments for glaucomatous optic neuropathy (Bouhenni et al. 
2012). A variety of techniques are used to induce OHT, including: impeding the aqueous 
humor from the eye by limbal injection of hypertonic saline, episcleral vein cauterization, 
microbead occlusion, or laser trabeculoplasty; altering trabecular meshwork biology; or 
delivering steroids to the eye (Morrison, Cepurna Ying Guo, and Johnson 2011; Urcola, 
Hernandez, and Vecino 2006; Morrison, Johnson, and Cepurna 2008). However, a 
difficulty with many of these inducible models is that the resulting IOPs can become very 
high (Morrison et al. 1997; Morgan and Tribble 2015; Shareef et al. 1995; Foxton et al. 
2013). For example, in awake Brown Norway rats Foxton et al. reported a mean peak IOP 
of 55.2 mmHg after microbead occlusion (Foxton et al. 2013) and Morrison et al. estimated 
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a mean IOP of up to 60 mmHg after injection of hypertonic saline (Morrison et al. 1997). 
In anesthetized rats, studies have reported IOPs up to 60 mmHg after episcleral vein 
cauterization (Shareef et al. 1995) and translimbal laser photocoagulation (Levkovitch-
Verbin et al. 2002). Moreover, the unanesthetized (true) IOP is likely much higher, since 
anesthesia can underestimate IOP by almost 50% in ocular hypertensive eyes (Jia et al. 
2000a). Such IOPs are higher than those typically seen clinically in open-angle glaucoma 
patients (32 ± 11 mmHg, mean ± SD)(Mafwiri et al. 2005).  
Severely elevated IOPs raise concerns of retinal ischemia, which is an undesirable 
confounding factor in experimental studies of glaucomatous optic neuropathy, inasmuch 
as ischemia can affect retinal function independent of retinal ganglion cell pathology. Zhi 
et al. examined the impact of IOP “spikes” on retinal ischemia, as assessed by retinal 
vascular occlusion, using optical coherence tomography/optical microangiography 
(OCT/OMAG) to image Brown Norway rat eyes at IOPs ranging from 10-100mmHg (Bui 
et al. 2013; Zhi et al. 2012). Blood flow in retinal vessels was affected by IOPs above 30 
mmHg and choroidal filling was affected at IOPs above 60 mmHg. Further analysis by Bui 
et al. utilized electroretinography (ERG) and found that retinal function was adversely 
affected at IOPs above 50 mmHg (Bui et al. 2005). These IOP spikes affected not only the 
retinal ganglion cell layer, but also caused functional changes in photoreceptors (as 
assessed by the ERG a-wave) and bipolar cells (b-wave). Although these functional 
changes recovered after IOP was returned to baseline levels (He, Bui, and Vingrys 2006), 
prolonged ischemic IOPs are known to permanently damage non-RGC cell types, 
especially the bipolar cells in the inner retina (Zhao et al. 2013; Schmid et al. 2014). 
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In an attempt to create models of OHT in which damage is isolated to RGCs alone, 
i.e. avoiding pan-retinal ischemia, several studies have defined IOP “thresholds” and 
excluded animals whose IOP exceeded this threshold value (Bunker et al. 2015; Struebing 
et al. 2018; Smedowski et al. 2014). However, for practical reasons, most studies conduct 
IOP measurements at most two or three times per week (Matsumoto et al. 2014; Dai et al. 
2012; Bunker et al. 2015; Foxton et al. 2013), which is insufficient to reliably detect IOP 
spikes throughout a study. Further, rodents show diurnal fluctuation in IOP; specifically, 
the IOP in normotensive rats can increase by approximately 10 mmHg at night (Jia et al. 
2000b), and OHT rats have a much more variable diurnal IOP response (Jia et al. 2000b; 
Kwong et al. 2013). These facts together suggest that ischemic levels of IOP can be 
frequently missed in OHT studies, especially with daytime IOP measurements, so that 
animals with ischemic damage can be inappropriately included in studies of the role of 
OHT in glaucomatous optic neuropathy. Thus, our goal was to develop an alternative 
technique to evaluate ischemia, based on analysis of the scotopic b-wave in ERGs 
previously used in the study of central retinal artery occlusion (Hayreh 2004; Hayreh, 
Kolder, and Weingeist 1980). We specifically compared two ischemic exclusion criteria 
based on: (1) an IOP threshold and (2) a threshold based on scotopic b-wave ERG 
amplitude. We hypothesize that an ERG-based exclusion criterion to identify eyes 




This study used 74 retired breeder (male, 8 - 10 months old) Brown Norway rats 
(Charles River Laboratories, Inc., Wilmington, MA). All procedures were approved by the 
Institutional Animal Care and Use Committee at the Georgia Institute of Technology and 
adhered to the Association for Research in Vision and Ophthalmology (ARVO) Statement 
for the Use of Animals in Ophthalmic and Vision Research. 
 Microbead Injection Preparation and Procedure  
The magnetic microbead model of glaucoma was used to induce unilateral ocular 
hypertension, using 2 µm and 6 µm diameter PEGylated magnetic microbeads 
(micromer®-M, Micromod, Rostock, Germany) mixed in a 1:1 ratio. Microbeads were 
autoclaved (manufacturer’s specifications: 3500 mbar pressure for 20 minutes at 121 
°C) and then thoroughly cleaned by washing five times with sterile Hank’s balanced salt 
solution (HBSS; H8264, Sigma-Aldrich, St. Louis, MO). Microbeads were suspended in 
HBSS at a concentration of 2.25 x 106 to 4.5 x 106 beads total per 25 µl injection. 
Rats were anesthetized with ketamine (60mg/kg) mixed with xylazine (7.5 mg/kg) 
and a drop of tetracaine (0.5%) was applied to the eye as a local anesthetic. A 25µl 
microbead suspension was vortexed to mix the suspension, pipetted onto a piece of 
parafilm, and drawn into sterile, disposable syringes with 31 G needles (BD 300 µl Insulin 
Syringe Ultra-Fine™ needle, Becton, Dickinson and Company, Franklin Lakes, New 
Jersey).  A neodymium, grade N40, nickel-plated annular magnet (H125D, Amazing 
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Magnets, Anaheim, CA) was placed around the limbus of the eye and the magnetic 
microbead suspension was injected into the anterior chamber. To minimize fluid reflux, 
the needle was held in the anterior chamber for a minute after injection and then slowly 
removed. The magnet was then held on the eye for 10 minutes to ensure that beads had 
settled into the iridocorneal angle. Both eyes (hypertensive and uninjected contralateral 
normotensive control) received topical antibiotic (Vetropolycin, Dechra Pharmaceuticals, 
Northwich, United Kingdom) to prevent infection. Saline eye drops were then placed on 
each eye to maintain hydration. Rats were placed on heating pads until ambulatory. If the 
experimental (injected) eye did not demonstrate at least one day of OHT, defined as an IOP 
elevation of  > 5 mmHg compared to the contralateral control eye within 7 days of injection, 
the eye was considered to be a non-responder and was then reinjected with 15 µl of 
microbead solution on Day 7 (n = 12 of 74 total rats).  
 Tonometry 
IOP measurements were taken between 7:00am and 10:00am using a Tonolab 
rebound tonometer (Icare Finland Oy, Vantaa, Finland). The rebound tonometer was 
previously calibrated on an intact post-mortem rat eye, by setting IOP from 5 to 50 mmHg 
in nine 5 mmHg steps using an external reservoir attached to a needle cannulating the eye 
and making Tonolab IOP measurements at each set IOP level (data not shown). Calibration 
results showed good agreement between set IOP values and measured IOP values, and thus 
no IOP correction was necessary. 
During each measurement session, eight tonometer measurements were taken from 
each eye of awake rats. The highest and lowest IOP measurements were discarded and the 
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remaining six values were averaged to obtain an IOP measurement for that eye. IOP 
measurements were recorded at day 0 (baseline), 1, 3, 5, 7, 10, and 14 days post-injection. 
We then calculated the IOP burden, also referred to as cumulative IOP difference 
(Frankfort et al. 2013), IOP exposure (Sappington et al. 2010), or positive integral IOP 
(Mabuchi et al. 2003), which provides an estimate of the total IOP “insult” to the 
hypertensive eye. We defined IOP burden as the area between the OHT and normotensive 
eyes on the IOP versus time plot.  If the measured IOP in the OHT eye was transiently 
lower than IOP in the contralateral (normotensive) eye, the IOP difference was set to zero 
at that time point, i.e. we did not allow negative contributions to the IOP burden.  
 Electroretinogram 
Retinal function was evaluated using dark-adapted bright flash ERG at baseline, 7, 
and 14 days after microbead injection. At each timepoint, rats were dark-adapted for 30 
minutes and anesthetized using ketamine (60 mg/kg) and xylazine (7.5 mg/kg). After 
induction of anesthesia, both eyes received a drop of tetracaine (0.5%) and tropicamide 
(1%) to locally anesthetize and dilate pupils, respectively. A ground electrode was inserted 
into the tail and reference electrodes were inserted subcutaneously into each cheek. Custom 
gold-loop electrodes were placed on the cornea of each eye and a layer of 
carboxymethylcellulose (Celluvisc, Allergan, Dublin, Ireland) was placed onto the corneal 
electrode to ensure electrical conductivity and prevent drying. Under dark-adapted scotopic 
conditions, a 6-step series of increasing flash intensities (-6.0 to 2.1 log cd s/m2) was used. 
Electrical responses to various full-field flash stimuli in a Ganzfield dome were recorded 
using a signal-averaging ERG system (UTAS BigShot; LKC Technologies, Gaithersburg, 
MD). Here, we only report data from the brightest flash (2.1 log cd s/m2) 14 days after 
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microbead injection, since bright scotopic flashes more reliably detect bipolar cell 
disfunction under ischemic conditions (Matsumoto, Shinoda, and Nakatsuka 2011). This 
flash intensity stimulates components from both the inner and outer retina, and the a-wave 
amplitude thus represents the combined response of the rod/cone photoreceptors. The a-
wave amplitude and corresponding implicit time were measured from baseline to the peak 
negative (trough) response after the flash stimulus (Aung et al. 2013)(Figure 29A). We also 
measured the b-wave amplitude and implicit time, which represent the function of the 
bipolar cells (Khan et al. 2015). The b-wave amplitude was measured from the trough (a-
wave) to the positive peak of the rising curve (Figure 29A). 
 
 RGC Axon Counting 
Rats were euthanized (via CO2 overdose) 14 days after microbead injection and 
optic nerves were dissected from whole globes to count retinal ganglion cell axons from 
cross sections using AxoNet, a fully convolutional neural-network program previously 
Figure 29: (A) Representative ERG waveform from a normotensive control eye. Green and red 
lines depict how a-wave and b-wave amplitudes were defined, respectively. (B) Peak measured IOP 
is plotted vs b-wave amplitude at day 14 in hypertensive eyes (n = 74 eyes). Blue line denotes peak 
IOP of 60 mmHg, above which rats were excluded based on the IOP Exclusion Criterion. Red line 
denotes the lower 99.5% confidence interval of b-wave amplitude at day 14 from contralateral 
normotensive control eyes, below which rats were excluded based on the ERG Exclusion Criterion. 
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developed in our lab (Ritch et al. 2019) and Appendix A. Optic nerves were fixed with 
isotonic Sorensen’s buffer containing 2.5% glutaraldehyde and 2% paraformaldehyde 
(EMS, Hatfield, PA), post-fixed in osmium tetroxide, dehydrated through an ethanol series 
and embedded in Araldite 502/Embed 812 resin (EMS, Hatfield, PA). Semithin sections 
(0.5 µm thick) were cut on a Leica UC7 Ultramicrotome (Leica Microsystems, Buffalo 
Grove, IL) and stained with toluidine blue (1%). Sections were imaged using a Leica DM6 
B microscope (Leica Microsystems, Buffalo Grove, IL) with a 63x lens and 1.6x multiplier 
for a total magnification of 100x. Z-stack tile scans of the entire optic nerve were imaged 
and the optimally focused image within each z-stack tile was chosen using the “find best 
focus” feature in the LAS-X software (Leica Microsystems, Buffalo Grove, IL). Contrast 
was then adjusted for each tile by maximizing grey-value variance and AxoNet was used 
to count normal axons in the entire optic nerve section as described in (Ritch et al. 2019) 
and Appendix A. We also sectioned and counted a representative subset of normotensive 
contralateral control eyes to provide a database of axon counts in normotensive eyes, 
finding axon counts of 80,546 ± 10,096 axons (mean ± SD, n = 53) which is similar to 
previous studies (Morrison 2005; Marina, Bull, and Martin 2010a).  
 IOP- and ERG-Based Exclusion Criteria 
Here, we explore two exclusion criteria for rats with OHT. The first is termed the 
“IOP Criterion”, and was adopted from Bunker et al. (Bunker et al. 2015). Specifically, we 
excluded rats if any IOP measurement exceeded a threshold of 60 mmHg (Figure 29B). 
This threshold value was based on previous research reporting decreased choroidal 
perfusion (Zhi et al. 2012) and significant reduction in ERG amplitude (Bui et al. 2013) in 
rats when IOP exceeded 60 mmHg. The second exclusion criteria is termed the “ERG 
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Criterion”, and was based on the expectation that rats experiencing damaging levels of IOP 
would have functional losses in bipolar cells and photoreceptors (Bui et al. 2005; Block 
and Schwarz 1998). We specifically focused on the b-wave amplitude at the conclusion of 
the study (day 14), since bipolar cell function (related to b-wave amplitude) is known to be 
sensitive to ischemic damage (Zhao et al. 2013; Block and Schwarz 1998; Hayreh, Kolder, 
and Weingeist 1980; Lima et al. 2010). We calculated the 99.5% confidence interval of the 
b-wave amplitude for all normotensive control eyes (n = 74) using the mean, standard 
deviation, and corresponding z-score (2.807). We then excluded both eyes of a rat if the 
measured b-wave amplitude in the OHT eye fell below this confidence interval (Figure 
29B).  
 Statistical Analysis 
IOP vs. time data were analyzed using a two-way repeated measures (RM) ANOVA 
with a Sidak post-hoc test. IOP burden and axon count data were analyzed using a one-way 
ANOVA with Sidak post-hoc test (GraphPad Software v8, San Diego, CA). Linear 
regressions were analyzed based on the null hypothesis that the slope significantly differed 





Of the 74 hypertensive eyes included in this study, 18 had peak IOP measurements 
exceeding 60 mmHg and were therefore excluded based on the IOP Criterion (Figure 29B). 
The 99.5% confidence interval for the b-wave amplitude (2.1 log cd s/m2) measured in 
normotensive contralateral control eyes was 217.47 – 754.84 μV. In the same cohort of 74 
hypertensive eye, 14 rats had a b-wave amplitude that fell below the lower bound of this 
confidence interval and were therefore excluded based on the ERG Criterion (Figure 29B). 
Of the 74 rats, 7 were excluded by both criteria, while 49 were included by both criteria. 7 
rats were included based on the IOP Criterion only and 11 rats were included based on the 
ERG Criterion only. 
IOP values in hypertensive eyes were lower in included rats vs. excluded animals, 
based on either the IOP Criterion or the ERG Criterion (Figure 30A and B; RM ANOVA, 
effect of IOP Criterion: F(1, 72) = 23.74, p < 0.0001; effect of ERG Criterion: F(1, 72) = 
Figure 30: IOP measurements from OHT eyes, showing rats that were included (solid) and 
excluded (hollow symbols) based on the IOP Criterion (A) or on the ERG Criterion (B). Excluded 
eyes had higher IOP values at 3, 5, 7, 10, and 14 days and 5, 7, and 14 days after microbead 
injection using the IOP Criterion or ERG Criterion, respectively (RM ANOVA, Effect of IOP 
Criterion: F(1, 72) = 23.74, p < 0.0001; Effect of ERG Criterion: F(1, 72) = 13.59, p = 0.0004; 
Sidak post-hoc). IOP burden (C) was larger for excluded rats than for included rats for either 
exclusion criteria (One-way ANOVA, F (3, 144) = 13.33, p < 0.0001; Sidak post-hoc: IOP 
Criterion p < 0.0001, ERG Criterion p = 0.0002). Data shown as mean ± SD (“ns” indicates not 
significant, * indicates p ≤ 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p 
< 0.0001). 
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13.59, p = 0.0004; Sidak post-hoc). Considering the IOP Criterion, excluded hypertensive 
eyes had higher IOP values at days 3, 5, 7, 10, and 14 (p< 0.002, p = 0.0035, p =0.0065, p 
= 0.0021, and p = 0.0194, respectively; Figure 30A), while hypertensive eyes excluded 
based on the ERG Criterion had higher IOP values at 5 (p = 0.0016), 7 (p < 0.0001), and 
14 (p = 0.0006) days after microbead injection (Figure 30B). Further, the IOP burden for 
excluded rats was significantly higher vs. that of the included rats using either exclusion 
criterion (Figure 30C; One-way ANOVA, F (3, 144) = 13.33, p < 0.0001; Sidak post-hoc: 
IOP Criterion p < 0.0001, ERG Criterion p = 0.0002).  
 
It is useful to consider several “case studies” of animals that were included and/or 
excluded by various criteria. First, we consider a representative rat that was included by 
both IOP and ERG criteria. The IOP trace and ERG waveform look normal/healthy (Figure 
31A and B), and the optic nerve demonstrates mostly healthy-looking axons (Figure 31C, 
Figure 31: Examples of data from rats included (A, B, and C) or excluded (D, E, F) by both IOP 
and ERG exclusion criteria. Plotted are IOP traces vs. time (A and D), ERG waveforms (B and E), 
and central region of optic nerve cross sections with the total axon count from the whole optic 
nerve superimposed (C and F). Data shown as mean ± SD, scalebar for optic nerve images is 10 
µm. 
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axon count = 63,456, or 78.8% of the mean value for normotensive control eyes). Next, we 
consider a rat that was excluded by both the IOP and ERG criteria (Figure 31D-F). The 
IOP reached a value slightly above 60 mmHg (Figure 31D), while the ERG waveform was 
completely flat (Figure 31E) and significant axon damage was evident in optic nerve cross-




Figure 32: Data from a rat that was included by ERG Criterion only, (A-C) and from two rats that 
were included by IOP Criterion only (D-I). Shown are IOP traces over time (A, D and G), ERG 
waveforms (B, E, and H), and central regions of optic nerve cross sections with the total axon count 
from the whole optic nerve superimposed (C, F, and I). Data shown as mean ± SD, scalebar for 
optic nerve images is 10 µm. 
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We next consider cases where the exclusion criteria did not agree (Figure 32). For 
example, some animals were included by ERG Criterion, but experienced a spike in IOP 
and thus were excluded by IOP Criterion (Figure 32A). In one such case, there was no 
significant decrease in b-wave amplitude (Figure 32B), yet a large loss of RGC axons was 
seen (Figure 32C, axon count = 25,503, or 31.7% of the mean value for normotensive 
control eyes). On the other hand, some rats were included by the IOP Criterion (only mild 
elevations in IOP), yet were excluded by the ERG Criterion, with extremely low b-wave 
amplitudes (Figure 32D – I). Even within this cohort, there were very dissimilar amounts 
of axon damage (axon count = 20,329, or 25.2% of normotensive control eyes [Figure 32F] 
vs. 50,436, or 62.6% of normotensive control eyes [Figure 32I]). 
 Discussion 
We here consider the vexing problem of how best to identify ischemic damage due 
to IOP “spikes” in rodent studies investigating the role of OHT in glaucomatous optic 
neuropathy, and propose a new method to exclude such ischemic animals. Currently, 
researchers identify potentially ischemic animals by defining IOP “thresholds” and 
excluding animals whose IOP exceeds this threshold (Bunker et al. 2015; Struebing et al. 
2018; Smedowski et al. 2014). However, measuring IOP at discrete time points provides a 
limited picture of the IOP history and thus little insight into the overall function of the 
retina. Our proposed ERG Criterion provides an alternative method to identify animals that 
have suffered ischemic retinal damage, known to lead to a loss of bipolar cell function as 
detected by abnormal ERG b-wave amplitudes. At the same time, this criterion allows for 
inclusion of rats who experience transient IOP spikes that are too short to induce permanent 
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ischemic damage (Bui et al. 2005; Bui et al. 2013; He, Bui, and Vingrys 2006) without the 
need to continuously monitor IOP.  
Our ERG Criterion was based only on b-wave amplitude and did not explicitly 
consider IOP. However, there was a large overlap between the excluded ERG and IOP 
Criterion groups; specifically, the ERG Criterion removed 66.2% of the same animals as 
the IOP Criterion. This is consistent with the idea that high IOP induces ischemic damage, 
as previously shown (Bui et al. 2005; He, Bui, and Vingrys 2006). Further, rats excluded 
by the ERG Criterion had higher IOPs and IOP burdens than those included based on the 
ERG Criterion (Figure 30), which indicates that assessing ERG function at the end of the 
study can identify a majority of rats that had very high IOPs. 
In the case study examples presented in Figure 31, the IOP traces and corresponding 
ERG waveforms showed the expected findings, i.e. rats with lower IOP measurements had 
better bipolar cell and photoreceptor function (Figure 31A-C), while those with higher IOP 
measurements had abnormal bipolar and photoreceptor function (Figure 31D-F). The more 
surprising finding was situations where there were conflicts between the two criteria 
(Figure 32). We suggest that such disagreement is due to the lack of continuous IOP 
monitoring. More specifically, in cases included by IOP Criterion only (Figure 32A-C), 
the observed IOP spike may have been of very short duration, thus allowing the bipolar 
and photoreceptor neurons to recover (Bui et al. 2013). On the other hand, in cases excluded 
by ERG Criterion only (Figure 32D-I), it is likely that these rats experienced an undetected 
significant interval of elevated IOP, i.e. between scheduled IOP measurement times, that 
induced permanent ischemic damage. For these reasons, it is important to evaluate the b-
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wave amplitude at the end of the study in order to obtain an accurate estimate of rats who 
may have acute (Figure 32A-C) vs. long-term (Figure 32D-I) retinal functional deficits. 
In our dataset, eye axon counts in hypertensive eyes did not differ between cohorts 
included by either IOP or ERG criterion (Supplemental: Figure 51; axon counts in eyes 
included by IOP Criterion = 44,458 ± 21,075; axon counts in eyes included by ERG 
Criterion = 42,869 ± 21,231; axon counts in entire cohort = 40,657 ± 20,541; mean ± SD). 
However, it is important to note that ischemia causes damage to all retinal neurons, 
including RGCs (Adachi et al. 1996) and thus we expect to observe a decrease in RGC 
axon counts in both glaucoma and ischemia. Thus, inability to suitably exclude animals 
with ischemic damage can lead to misleading conclusions. For example, if a treatment 
designed to preserve vision is tested in an OHT model and provides preservation of RGC 
axons, an investigator might conclude that this treatment was efficacious. However, 
without suitably excluding animals with ischemic damage, the observed protection against 
axon loss could in fact mean that the treatment protected against axon loss due to ischemia, 
rather than IOP-associated glaucomatous damage. Our ERG Criterion provides a way to 
exclude animals with permanent loss of bipolar cell function, focusing on animals with 
RGC-specific damage. 
In future, it would be useful to continuously monitor IOP to determine the duration 
and magnitude of elevated IOP that leads to ischemic damage as measured by ERG. 
Although continuous IOP monitoring in rodents is rarely performed, the exact IOP history 
is also available in the acute CEI model (Morrison et al. 2016). Further, Bello et al. recently 
developed a “smart pump” to continuously monitor a rat’s IOP (Bello, Malavade, and 
Passaglia 2017b), i.e. allowing determination of the exact IOP history of an eye. 
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Continuous IOP monitoring could also be used to obtain a more exact IOP burden 
measurement, which would lead to more accurate results in analyses which use IOP burden 
as a covariate (Huang et al. 2018; Frankfort et al. 2013; Mabuchi et al. 2003). However, 
even with continuous IOP monitoring, an ERG Criterion should still be considered because 
the exact level and duration of IOP elevation that result in ischemic damage is variable 
between animals (Bui et al. 2013). 
 Conclusion 
We suggest that an exclusion criterion based on the ERG may detect unwelcome, 
undetected IOP-induced ischemic damage in animal models of OHT. Since brief IOP 
spikes do not necessarily lead to permanent retinal damage, and because extended periods 
of elevated IOP may be missed, an ERG-based exclusion criterion may prove useful in 




Authors: Bailey G. Hannon*, Brandon G. Gerberich*, A. Thomas Read, Matthew D. 
Ritch, Elisa Schrader, Lauren Nichols, Cahil Pontis, Shreesh Sridhar, Stephen A Schwaner, 
Maya G. Toothman, Hannah Huang, Gabby S. Gershon, Andrew J. Feola, Machelle T. 
Pardue, Mark R. Prausnitz, C. Ross Ethier 
Target Journal: Proceedings of the National Academy of Sciences (will be reformatted to 
fit the specifications of this journal).  
Contribution: Bailey G. Hannon co-authored this chapter and performed IOP, OMR, 
ERG, and OCT experiments, determined proper timepoints and protocols for each outcome 
parameter tested, implemented and further developed the microbead model of OHT, 
performed data analysis, and helped to write this chapter.  
Brandon G. Gerberich co-authored this chapter and executed DIC inflation tests, aided with 
induction of microbead model of glaucoma, organized data from outcome parameters, 
researched and implemented the complex statistical analysis, and helped to write this 
chapter. 
 Introduction 
Glaucoma is the leading cause of irreversible blindness and affects an estimated 80 
million people worldwide (Quigley and Broman 2006). This optic neuropathy is 
characterized by the loss of retinal ganglion cell axons in the optic nerve head, which is the 
main and early site of damage in the disease (Quigley et al. 1981). Since a major risk factor 
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for glaucoma is elevated intraocular pressure (IOP), current treatments aim to lower IOP 
by increasing aqueous outflow or by decreasing aqueous humor production (Weinreb and 
Khaw 2004; Klein et al. 1992). Although these treatments can be successful in slowing or 
preventing progression of glaucomatous damage, they are not always effective; further, 
medication-based treatments have poor patient compliance (Heijl et al. 2002; Gurwitz et 
al. 1998). Therefore, treatments that overcome the limitations of current therapies are 
desirable. 
It is known that elevated IOP leads to increased biomechanical strain in the ONH 
tissues which is thought to promote RGC loss in glaucoma, and thus a promising alternative 
treatment approach for glaucomatous optic neuropathy is to protect against mechanical 
insult at the ONH due to ocular hypertension. Finite element modelling studies have 
analyzed the main factors that influence ONH mechanical insult, finding that scleral 
stiffness is the main such factor (Sigal, Flanagan, and Ethier 2005; Sigal et al. 2004). 
Experimentally, Coudrillier et al. found that localized stiffening of the peripapillary sclera 
reduced strain in the lamina cribrosa in ex vivo porcine eyes (Coudrillier, Campbell, et al. 
2016). Therefore, it is hypothesized that scleral stiffening may confer protection against 
IOP-induced glaucomatous damage (Campbell, Coudrillier, and Ethier 2014).  
A previous study (Kimball et al. 2014) assessed the effects of scleral stiffening on 
glaucomatous damage in mice. Specifically, Kimball et al. induced scleral stiffening in 
ocular hypertensive mice using the collagen crosslinking agent glyceraldehyde. Contrary 
to the expected outcome, they found that scleral stiffening increased rather than decreased 
glaucomatous damage. There are several possible explanations for this observed outcome. 
For example, whole globe scleral stiffening is known to increase the magnitude of IOP 
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fluctuations (Clayson et al. 2017), which may in turn damage RGC axons (Asrani et al. 
2000). Alternatively, glyceraldehyde toxicity may have outweighed the neuroprotection 
due to scleral stiffening.  
To further investigate the neuroprotective potential of scleral stiffening, we 
considered two different stiffening approaches (Table 10). In the first, we specifically 
stiffened only the peripapillary sclera, hypothesizing that such a localized stiffening would 
prevent glaucomatous damage by reducing ONH strain while maintaining the native 
compliance of the globe and thus minimizing IOP fluctuations. Our second approach was 
to stiffen the entire posterior sclera using a well-tolerated collagen crosslinking agent. For 
this purpose we used genipin, which has recently been shown to provide prolonged scleral 
stiffening at a much lower concentration than glyceraldehyde (Campbell et al. 2017; 
Hannon et al. 2019) and which has a promising safety profile (Huang et al. 1998; Avila 
and Navia 2010; Liu and Wang 2017; Song et al. 2017). We here assess the protective 
effects of these two stiffening paradigms in a rodent model of ocular hypertension.  
 Methods 
 Rationale for Using the Rat Model of Glaucoma 
We chose to use the widely-used rat model of glaucoma because of its many 
parallels to glaucoma in humans. Specifically, rat models of OHT demonstrate several of 
the clinical hallmarks of glaucoma, including: the ONH being a main and early site of 
damage, RGC apoptosis, remodeling of extracellular matrix components in the ONH, and 
ONH ‘cupping’ (Johnson et al. 2000; Guo et al. 2005; Morrison, Cepurna Ying Guo, and 
Johnson 2011). Rodents are also more cost-effective and ethically defensible than non-
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human primates. Considering only rodents, rat eyes are twice the size of mouse eyes and 
are therefore easier to work with than mice, e.g. for surgical techniques related to our 
targeted crosslinking procedure and for mechanical testing (Remtulla and Hallett 1985). 
Additionally, IOP measurements in mice are typically performed under anesthesia, which 
has been shown to underestimate the IOP by as much as 50% in OHT mice (Jia et al. 
2000a). Our chosen strain of rat, the Brown Norway rat, is notably more docile than other 
strains and therefore IOP can be measured without anesthesia. Further, we can confidently 
assess visual function in Brown Norway rats because they are a pigmented strain, and thus 
have a strong optomotor response (OMR), whereas albino rodents have little to no OMR 
(Douglas et al. 2005). Together, these reasons make the Brown Norway rat model of 
glaucoma suitable for evaluating our two stiffening paradigms. 
 Decision to Implement an Unpaired Treatment Paradigm 
Our study design (Figure 33) was guided by the desire to prioritize statistical power 
for comparing axon counts between crosslinking treatment groups in microbead-treated 
eyes. In other words, we wished to minimize variance for axon counts in crosslinked 
microbead-treated eyes. Thus, an unpaired experimental design (“Design A”) was used in 
this study in which, for each rat, one eye was received both a scleral stiffening treatment 
and microbeads to induce OHT (hypertensive experimental), while the contralateral eye 
was untreated (naïve normotensive control). Three alternative study designs were 
considered involving the hypertensive experimental eye treatment above but with different 
normotensive control eye treatments, including: (1) a paired design in which the control 
eye received a crosslinking treatment only (“Design B”), (2) a paired design in which the 
control eye received an HBSS (vehicle) injection only (“Design C”), and (3) a paired design 
 119 
in which the contralateral eye received a microbead injection only (“Design D”). Design C 
was eliminated because preliminary data suggested that HBSS injections do not cause 
significant axon loss and would only risk adding potential damage due to bilaterial injection 
. Design D was eliminated due to ethical concerns for animal wellbeing. 
 In addition to the two remaining options (Designs A and B) for control eye 
conditions discussed above, we considered two ways to assess RGC axon count differences 
between crosslinking treatment groups, including: (1) using raw values of axon counts in 
crosslinked hypertensive eyes (“Comparison I”), or (2) computing the difference in axon 
counts between the crosslinked hypertensive eye and control eye for each rat (“Comparison 
II”). The four possible combinations of two study designs and two comparisons are listed 
in Table 5 with our assessment of advantages and disadvantages of each. 
The key advantage of a paired design is the ability to account for (or explain) 
animal-specific variance in axon count comparisons between crosslinking groups. 
However, a paired design only increases statistical power if the required control eye 
treatment does not introduce greater variability. Therefore, merits of various design and 





A (Unpaired) I (Unpaired) Lowest variance 
Does not account for parity between 
eyes or for treatment toxicity in 
individual rats 
A (Unpaired) II (Paired) 
Moderate variance due to 
computed difference 
Accounts for parity between eyes of 
individual rats 
B (Paired) I (Unpaired) 
Moderate variance due to 
injection variability 
Accounts for treatment toxicity in 
individual rats 
B (Paired) II (Paired) 
High variance due to both 
computed difference and 
injection variability 
Accounts for both parity between eyes 
and for treatment toxicity in individual 
rats 
Table 5: Relative variance and strengths/weaknesses of various treatment designs and statistical 
comparisons considered for our scleral stiffening study design. 
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same rat and the expected variance between rats, and (2) the expected variance in axon 
counts attributed to the control eye treatments. While axon count parity between eyes of 
healthy rats has been demonstrated previously (Morrison et al. 2005), we believe that 
injection variability and measurement variability offset the potential statistical advantage 
gained by using a paired design. Additionally, we did not observe significant contralateral 
parity in outcomes from baseline electroretinography (ERG), OMR, or optical coherence 
tomography (OCT) measurements (Appendix E: Figure 53). 
In further support of an unpaired design, we have previously observed that 
crosslinking treatments increase variance in axon counts. Additionally, preliminary data in 
our lab suggested that bilateral crosslinking treatment leads to greater axon loss than a 
unilateral treatment, possibly due to increased systemic inflammation from two injections 
instead of one. In conclusion, we considered consequences of control eye injections and 
statistical comparisons involving parity between eyes. We concluded an unpaired design 
would maximize statistical power while sacrificing the ability to account for within-rat 
toxicity effects of each treatment. 
 Animals and Study Design 
86 male, retired breeder Brown Norway rats (8 - 10 months old) were purchased 
from Charles River Laboratories (Wilmington, MA). All procedures involving animals 
were approved by the Georgia Institute of Technology Institutional Animal Care and Use 
Committee and the Atlanta VA Medical Center Institutional Animal Care and Use 
Committee (IACUC). All procedures complied with the ARVO statement for the Use of 
Animals in Ophthalmic and Vision Research.    
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Our study design followed a “crosslink then OHT” approach. In other words, 
animals received a scleral stiffening treatment (or sham) unilaterally, were allowed to 
recover for one week, and then received a treatment to induce ocular hypertension in the 
same crosslinked eye. We chose to stiffen the sclera prior to inducing OHT to facilitate 
comparison of our results with those of Kimball et al. (Appendix E: Table 10) (Kimball et 
al. 2014). We used the well-established magnetic microbead model to induce OHT, which 
was applied to all eyes that received scleral crosslinking treatment (or sham). As noted 
above, all contralateral eyes were naïve, i.e. received no scleral crosslinking treatments (or 
sham) and no microbead injections. Animals were followed for 2 weeks after induction of 
OHT and then sacrificed.  
Figure 33: A) Scleral crosslinked eyes received one of three treatments by retrobulbar injection: 
HBSS (vehicle), Genipin (GP), or Methylene blue (MB). Those in the MB group also received 30 
minutes of localized red light (660nm) to selectively stiffen the peripapillary (but not peripheral) 
sclera. B) Timeline of experiments. Seven days after scleral stiffening treatment. the treated 
(“experimental”) eye received a microbead injection to induce ocular hypertension. Ocular 
hypertension was induced at Day 0. Rats were sacrificed at Day 14. C) Timing of experiments. IOP 
measurements were taken at Days -7, 0, 1, 3, 4, 7, 10 , and 14. OMR measurements were taken at 
Days 0, 7, and 14. ERG measurements were taken at Days -7, 7, and 14, and OCT measurements 
were taken at Days -7 and 14. DIC and axon count measurements were necessarily taken post 
mortem after collecting the sclerae and optic nerves on Day 14 immediately after euthanasia. 
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In more detail, rats were randomly divided into three “treatment groups” (Figure 
33A and Figure 52). Hanks balanced salt solution (HBSS) was used as the vehicle for 
treatments and as the sham injectate. One group (HBSS rats, n = 32) received this sham 
injection. The second group (GP Rats, n = 27) received genipin chemical crosslinking. The 
third group (MB Rats, n = 27) received methylene blue photocrosslinking. Treatments were 
applied unilaterally seven days prior to microbead injections using retrobulbar injections 
for the HBSS Rats (“HBSS hypertensive experimental” eyes), GP Rats (“GP hypertensive 
experimental” eyes), and MB Rats (“MB hypertensive experimental” eyes). Contralateral 
eyes received no injections and therefore served as normotensive controls for each animal 
(“HBSS normotensive control” eyes, “GP normotensive control” eyes, and “MB 
normotensive control” eyes). Within each animal, the eye (left (OS) or right (OD)) 
receiving treatment was randomly assigned.  
 Intraocular Pressure Measurements  
IOP measurements for each rat were taken between 7:00am and 10:00am using a 
Tonolab rebound tonometer (Icare Finland Oy, Vantaa, Finland) at baseline and at Day 0, 
1, 3, 5, 7, 10, and 14 after microbead injection. Awake rats were gently restrained by hand 
while eight tonometer readings were acquired from each eye. The lowest and highest IOP 
values were excluded from each set of daily measurements and the remaining six IOP 
values were averaged to obtain a representative IOP measurement. Prior to this study, the 
rebound tonometer was calibrated using a cannulated intact rat eye in which IOP was 
externally imposed using a hydrostatic pressure reservoir set to heights ranging from 5 to 
50 mmHg (data not shown). Calibration results showed good agreement between set IOP 
values and measured IOP values, and thus no IOP correction was necessary. We then 
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calculated the IOP burden, also referred to as cumulative IOP difference (Frankfort et al. 
2013), IOP exposure (Sappington et al. 2010), or positive integral IOP (Mabuchi et al. 
2003), which provides an estimate of the total IOP “insult” to the hypertensive eye. We 
defined IOP burden as the area between the OHT and normotensive eyes on the IOP versus 
time plot.  If the measured IOP in the OHT eye was transiently lower than IOP in the 
contralateral (normotensive) eye, the IOP difference was set to zero at that time point, i.e. 
we did not allow negative contributions to the IOP burden. 
 Crosslinking Injection Preparation  
Genipin and methylene blue solutions were both freshly prepared the morning of 
the retrobulbar injection. Genipin (Wako Pure Chemical Industries, Ltd., Richmond, VA) 
and methylene blue of USP grade (Apollo Scientific, Stockport, UK) were obtained in 
powder form and dissolved in Hank’s balanced salt solution (HBSS). Genipin was 
solubilized at a concentration of 15 mM by vortexing the solution for 15 minutes. 
Methylene blue was solubilized at a concentration of 3 mM by vortexing the solution in a 
microcentrifuge tube and heating to a temperature not greater than 100 degrees Celsius for 
5 minutes. Care was taken to minimize light exposure of the methylene blue solution to 
prevent possible photodegradation.  
 HBSS and Genipin Crosslinking Injection Procedures  
For HBSS and genipin retrobulbar injections, rats were anesthetized with a 
ketamine (60 mg/kg) and xylazine (7.5 mg/kg) cocktail. Once anesthetized, rats were 
placed on a heating pad and received a drop of topical tetracaine (0.5 %, Tetracaine Steri-
Units, Alcon, Geneva, Switzerland) as a local anesthetic. Retrobulbar injections were 
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performed on the eye designated as hypertensive experimental by gently proptosing the 
eye with curved forceps and inserting a disposable insulin syringe with a 31 G needle (BD 
300 µl Insulin Syringe Ultra-Fine™ needle, Becton, Dickinson and Company, Franklin 
Lakes, New Jersey) into the muscle cone through the inferior quadrant of the conjunctiva. 
150µl of either HBSS or genipin (15 mM) was then injected into the muscle cone. After 
injections, rats were given topical antibiotic (Vetropolycin, Dechra Pharmaceuticals, 
Northwich, United Kingdom) to prevent infection and antisedan (1 mg/kg) to reverse 
anesthesia (Turner, 2005).  
  Methylene Blue Photocrosslinking Procedure  
Rats were anesthetized with isoflurane/oxygen (5%/700 mL/min) and placed in a 
stereotaxic head mount (Kopf Instruments, Tujunga, CA) equipped with tooth bar over a 
heating pad, allowing facile manipulation of head position. 0.5% tetracaine (Tetracaine 
Hydrochloride Ophthalmic Solution, Amici Pharmaceuticals, Melville, New York) was 
applied topically as a local anesthetic to the eye designated as MB hypertensive 
experimental, followed by topical application of a 1% tropicamide eye drop (Tropicamide 
Ophthalmic Solution, Henry Schein, Melville, New York). An additional eye drop of 1% 
tropicamide was applied after 5 minutes and allowed to take effect for another 10 minutes 
to ensure maximal dilation of the iris. A hydrating eye lubricant (Puralube Vet Ointment, 
Dechra Pharmaceuticals, Northwich, United Kingdom) was applied to the contralateral eye 
designated as normotensive control, to prevent dehydration during the procedure. After 
dilation of the eye designated as MB hypertensive experimental, a 100 µL retrobulbar 
injection of 3 mM methylene blue was administered using a sterile 31 G insulin needle and 
syringe.   
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Immediately after injection, a contact lens was placed on the corneal surface to 
eliminate refraction from the cornea/lens, allowing for visualization of the fundus 
(Appendix E: Figure 54). The rat’s head was positioned with the eye designated as 
hypertensive experimental aligned on the optical axis of a custom-designed microscope 
capable of simultaneously imaging the fundus and projecting an annular beam of light 
tuned to excite methylene blue at 660 nm wavelength. Upon alignment of a low intensity 
guide beam (<0.1 mW) with the optic nerve, the light intensity was increased to a dose of 
10mW for 30 minutes to facilitate scleral crosslinking. During this time, beam position 
relative to the optic nerve head was monitored with the microscope and adjusted if 
necessary, using micropositioners to move the microscope position relative to the eye. At 
the conclusion of the 30-minute illumination period, the light source was turned off, the 
contact lens was removed, and once ambulatory on the heating pad, the rat was returned to 
its cage.  
  Microbead Injection Preparation and Procedure  
The magnetic microbead model of glaucoma was used to induce unilateral ocular 
hypertension in the eyes designated as hypertensive experimental. All microbead injections 
occurred at Day 0, which was seven days after crosslinking procedures.  A mixture (1:1) 
of 2 µm and 6 µm magnetic polystyrene microbeads (micromer®-M, Micromod, Rostock, 
Germany) with PEG-COOH surface chemistry (to promote biocompatibility) was used for 
microbead injections. Beads were autoclaved according to manufacturer’s specifications 
(20 minutes at 121 °C and 3500 mbar pressure) and then rinsed five times with sterile 
HBSS using cell culture sterility practices. Rats were anesthetized with a single dose of 
ketamine (60mg/kg) mixed with xylazine (7.5 mg/kg) and placed on a heating pad. 
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Tetracaine (0.5%, Tetracaine Steri-Units, Alcon, Geneva, Switzerland) was then applied to 
the eye. The bead suspension was vortexed for 15 seconds to suspend the beads, and a 
volume of 25µl was pipetted onto a sheet of wax parafilm. Deposited solutions were then 
drawn into sterile, disposable syringes with 31 G needles.   
The eye designated as hypertensive experimental was proptosed with a small 
section of a latex glove so that an annular magnet could be placed within the same plane 
as the iridocorneal angle. A neodymium, grade N40, nickel plated annular magnet (H125D, 
Amazing Magnets, Anaheim, CA) with dimensions of 7.14 mm inner dimeter, 12.70 mm 
outer diameter, and thickness of 3.18 mm was placed around the limbus after proptosing, 
and the eye received a intracameral injection of magnetic microbeads (2.25 x 106 to 4.5 x 
106 beads total per 25 µl injection) into the anterior chamber. The needle was held in the 
anterior chamber for 60 seconds following injection and then slowly removed to minimize 
fluid reflux. After injection, the section of latex glove was removed, and the magnet was 
placed back on the eye for 10 minutes to ensure that beads had settled into the iridocorneal 
angle. Both eyes (hypertensive experimental and normotensive control) of each rat 
received topical antibiotic (Vetropolycin, Dechra Pharmaceuticals, Northwich, United 
Kingdom) to prevent infection and hydrate the eye. Rats were placed on heating pads until 
ambulatory.   
IOP was measured 1, 3, 5, and 7 days following induction of ocular hypertension 
via microbead injection. If the experimental (injected) eye did not demonstrate at least one 
day of OHT, defined as an IOP elevation of >5 mmHg compared to contralateral control 
eye within 7 days of injection, the eye was considered to be a non-responder and was then 
reinjected with 15 µl of microbead solution on Day 7 (n = 12 of 74 total rats). Rats for 
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which IOP elevation failed 7 days after reinjection were removed from the study (n = 3) 
and therefore no rat was reinjected with microbeads more than once. Additionally, 7 rats 
were removed from the study upon reaching IACUC endpoint criteria for health/safety and 
2 rats died during anesthesia recovery, leaving a total of 74 rats analyzed in the study.   
 Assessment of Retinal Function: Electroretinography 
Dark-adapted ERGs were used to assess inner and outer retinal neuronal function. 
ERG measurements were taken at baseline, before both the crosslinking procedure and 
microbead injection, and at 7 and 14 days after microbead injection. At each timepoint, rats 
were dark-adapted for 30 minutes under dim red light and anesthetized using a cocktail of 
ketamine (60 mg/kg) and xylazine (7.5 mg/kg). Once asleep, both eyes received drops of 
tetracaine (0.5%) and tropicamide (1%) topically to anesthetize corneas and dilate pupils, 
respectively. A ground electrode was inserted into the tail of the rat and reference needle 
electrodes were inserted subcutaneously into the cheek by each eye. Custom gold-loop 
electrodes were placed on the cornea of each eye and a layer of carboxymethylcellulose 
(Celluvisc, Allergan, Dublin, Ireland) was applied over the corneal electrode to ensure 
electrical conductivity and prevent drying. Under dark-adapted conditions, a 6-step series 
of increasing flash intensities (-6.0 to 2.1 log cd s/m2) was used. Electrical responses to 
various full-field flash stimuli in a Ganzfield dome were recorded using a signal-averaging 
ERG system (UTAS BigShot; LKC Technologies, Gaithersburg, MD). Oscillatory 
potentials (OPs) were filtered with a 65-275 Hz bandpass fifth order Butterworth filter. 
Amplitudes and implicit times were measured in the following way: baseline to peak 
(positive scotopic threshold (pSTR)), baseline to trough (negative scotopic threshold 
(nSTR) and a-wave), trough to peak (b-waves and OPs). We elected to analyze ERG 
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amplitudes of the positive scotopic threshold (pSTR) and negative scotopic threshold 
(nSTR) at -6.0 log cd s/m2, the b-wave at -3.0 log cd s/m2 (b-wave), and the third OP (OP3) 
at 2.1 log cd s/m2 because these amplitudes have been shown to be associated with retinal 
ganglion cell damage in rodent models of glaucoma (Chen et al. 2015; Bui et al. 2005; Bui 
and Fortune 2004; Bui et al. 2013). 
 Ischemic Damage Exclusion Criteria  
Rats with likely ischemic damage to the retina were excluded from analysis. As 
described in detail in Chapter 6, exclusion was based on the b-wave amplitude from the 
brightest flash (2.1 log cd s/m2) at Day 14, since bipolar cell function (which drives b-wave 
amplitude) is known to be sensitive to ischemic damage at bright scotopic flashes 
(Matsumoto, Shinoda, and Nakatsuka 2011; Zhao et al. 2013). The 99.5% confidence 
interval of the b-wave amplitude was computed for all normotensive control eyes (n = 74). 
If the b-wave amplitude of the hypertensive experimental eye lay below this 99.5% 
confidence interval, that rat was excluded from analysis. Of the 74 rats analyzed, 14 rats 
were excluded by this criterion. The final total number of animals was thus 60, divided into 
HBSS rats (n = 21), GP rats (n = 20), and MB rats (n = 19). 
 Assessment of Visual Function: Optomotor Response  
Visual function was assessed via quantitative analysis of OMR thresholds of spatial 
frequency and contrast sensitivity (OptoMotry®; Cerebral-Mechanics, Lethbridge, AB, 
Canada). OMR was measured at baseline (prior to crosslinking treatment), Day 0 (7 days 
after crosslinking procedure, but prior to microbead injection that day), Day 7, and Day 14, 
following a protocol similar to that of Prusky and Douglas (Douglas et al. 2005; Prusky et 
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al. 2004). In brief, rats were placed on a raised platform in the middle of a box consisting 
of four flat screen monitors which displayed black and white vertical gratings that rotated 
at a speed of 12 degrees/second (d/s) to create a virtual drum. A trained observer then 
monitored the rat for a positive or negative reflexive head movement in response to the 
rotating gratings moving in a clockwise or counterclockwise direction, assessing the 
responses of the OS and OD eyes, respectively (Douglas et al. 2005). To determine an 
animal’s spatial frequency threshold, the vertical bands were held at 100% contrast and 
spatial frequency was adjusted in a staircase paradigm starting at 0.042 cycles/degree (c/d) 
until the threshold where the rat could no longer see the gratings was established. Contrast 
sensitivity threshold was determined using a similar staircase paradigm, but the spatial 
frequency was held at 0.064 (c/d) while the contrast was decreased from 100% until the 
threshold was determined. Contrast sensitivity is reported as the reciprocal of the 
Michelson contrast from the screen’s luminance, as previously described (Prusky et al. 
2004). Prior to OMR measurements, each rat eye was carefully inspected for any opacity 
or speckling of microbeads in the anterior chamber that might occlude the rat’s visual axis. 
If this was the case, that eye’s OMR was not recorded, making the final number of data 
used in OMR analysis 48, with 16 rats in each treatment group.  
 Assessment of Retinal Morphology: Optical Coherence Tomography  
A spectral-domain OCT system (Bioptigen 4300, Leica Microsystems, Buffalo 
Grove, IL) was used to measure total retinal thickness and qualitative retinal morphology 
in the posterior eye at baseline and Day 14. Total retinal thickness was measured at  
locations 0.5 mm and 1.2 mm from the center of the ONH. Rats were anesthetized using 
ketamine/xylazine, and eyes received drops of tetracaine and tropicamide as described 
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above. A 3-mm radial scan (1,000 A-scans per B-scan) centered at the optic nerve head 
was acquired in both normotensive control and hypertensive experimental eyes. B-scans 
from the superior-inferior and nasal-temporal axes of all eyes were assessed manually by 
a trained technician blinded to treatment group using a customized MATLAB program 
(MATLAB R2019a, Mathworks, Natick, MA). If fewer than two scans were of sufficient 
quality to measure retinal thickness accurately, the rat was eliminated from the OCT retinal 
thickness dataset. Measurements were taken at locations avoiding local vasculature, and 
these individual values from each quadrant were averaged together.  
 Optic Nerve Sectioning and Axon Counting  
Immediately after euthanasia via CO2 overdose, rat optic nerves were dissected 
from enucleated eyes and fixed in isotonic Sorensen’s buffer containing glutaraldehyde 
(2.5%) and PFA (2%, EMS, Hatfield, PA). Tissue was post-fixed in osmium tetroxide, 
dehydrated in an ethanol series, infiltrated and embedded in araldite-epon plastic (Araldite 
502/Embed 812, EMS, Hatfield, PA). Semi-thin sections of (0.5 µm thick) were cut on a 
Leica UC7 Ultramicrotome (Leica Microsystems, Buffalo Grove, IL) approximately 
1.5mm posterior to the sclera. Sections were stained with 1% toluidine blue and imaged 
with a Leica DM6 B microscope (Leica Microsystems, Buffalo Grove, IL) using a 63x lens 
and 1.6x multiplier for a total magnification of 100x. The entire nerve was imaged with a 
series of z-stack tile scans from which, the optimally focused image within each z-stack 
tile was selected using the “find best focus” feature in the LAS-X software (Leica 
Microsystems, Buffalo Grove, IL). Contrast was then adjusted for each tile by maximizing 
grey-value variance. Finally, normal axons were automatically counted using AxoNet, a 
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fully convolutional neural-network previously developed in our lab (Ritch et al. 2019) and 
Appendix A.  
 Whole Globe Inflation Testing  
After euthanasia, eyes underwent inflation testing as previously described (Hannon 
et al. 2019). A few modifications to the previously published method were made to adapt 
to the altered mechanical properties of microbead-injected eyes. In brief, when eyes were 
pressurized during whole globe inflation testing, we observed leakage of phosphate 
buffered saline (PBS) through the scleral shell via vasculature and the scleral canal. Such 
leakage was not previously observed in untreated eyes. Therefore, to reduce leaking, we 
substituted previously used PBS or mineral oil with a more viscous silicone oil as the 
pressurization medium. 
After enucleation, eyes were refrigerated on ice in PBS until preparation for 
inflation testing. Orbital muscle, fat, and connective tissues were removed to expose the 
posterior sclera. Eyes were blotted dry and adhered to a custom-designed thin aluminum 
plate incorporating a machined cup in the surface perforated with a hole, as follows. The 
cornea was positioned in this cup so the posterior sclera faced upward (away from the 
plate), and cyanoacrylate-based adhesive was cured with PBS to adhere the eye to the plate, 
taking care to remove any air bubbles that might have been trapped in the adhesive with 
the tip of a 30-gauge needle. The cornea was then carefully excised through the hole in the 
bottom side of the mounting plate, allowing for removal of the aqueous humor, lens, and 
vitreous humor. Silicone oil was used to replace the contents of the eye to reduce leakage 
of fluid through the sclera upon pressurization as noted above. The eye and aluminum plate 
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were then mounted onto a threaded acrylic base with screws such that the interior of the 
eye was in fluidic communication with channels in the acrylic plate. PBS was perfused 
through tubing connecting an adjustable pressure reservoir to the acrylic base. The eye was 
then pressurized to maintain its natural shape and blotted dry atop the aluminum plate. 
Black graphite powder (#970 PG, General Pencil Company, Inc., Redwood City, CA) was 
applied to the scleral surface with a cotton Q-tip to form a speckled pattern on the surface. 
Residual powder was flushed away with water and the eye was covered with PBS solution 
facilitated by placement of a removable reservoir atop the aluminum plate. Silicone oil was 
added to cover the surface of PBS in the reservoir, thus reducing loss of water through 
evaporation during testing as visualized in (Hannon et al. 2019) and Figure 16. 
Mounted scleral shells were subsequently prepared for inflation testing. Sensors 
were used to monitor pressure (142PC01G; Honeywell, Charlotte, NC) and flow rate 
(SLG64-0075; Sensirion, Stafa, Switzerland) of PBS into the eye. After confirming 
absence of major leaks at 15 mmHg, pressure was maintained at 15 mmHg for 5 minutes. 
Shells were then preconditioned for 10 cycles at a rate of 1 cycle per minute with pressure 
linearly varied from 3 mmHg to 15 mmHg and back to 3 mmHg as previously described 
(Hannon et al. 2019). At the conclusion of preconditioning, pressure was set to 1 mmHg 
and allowed to stabilize for 10 seconds. Pressure was then increased sequentially to 3, 10, 
20, and 30 mmHg at time intervals dictated by a flow rate stabilization criterion. 
Specifically, we required the magnitude of the measured rate of change in flow rate to be 
less 2 (nl/min)/s over a 10 minute window, thus allowing the shells to reach steady state at 
each pressure level. During inflation, images of the scleral surface were captured using a 
digital image correlation system (Dantec Dynamics, Skovlunde, Denmark).   
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At the conclusion of testing, Lagrange first principal strain over the scleral shell 
was computed from images using Dantec’s Istra 4D software (v4.4.1, Dantec Dynamics, 
Holtsville, NY). Data were exported to MATLAB for analysis with a customized script 
which identified/removed outliers as previously specified (Hannon et al. 2019). Steady 
state strain values at each pressure step were averaged over the peripapillary and over the 
non-peripapillary regions, and a Fung model was fit to the data. For each region an average 
strain value at 22 mmHg (physiological condition) was calculated and reported. 
  Data Analysis  
Data were analyzed using SPSS (IBM Corp. IBM SPSS Statistics for Windows, 
Version 25.0. Armonk, NY: IBM Corp) and GraphPad software (GraphPad Software, San 
Diego, California) and graphed using GraphPad. For each outcome measure, a linear 
regression was calculated for each treatment group, and outliers were removed by 
controlling the false discovery rate at 1% in GraphPad. Subsequently, the remaining data 
were analyzed using a two-way ANCOVA in SPSS with cumulative IOP burden at Day 14 
as the covariate. IOP burden was chosen as the covariate since it is a measurable indicator 
of the degree of biomechanical insult. All data are reported as mean ± standard deviation, 
unless otherwise stated. 
A two-way ANCOVA was used to analyze mean differences for each measured 
experimental parameter. Simple comparisons were made between hypertensive and 
normotensive eyes in each of the three crosslinking treatment groups (3 comparisons). 
Additionally, simple comparisons were made between mean values of the hypertensive 
eyes of each crosslinking group (3 comparisons).  Bonferroni correction was applied for 
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each parameter analyzed. For DIC strain analysis, a two-way ANCOVA was used with 
factors of: (1) “Region” having levels of (a) peripapillary sclera and (b) peripheral sclera; 
and (2) “Crosslinking Treatment” with levels of (a) HBSS, (b) GP, and (c) MB. Unless 
otherwise specified, all other outcome measures were analyzed with two-way ANCOVAs 
having two factors defined as: (1) “Microbead Treatment” having levels of (a) 
normotensive and (b) hypertensive; and (2) “Crosslinking Treatment” with levels of (a) 
HBSS, (b) GP, and (c) MB. Levene’s test was used to assess inequality of variance. 
Homogeneity of regression slopes was assessed using interaction terms of the factors and 
IOP burden covariate. In cases where statistically significant interactions existed for either 
factor and the IOP burden covariate, significance was interpreted only at the mean value 
of IOP burden for comparisons involving that factor. Number of animals in each outcome 
parameter are in Appendix E: Table 9. 
We created correlation matrices for ease of visualizing all outcome parameters at 
once. Parameters were grouped into the categories of “biomechanical”, “morphological”, 
or “functional”. Specifically, biomechanical parameters were those related to elevated IOP 
insult, including IOP burden, peripapillary scleral strain, peripheral scleral strain, 
equatorial diameter, axial length, and anterior chamber depth. Morphological parameters 
were those related to ON and retinal structure, including ON cross-sectional area, ON axon 
count, ON axon density, and retinal thicknesses 0.5 mm and 1.2 mm from the ON. 
Functional parameters were those related to visual acuity and retinal function, including 
contrast sensitivity, spatial frequency, pSTR amplitude, nSTR amplitude, b-wave 




 Microbead Injection Successfully Increased IOP 
Induction of ocular hypertension after microbead treatment at Day 0 produced an 
IOP elevation with an initial rapid rise peaking at Day 3, followed by a gradual decrease 
until Day 14 (Figure 34D). Though not statistically significant, we observed that HBSS-
treated eyes tended to have higher mean IOP burden compared to both GP- and MB-treated 
eyes. We accounted for any possible differences in IOP burden between individual rats or 
groups of rats by incorporating IOP burden as a covariate in our statistical analyses. 
Furthermore, to eliminate those rats which may have experienced IOP levels corresponding 
to ischemic damage, we introduced an ERG-based exclusion criterion. This functional 
ERG criterion eliminated rats with non-glaucomatous retinal damage. 
At all time points after microbead injection, mean IOP in microbead eyes was 
significantly elevated compared to normotensive controls (two-way RM ANOVA, time x 
treatment: F (30, 684) = 8.716, p < 0.0001, Tukey post-hoc) except for the GP cohort at 
Day 14. No significant differences in IOP were found between experimental treatment 
groups at any time point. Mean IOP burden values did not differ statistically significantly 




Figure 34: A) Representation of the posterior eye showing the peripapillary sclera, here defined 
as the region enclosed by a 2 mm diameter circle centered at the ON. The peripheral sclera was 
defined as the sclera outside this region.  B) Whole globe inflation tests indicated whole sclera 
stiffening with GP and targeted peripapillary sclera stiffening with MB. Mean values are plotted. 
Statistical comparisons were performed using an ANCOVA and therefore are comparisons of 
adjusted means. C) Mean IOP burden (pressure x time) did not differ significantly between 
crosslinking treatment groups. D) IOP levels increased after induction of ocular hypertension at 
Day 0 in microbead-injected eyes compared to normotensive control eyes. Statistical significance 
is indicated using the following convention: “*” for p < 0.05, “**” for p <0.01, “***” for p < 
0.001, and “****” for p < 0.0001. 
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 Mechanical Testing Confirmed That Crosslinking Effectively Increased 
Scleral Stiffness 
It was important to verify that Genipin and MB stiffened the sclera in treated eyes. 
For this purpose, we conducted inflation testing of post-mortem eyes and quantified their 
deformation using DIC analysis. We report adjusted mean strains from the ANCOVA 
analysis over the peripapillary and peripheral scleral regions (Figure 34A), a quantity that 
is inversely proportional to scleral stiffness. Peripapillary strain was greater than peripheral 
strain (p < 0.01, Figure 34B) in HBSS-injected (control) eyes, likely due to presence of the 
scleral canal in the peripapillary region. We found that mean scleral strain was 2- to 3-fold 
lower in both scleral regions in GP eyes compared to the corresponding regions in HBSS 
eyes (p < 0.0001, Table 6), indicating successful whole-scleral crosslinking by GP. There 
was no significant difference in scleral strains between regions within GP eyes. In MB 
eyes, peripapillary scleral strain was approximately 3-fold lower than in HBSS-treated eyes 
(p < 0.001, Table 6), but strains in the peripheral sclera did not differ significantly between 
HBSS and MB eyes, indicating that targeted peripapillary MB stiffening was successful. 
MB eyes had significantly reduced strain in the peripapillary region compared to the 
peripheral region within the same MB eye (p < 0.0001). Mean scleral strain values in 
hypertensive experimental eyes were analyzed using a two-way ANCOVA with IOP 
burden as the covariate (Figure 55; see Methods: Data Analysis). Strains were significantly 
correlated with IOP burden (p < 0.01, Appendix E: Figure 55).  
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 Retinal Thickness Measurements Suggested Protective Effects of Scleral 
Stiffening 
We used OCT imaging to measure total retinal thickness, expected to be decreased 
in eyes experiencing RGC axonal loss. Total retinal thickness at 0.5 mm from the ONH 
was not significantly different between hypertensive GP and HBSS eyes (Figure 35A, 
Table 2), and was less in hypertensive MB eyes compared to HBSS eyes (p < 0.05, Table 
6) and GP eyes (p < 0.0001, Table 6). Total retinal thickness at 0.5 mm from the ONH was 
significantly decreased in hypertensive experimental eyes for both HBSS and MB cohorts 
compared to respective normotensive controls (p < 0.0001, Figure 35A) but not for GP 
eyes. Total retinal thickness at 0.5 mm from the ONH significantly correlated with IOP 
burden (p < 0.05, Appendix E: Figure 56). Thus, there was a trend (not reaching statistical 
significance) suggesting that scleral stiffening using GP (but not MB) preserved retinal 
thickness at 0.5 mm from the ONH in hypertensive eyes.  
In contrast to the situation at 0.5 mm from the ONH, hypertensive GP eyes showed 
significantly larger mean total retinal thickness at 1.2 mm from the ONH compared to 
HBSS eyes (p < 0.0001, Table 6), potentially indicating a protective effect of GP against 
retinal changes (Figure 35B). No significant differences were observed in this measure of 
retinal thickness between hypertensive GP eyes and MB eyes, or between MB eyes and 
HBSS eyes. Total retinal thickness was significantly less in hypertensive experimental eyes 
compared to normotensive control eyes for HBSS eyes (p < 0.0001, Table 6) but not for 
GP or MB eyes. Representative OCT images shown in Appendix E: Figure 57 reveal minor 
qualitative differences as well as indications of ‘cupping’ at higher IOP burdens. We 
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conclude that GP, but not MB, treatment offers some protection against retinal thinning 
induced by OHT but that this thinning is spatially heterogeneous.  
 
 
Figure 35: A) Total retinal thickness measured 0.5 mm from the ONH. Retinal thickness in 
hypertensive GP eyes was not different than in GP normotensive controls, while thickness in 
hypertensive HBSS eyes was significantly less than in HBSS normotensive controls. Thickness in 
hypertensive MB eyes was less than in hypertensive GP and HBSS eyes. B) Total retinal thickness 
measured 1.2 mm from the ONH. Thicknesses in both GP- and MB-treated hypertensive eyes were 
not significantly different from their respective contralateral eye (normotensive) thicknesses, while 
thickness in hypertensive HBSS-treated eyes was significantly less than in HBSS normotensive 
control eyes. Thickness in hypertensive GP eyes was significantly greater than in hypertensive 
HBSS-treated eyes, suggesting a protective effect of GP against retinal thinning. C) Axon counts 
derived from ON cross-sections showed no significant protective effects of crosslinking. D) Percent 
axon loss in hypertensive experimental eyes (compared to normotensive control) ranked by rat 
number from least to greatest axon loss suggests that axon loss is decreased in GP and MB treated 
eyes. 
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Table 6: Adjusted means and simple comparisons for each parameter measured from rat microbead study. Two-way ANCOVAs were used to analyze 
each parameter with IOP burden as the covariate. Highly significant (p < 0.0001) p-values are bolded. 
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 Axon Counts are Not Preserved by Scleral Stiffening 
We quantified optic nerve axons using a machine learning-based software package 
(Ritch et al. 2019) in Appendix A. No significant differences were found between any 
hypertensive eye treatment groups (Figure 35C and Table 6), with adjusted mean axon 
counts of 78,900 and 39,400 axons in HBSS normotensive and hypertensive eyes, 
respectively; 82,400 and 46,200 axons in GP normotensive and hypertensive eyes, 
respectively; and 83,700 and 45,500 axons in MB normotensive and hypertensive eyes, 
respectively. Axon count and axon density were both lower in hypertensive experimental 
eyes compared to their respective normotensive controls (all p < 0.0001, Table 6). Axon 
counts and axon density were also significantly correlated with IOP burden (p < 0.001, 
Appendix E: Table 11 and Figure 58). Representative optic nerve images in Appendix E: 
Figure 59 qualitatively show a increase in axonal damage with increased IOP burden. As 
alternative measures of RGC axon count, we calculated axon density (axon count divided 
by ON cross-sectional area). We observed no significant differences between any 
hypertensive eye treatment groups (Table 6) when considering axon density and ON cross-
sectional area, nor a significant correlation with IOP burden (Appendix E: Table 11).  
 Eye Size Increased with IOP Burden 
Eye size was measured to understand possible sources of glaucomatous damage 
and physiological differences compared to clinical glaucoma. Hypertensive experimental 
eyes were significantly larger than normotensive control eyes for all three crosslinking 
treatment groups, as measured by axial length, equatorial width, and anterior chamber 
depth (all p < 0.05, Table 6). Further, all eye size measurements were correlated with IOP 
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burden (p < 0.0001, Appendix E: Table 9 and Figure 60). No significant differences in any 
eye size measurements were found between any hypertensive eye treatment groups. This 
increase in eye size differs from the situation in human adult glaucoma, where elevated 
IOP is not known to lead to ocular enlargement. However, other rodent models of OHT 
have observed similar findings of OHT-induced globe enlargement (Frankfort et al. 2013; 
Kimball et al. 2014). 
 Visual Function is Not Preserved by Scleral Stiffening 
Spatial frequency and contrast sensitivity thresholds were measured to assess 
possible preservation of visual function due to crosslinking treatment. No significant 
differences were found between mean resolved spatial frequencies of any hypertensive eye 
treatment groups. Spatial frequency and contrast sensitivity thresholds were significantly 
decreased in hypertensive experimental eyes compared to normotensive control eyes for 
all three crosslinking treatment groups (p < 0.0001, Table 6). Both spatial frequency and 
contrast sensitivity were significantly correlated with IOP burden (p < 0.0001, Appendix 
E: Table 11). Hypertensive eye spatial frequency and contrast sensitivity were not 






Figure 36: Functional outcome measurements across crosslinking treatment groups. We show 
OMR measurement outcomes, namely A) spatial frequency and B) contrast sensitivity; and ERG 
outcomes, namely C) pSTR amplitude, D) nSTR amplitude, E) b-wave amplitude, and F) oscillatory 
potential 3 amplitude. In all cases, a significant deficit was observed for hypertensive experimental 
eyes compared to normotensive control eyes. No significant differences were found between 
hypertensive eye treatment groups. These data indicate crosslinking did not preserve visual acuity 
or retinal function as measured by OMR and ERG. 
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 RGC Function is Not Preserved by Scleral Stiffening 
No significant differences in mean pSTR, nSTR, b-wave, nor oscillatory potential 
3 (Figure 36C-F) amplitudes were found between any hypertensive eye treatment groups 
(Table 6). Significant decreases in mean pSTR, nSTR, b-wave, and oscillatory potential 3 
amplitudes were observed in hypertensive experimental eyes compared to normotensive 
control eyes for all three crosslinking treatment groups (all p < 0.05, Table 6). pSTR and 
Oscillatory potential 3 amplitudes were significantly correlated with IOP burden (p < 0.05, 
Appendix E: Table 11 and Figure 61). Hypertensive eye ERG outcomes were not 
significantly different for comparisons between crosslinking treatment groups, indicating 
that our treatments did not protect against RGC functional loss. 
 Outcome Parameter Correlation Trends Differ by Treatment 
Parameters measured in the study were cross correlated to detect associations 
between biomechanical, morphological, and functional outcomes within treatment groups, 
and differences in these associations across treatment groups (Figure 37). We found that 
the strength of associations (either positive or negative) were different between groups, 
with ranking HBSS > GP > MB (ranked stronger to weaker). This was particularly evident 
for the comparison of morphological and functional outcomes with biomechanical insult. 
We believe this indicates that either: (1) MB treatment generally reduced the impact of 
biomechanical insult on morphological and functional outcomes, or (2) that MB-treated 
eyes experienced greater variability in the relationship between functional/morphological 
outcomes and mechanical insult, leading to the observed weaker correlation.  
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 Discussion  
We assessed the effects of peripapillary (targeted) scleral stiffening and whole-
globe scleral stiffening on glaucomatous outcomes in a microbead model of ocular 
hypertension in rats. We successfully stiffened the sclera, as confirmed by inflation testing 
of whole globes, and, as expected, we observed significant changes in morphological and 
functional outcomes in hypertensive eyes compared to normotensive eyes.  
In general, we did not observe significant protective effects of scleral stiffening on 
retinal ganglion cell function as measured by ERG, nor on visual function as measured by 
spatial frequency or contrast sensitivity. Further, we did not observe a significant 
preservation of retinal ganglion cell axons by scleral stiffening. However, we did observe 
preservation of retinal thickness at 1.2 mm from the ONH in GP-treated eyes compared to 
HBSS treated eyes (although not in MB-treated eyes), suggesting that stiffening may confer 
Figure 37: Parameters measured in hypertensive rat eyes were cross correlated and organized by 
mechanical, morphological, and functional categories for each crosslinking treatment. Stronger 
correlations were found for HBSS than for GP-treated rats, and for GP-treated rats compared to 
MB-treated rats, particularly in the relationship between morphological/functional with 
biomechanical parameters. Mechanical parameters included IOP burden, scleral strain, and eye 
dimensions. Morphological parameters include optic nerve size, axon count/density, and retinal 
thickness. Functional parameters include OMR and ERG data. A) HBSS hypertensive experimental 
eye matrix. B) GP hypertensive experimental eye matrix. C) MB hypertensive experimental eye 
matrix. Statistical significance was calculated for null hypothesis of zero correlation (significance 
indicated with “*” for the Bonferroni-corrected p<0.05 level). 
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some protective effects against hypertension-induced morphological changes in the retina. 
We conclude that scleral crosslinking did not preserve retinal or visual function but might 
slow the progression of morphological glaucomatous damage. Importantly, we saw no 
evidence to conclude that scleral stiffening worsens glaucomatous damage, in contrast to a 
previous report (Kimball et al. 2014).  
 Toxicity of Crosslinking Treatments May Have Contributed to RGC Loss 
We have previously evaluated the toxicity of HBSS, GP, and MB treatments in 
healthy rats at 4 weeks, 4 weeks, and 6 weeks (respectively) following injections. The 
average axon losses in these cohorts, compared to untreated controls, were 0%, 8%, and 
24% for HBSS, GP, and MB respectively. Additionally, deficits in retinal function as 
measured by ERG were observed in MB-treated rats. In the current study, we observed 
deficits in visual function measured by OMR seven days following crosslinking treatments,  
but prior to microbead injections (Figure 62). Thus, it is clear that GP and MB-treatments 
have inherent toxicity in the absence of ocular hypertension, which likely accounts for 
some of the damage observed in this study. With this understanding, one could interpret a 
finding of no difference in axon counts between stiffened eyes and sham-treated eyes as 
indicating protection by scleral stiffening against IOP-induced axon loss, which was offset 
by inherent toxicity of the stiffening agent. Indeed, there was a trend (that did not reach 
statistical significance) of axon preservation in GP- and MB-treated eyes, suggesting some 
inherent benefit of stiffening due to IOP-induced axon loss. Unfortunately, it is difficult to 
statistically separate the contributions of treatment toxicity and hypertension-induced 
damage, and thus we cannot make definitive conclusions in this regard.  
 147 
 Limitations of the Microbead Model Complicate Interpretation of Results 
Intracameral delivery of microbeads may be associated with some inflammation 
which could lead to retinal/RGC axon injury. It was thus of interest to estimate microbead 
procedure “toxicity”, which we did by extrapolating axon counts in low-IOP burden rats. 
More specifically, the y-intercept of the linear axon loss regression versus IOP burden can 
be considered to yield an estimated value of axon loss due to the microbead procedure 
alone without IOP elevation. These y-intercepts for the hypertensive HBSS, GP, and MB 
groups were 69,400 ± 14,000, 68,000 ± 9,000, and 62,300 ± 9,100 axons, respectively, 
which can be compared to average axon count values for normotensive controls in our 
study of 78,100 ± 7,200, 82,400 ± 4,700, and 83,800 ± 7,400 axons, respectively. 
Comparing the axon counts in low IOP burden rats to those of the normotensive controls, 
we estimate axon losses of 11% for HBSS, 17% for GP, and 26% for MB rats due to the 
crosslinking and microbead injections alone. These values are higher than the losses due 
to crosslinking treatment alone which were 0%, 8%, and 24% for HBSS, GP, and MB, 
respectively. Subtracting axon losses due to crosslinking toxicity alone from axon losses 
calculated in this study at low IOP burden, we find losses due to microbead treatment to be 
11%, 9%, and 2% for HBSS, GP, and MB treatments. These data support the hypothesis 
that the microbead procedure itself in Brown Norway rats leads to some axon loss, in an 
IOP-independent manner.  
In interpreting our results, it is important to recall that the model of ocular 
hypertension that we used caused rapid and large pressure elevations after microbead 
delivery, representing a severe challenge compared to a typical IOP history seen in open-
angle glaucoma. In other words, the biomechanical insult seen in our study was perhaps 
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more severe than would be observed clinically. Furthermore, our 14-day study duration 
was far shorter than time scales in open-angle glaucoma with OHT, so that adaptive 
responses such as collagen remodeling in the sclera would have had less chance to take 
effect in our study. Therefore, we interpret the results of our study to conservatively support 
the conclusion that scleral stiffening does not worsen glaucomatous damage and may 
confer some protection against aggressive mechanical insult.  
 Scleral Stiffening May Protect Against Morphological, but Not Functional 
RGC Damage 
Interestingly, we did not observe functional protection due to crosslinking, yet did 
observe some evidence of structural protection (retinal thickness preservation, a trend 
towards RGC axon preservation). Previously it has been shown that axon loss precedes 
retinal thinning, which may explain the relatively large deficit in axon count observed 
compared to the more minor retinal thinning in our study (Calkins 2012). We attribute the 
loss of retinal thickness in MB eyes at 0.5 mm distance from the ONH to localized toxicity 
of the photocrosslinking procedure. Recall that the region 0.5 – 1.0 mm from the ONH was 
selectively targeted for treatment in these eyes, likely inducing more damage at 0.5 mm 
than at 1.2mm. Another interpretation of this result is the potential of retinal edema which 
would balance out the loss of RGCs. However, histological analysis of the retina after GP 
and MB treatment alone did not show any signs of retinal edema (data not shown). 
It should be noted that our OCT measurements are of total retinal thickness because 
we could not confidently resolve the retinal nerve fiber layer in our imaging. However, we 
suspect our measurement of total retinal thinning at both locations (0.5 mm and 1.2 mm 
 149 
from the ONH) was caused in part by retinal nerve fiber layer thinning since we also 
observed significant loss of RGC axons (Figure 35C) and RGC function (Figure 36C-F) in 
HBSS hypertensive experimental eyes compared to normotensive controls. 
Although we did not observe any significant differences in RGC axon counts 
among hypertensive experimental eyes treated with GP or MB compared to HBSS eyes, 
we did see a trend towards preservation of axons with both treatments (Figure 35C). We 
hypothesize that over the short timescale of our experiment (14 days) RGC bodies were 
still present in the retina despite RGC axonal death, which explains why we saw 
preservation of the retinal thickness, but not RGC axon counts.  
Although our ERG results suggest a loss of RGC function across all treatment 
groups, differences were not seen between HBSS and GP or MB groups, suggesting that 
variability in the ERG and OMR data was large compared to effect size, thus yielding 
statistically insignificant differences. Functional outcomes are perhaps most relevant to 
clinical translation irrespective of morphological changes. Although we observed some 
protection against retinal thinning, we hypothesize that remaining RGCs had impaired 
function which may indicate scleral stiffening has the ability to slow the progression of 
glaucomatous damage.   
 We Were Able to Successfully Stiffen the Posterior Sclera with Both 
Targeted and Non-Targeted Treatments 
Scleral strain measured post mortem by whole globe inflation testing confirmed 
successful targeted peripapillary stiffening with MB and whole sclera stiffening with GP. 
We observed increasing strain values (decreased stiffness) with increasing IOP burden in 
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HBSS eyes, indicating weakening of the sclera under hypertensive conditions in this study. 
These effects have been observed on short time scales previously (Fazio et al. 2019).  
An unexpected observation in this study was the apparent similarity in measured 
strain values of HBSS eyes with those of GP and MB treated eyes at low IOP burdens. We 
have previously shown that MB and GP treatments reduce scleral strain significantly 
compared to HBSS in healthy rats. Since microbead-treated rats experiencing low IOP 
burdens should have scleral mechanical properties comparable to those of healthy rats, the 
observed similarity is difficult to explain. This observed effect could be an artifact of low 
sample (n = 2) size when only considering low IOP burden values, or due to inflammatory 
processes associated with the microbead model as discussed above. 
 Key Differences Exist Between This Study and a Similar Previous Study 
It is of interest to compare our results with those of the related study of Kimball et 
al. To stiffen the sclera, Kimball et al. used glyceraldehyde in 100 mM sodium phosphate 
(Na3PO4), the latter having an osmolarity of 400 mOsm (Kimball et al. 2014). After addition 
of 500 mM glyceraldehyde, the solution’s final osmolarity would have been 900 mOsm, 
well in excess of the physiological osmolarity of 285-295 mOsm (Fox 2011). Therefore, 
some of the axon loss observed may be attributed to hyperosmolarity of the injection 
solution. 
Additionally, Kimball et. al did not assess any functional or morphological 
outcomes in glaucomatous eyes. We have expanded upon this previous research by 
including assessments of visual function (OMR), retinal function (ERG), and retinal 
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thickness (OCT), helping to paint a more complete picture of the effects of scleral stiffening 
on clinically relevant outcomes. 
  Conclusion  
 Neither targeted peripapillary nor non-targeted posterior scleral stiffening 
worsened morphological and functional outcomes in a glaucomatous rat model. We found 
a modest potential preservation of total retinal thickness by genipin-induced scleral 
stiffening. Interpretation of these results is hindered by drawbacks of the microbead model 
of ocular hypertension (high variability, some inherent retinal toxicity). Further research is 
needed to investigate the impact of scleral stiffening on glaucomatous damage.  
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There is a need to develop glaucoma treatments which go beyond simply lowering 
IOP and instead provide neuroprotection. One possible route towards this goal is to 
decrease the damage due to IOP-induced strains in the ONH. Previous biomechanics 
research suggests that stiffening the posterior sclera can reduce ONH strains, and thus 
could potentially preserve RGC function in glaucoma. The purpose of this dissertation was 
to develop and evaluate a scleral stiffening treatment meant to decrease ONH strain and 
thereby mitigate glaucomatous damage, as laid out in three specific aims. Below, I 
summarize the conclusions, limitations, and future directions for each aim. 
 Specific Aim 1: Evaluate the efficacy of potentially biocompatible non-
photoactivated collagen crosslinking agents on posterior rat sclera ex 
vivo.  
 Conclusions 
In Chapter 3 of this dissertation we showed that we can successfully stiffen the 
posterior rat sclera ex vivo using three non-photoactivated collagen crosslinking agents: 
glyceraldehyde, genipin, and methylglyoxal. These results demonstrated the efficacy of 
using DIC whole globe inflation tests to discern changes in scleral mechanical properties. 
From these data, we selected genipin for future in vivo use in Aims 2 and 3, because genipin 
yielded the highest stiffening to concentration ratio with a promising toxicity profile (Liu 




Although our partial incubation technique minimized the effects of inter-eye 
variability, it allowed potential diffusion of crosslinking agents from the incubated 
(experimental) region to the control region of the eye. This likely explains why we 
observed slightly lower strains in the control regions at higher concentrations of 
glyceraldehyde and genipin, i.e. control regions in these eyes may have been stiffened, 
causing an artificially lower magnitude of relative stiffening at higher concentrations of 
genipin and glyceraldehyde. Further, strains in the experimental portions of 
glyceraldehyde- and genipin-treated eyes only decreased as concentrations increased up to 
a point, indicating a possible upper limit to stiffening.  
There were also several limitations with the inflation testing set-up which introduced 
error and caused us to exclude several eyes from analysis. These included: 1) optical issues 
from glare or poor speckling coverage, 2) undesired movement of speckles due to flow 
from the peristaltic pump, 3) decreased IOP from undetected leaks in the eye, and 4) eyes 
not reaching an equilibrium within the set pressure step time. We acknowledged these 
limitations and made subsequent significant improvements to the DIC inflation testing set-
up as described in Chapter 4. These modifications included the addition of a 
preconditioning procedure to reduce testing variability and a flow sensor to better 
determine when and if an eye had reached equilibrium. 
 Future Work 
Each of the small molecule crosslinking agents were able to stiffen the posterior rat 
sclera by several hundred percent, which can inform future studies investigating effective 
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dosages for stiffening the posterior rat sclera. Additionally, these results provide evidence 
of an apparent saturation of stiffening, as seen in our genipin and glyceraldehyde results 
and consistent with other studies (Mi et al. 2001; Bi et al. 2011). Since crosslinking agents 
are potentially toxic, in vivo concentrations should be chosen as to not exceed this “point 
of diminishing returns”, where increasing an agent’s concentration no longer results in an 
increase in the tissue’s stiffness. This saturation point has been evaluated using a ninhydrin 
assay, in which crosslinking extent is determined by quantifying the amount of free 
crosslinking sites (Bi et al. 2011; Sung et al. 2001). Results from this assay could be used 
to determine the magnitude of crosslinking necessary to obtain significant changes in 
material stiffness. Future work could also observe the duration of genipin crosslinking in 
vivo by assessing the percentage of crosslinking at various timepoints after injection.   
In this current study, we assessed the efficacy of natural, non-enzymatic collagen 
crosslinking agents. Enzymatic collagen crosslinkers such as lysyl oxidase act as catalysts 
for collagen crosslinking reactions in vivo and are more biocompatible than non-native 
crosslinking agents (Gacheru et al. 1990). Further, exogenous lysyl oxidase has been used 
to stiffen cartilage (Hadidi et al. 2017) and thus may be an attractive method of scleral 
stiffening in the future. However, lysyl oxidase is much larger (~32,000 Daltons) than the 
small molecules used in this study (72 to 226 Daltons), reducing lysyl oxidase’s ability to 
penetrate the entire scleral thickness (Ambati et al. 2000). If scleral penetration is a 
significant problem, genetic modification to upregulate scleral production of lysyl oxidase 
could be an alternate approach. Future work should consider using enzymatic crosslinking 
if small molecule crosslinking methods fail to produce safe and efficacious results.  
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 Specific Aim 2: Optimize the in vivo delivery technique of a chosen 
stiffening agent selected in Aim 1, and characterize the resulting 
duration of increased scleral stiffness, and potential adverse effects in 
vivo. 
 Conclusions 
After selecting genipin as our crosslinking agent in Aim 1, we conducted in vivo 
assessment of genipin-induced scleral stiffening. In Chapter 4, we successfully stiffened 
the posterior rat sclera both at one day and four weeks after a single genipin treatment and 
confirmed the presence of autofluorescent genipin crosslinks. In Chapter 5, we assessed 
the toxicity of genipin-induced scleral crosslinking. These results show that genipin 
treatment did not cause sustained deficits in retinal or visual function over four weeks, but 
did induce a slight, nonsignificant loss of RGC axons (approximately 8%) and minor ocular 
inflammation. 
 Limitations 
One obvious limitation is that whole globe inflation testing is a post-mortem 
mechanical analysis and therefore cannot be used for longitudinal analysis of genipin-
induced scleral stiffening in vivo, which would be ideal. Further, although we made several 
improvements to the DIC inflation testing system for this aim, there remained limitations 
(detailed in Chapter 4) which led to the exclusion of approximately half of the eyes tested.  
The ERG protocol used in Chapter 5 was extremely robust because it selectively 
stimulated each layer of retinal neurons for a complete assessment of retinal toxicity. At 
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the time of these experiments, we chose to evaluate RGC function using the photopic 
negative response (PhNR) which has been shown to decline in glaucoma patients 
(Viswanathan et al. 2001) and ocular hypertensive rats (Huang et al. 2018). In hindsight, 
the PhNR recordings may not have thoroughly assessed rat RGC function, as we failed to 
observe significant decreases in the PhNR of OHT eyes, even with confirmed loss of visual 
function and RGC axons. Instead, using the STR (as was done in Chapter 7) would have 
improved our evaluation of RGC function. 
Our chosen retrobulbar injection technique for genipin delivery to the posterior eye 
likely caused collagen crosslinking of the extraocular muscles. This is a serious limitation 
of our injection technique because stiffening the extraocular muscles could restrict eye 
movements, which are essential to prevent image blur and preserve image resolution (Land 
2019). We attempted to target genipin more closely to the sclera by using a sub-Tenon’s 
injection, but we had difficulties implementing this technique in the rat eye because of its 
small size and thus, proceeded to use retrobulbar injections with this limitation in mind.  
Although our observed RGC axon loss was relatively low, there was a large amount 
of variability within these measurements. This variability could be attributed to a limitation 
of our retrobulbar injection technique. Specifically, since the retrobulbar injection is a 
“blind” injection, we hypothesize that genipin could have been injected at a location closer 




 Future Work 
The results from Chapter 4’s inflation experiments show promise of extended 
duration genipin-induced scleral stiffening. Future work should assess potential use of in 
vivo methods to longitudinally assess scleral stiffness. One promising new method for 
future implement  is optical coherence elastography, in which OCT imaging is used to 
perform elastography (Larin and Sampson 2017). This method has been applied ex vivo to 
evaluate corneal properties (Ford et al. 2011), in vivo to measure retinal properties using 
acoustic radiation force (Qu et al. 2018), and in situ to measure scleral properties (Singh et 
al. 2017). This method could be applied in vivo by altering the IOP via cannulation of the 
anterior chamber and measuring the scleral displacements using OCT. Currently, it is very 
difficult to image the posterior scleral thickness accurately with OCT in rats, but with more 
advancements in OCT this could be possible in the future. 
Although the work described in Chapters 4 and 5 show the feasibility of genipin-
induced scleral crosslinking in vivo, we are still concerned about the minor, nonsignificant 
loss in RGC axons. Future work should determine if a lower concentration or volume of 
genipin is able to reduce this minor toxicity, while stiffening the posterior sclera to a similar 
extent as reported in Chapter 4. 
If genipin-induced scleral stiffening is applied clinically in the future to treat 
glaucoma (or myopia), several caveats must be addressed since there are differences 
between rat and human eyes. For one, the rat has an estimated eye diameter of 6.5 mm and 
scleral thickness of 0.1 mm (Pazos et al. 2016), while the human has an estimated eye 
diameter of 24 mm and scleral thickness of almost 1.0 mm near the optic nerve (Olsen et 
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al. 1998; Silver and Geyer 2000). Because of these eye size differences, we would need to 
modify the volume and concentration of genipin for crosslinking of the human sclera. We 
can estimate based on the volume of rat and human eyes that the 150 µl injection volume 
used in this thesis would be approximately equivalent to a 6.5 ml injection volume in a 
human, although this is likely an overestimate since the desired injected volume may scale 
with eye surface area rather than volume. Nonetheless, we do not know the exact volume 
or concentration necessary for in vivo stiffening in humans, because of the complex kinetics 
of genipin diffusion in the sclera. 
With diffusion in mind, some studies have assessed the depth of genipin-induced 
crosslinking, observing more crosslinking towards the outer layers and less towards the 
inner layers (Mi et al. 2001).  In our study, we were able to confirm full scleral penetration 
of genipin using cryosections that showed autofluorescent crosslinks throughout the entire 
scleral thickness. In the thicker human sclera, a higher concentration and/or volume will 
likely be necessary to achieve uniform genipin crosslinking throughout the sclera. Further, 
scleral penetration should be confirmed in human eyes, possibly by imaging the 
autofluorescent genipin crosslinks in scleral cross-sections as we have done. 
Future work should evaluate other genipin delivery techniques, such as using a sub-
Tenon’s injection instead of a retrobulbar injection. A sub-Tenon’s injection may be 
advantageous because Tenon’s capsule immediately surrounds the sclera, which would 
create a more targeted delivery of genipin to the sclera while possibly limiting the stiffening 
of the extraocular muscles. However, in other studies that have used a sub-Tenon’s 
injection instead of a retrobulbar injection to deliver genipin to the posterior sclera in vivo, 
multiple injections of genipin were needed to obtain the desired stiffening effect (Liu and 
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Wang 2017; Wang and Corpuz 2015). Since ocular injections are known to have serious 
complications (Patel et al. 1996; Vasavada, Baskaran, and Ramakrishnan 2017; Wessels 
and Bowers 1998), keeping the number of injections to a minimum is extremely important 
when developing a new treatment. With regards to our study in Chapter 4, future work 
should assess the maximum duration of our genipin-induced stiffening effect to determine 
when (or if) multiple treatments are needed. 
 Specific Aim 3: Determine efficacy of stiffening the posterior sclera as 
a possible neuroprotective therapy in glaucoma. 
 Conclusions 
Finally, with our safe, efficacious, stiffening treatment developed in Aims 1 and 2, 
we aimed to evaluate our treatment’s ability to mitigate glaucomatous damage. We induced 
OHT using the magnetic microbead model, assessed retinal and visual function, evaluated 
RGC morphology, and confirmed scleral stiffening. In Chapter 6, we detail our ERG 
exclusion criterion capable of removing animals from the study that likely had permanent 
ischemic damage. The results from our glaucoma model study (Chapter 7) revealed that 
genipin-induced scleral stiffening potentially prevented OHT-induced retinal thinning, but 
failed to provide protection against OHT-induced loss of RGC axons and their function. 
It is of interest that our results differed from the findings reported by Kimball et al., 
who reported that scleral stiffening increased glaucomatous damage in OHT mice (Kimball 
et al. 2014). Our results indicate scleral stiffening minimally reduces or does not change 
glaucomatous damage in OHT rats. We here propose several explanations for the 
discrepancy: 
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1) Glyceraldehyde-induced scleral stiffening is toxic, and thus was the cause of the 
observed increase in glaucomatous damage. 
We have reason to believe that the glyceraldehyde treatment may have been toxic, 
and thus the treatment alone caused the observed increase in damage. The treatment 
paradigm used by Kimball et al. included three 400µl injections of a hyperosmolar 
concentration of glyceraldehyde within seven days. The number of injections, volume, 
and hyperosmolarity are all a concern and it is surprising that the study showed no loss 
of RGC axons from the treatment alone. Additionally, the ERG analysis of toxicity did 
not include an evaluation of RGC-specific function, and overall visual function using 
OMR was not evaluated. All in all, we feel that a more thorough assessment of 
glyceraldehyde might be necessary to confirm that the glyceraldehyde stiffening 
treatment was not toxic. 
 
2) Both studies had disproportionate IOP burdens in treatment groups which led to the 
contrast in findings. 
Although Kimball et al. did account for IOP burden using a regression analysis as 
we did in our study, it is important to point out that in both studies, treatment groups 
did not have the same distribution of IOP burdens. In the Kimball et al. study, eyes 
treated with glyceraldehyde had significantly higher IOP burdens than untreated eyes 
which could contribute to the increase in damage. In our study, HBSS treated eyes had 
a trend towards a higher overall IOP burden compared to our genipin eyes, which could 
contribute to our results showing little to no changes in damage. These differences in 
IOP burdens could be the main component affecting both study’s conclusions. Further, 
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the IOP burdens used in these analyses were likely not accurate as stated previously in 
this section, and thus need to be assessed with caution.  
 
3) Axonal damage differences observed in Kimball et al.’s study was due to ischemia. 
Kimball et al. used five IOP measurements over the six-week period: 1, 4, 7, 14, 
and 42 days after the microbead injection and did not apply any exclusion criterion to 
account for ischemic damage. Further, the measured IOP elevation was 20 mmHg one 
day after microbead injection in anesthetized mice. As stated previously in this thesis, 
anaesthesia has been shown to underestimate the IOP by 50%, thus suggesting the 
possibility that mice had permanent ischemic damage. Therefore, the findings from this 
study could in fact show that glyceraldehyde-induced scleral stiffening increased 
ischemic, rather than glaucomatous, damage to RGCs. 
 
4) Scleral stiffening does increase glaucomatous damage as seen in Kimball et al., but 
our acute model of glaucoma prevented us from observing similar results. 
Both studies used the microbead model of OHT, but our study was shorter (2-week 
duration) than the Kimball et al. study (6-week duration), even though the duration of 
IOP elevation was approximately two weeks in both studies. Due to the aggressive 
nature of our microbead model of OHT, we felt that extending the study duration would 
have led to massive axon loss, making the discovery a potential treatment effect 
extremely difficult. Even with our shorter 2 week duration, it is possible that scleral 
stiffening did cause some axonal loss, but because our acute model of OHT was so 
aggressive, any modest damage induced by scleral stiffening alone was overwhelmed 
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by the damage from OHT. Further research would be required to evaluate this 
hypothesis. 
 
5) Rats and mice are different animals and thus respond differently to scleral stiffening. 
Although rats and mice are both rodents, these animals do have differences, and thus 
respond differently to treatments affect glaucoma pathophysiology. Using just the 
simple size comparison from these two studies, scleral stiffening is potentially more 
efficacious in larger animals, although we only have two data points here to suggest 
this hypothesis. 
 Limitations 
The major limitation of this aim lies with the chosen model of OHT. Even after four 
years of fine-tuning our microbead model procedure, we still struggled to induce a mild 
IOP elevation of OHT in a repeatable manner that did not cause ischemic-level IOPs. The 
ERG Criterion described in Chapter 6 attempted to account for this by excluding animals 
with severe, non-glaucomatous retinal damage. However, this criterion still allowed 
animals with mild functional deficits in non-RGC layers to be included in analysis. 
Although other studies have also reported slight deficits in a- or b-wave amplitudes, these 
deficits seem to closely correlate with a high IOP burden (Chen et al. 2015; Fortune et al. 
2004). This is incredibly concerning for the glaucoma community since ERG 
measurements are not typically made, leading to the potential inclusion of animals with 
non-RGC specific damage in experimental studies. Further, even if a study suitably 
excludes animals with obvious ischemic damage, most models of OHT may only be 
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modelling an advanced form of glaucoma, in which retinal function in other layers is 
impaired (Fazio et al. 1986). 
Our complex statistical analysis incorporated IOP burden as a covariate to account 
for the variable degree of IOP insult each animal experienced. This introduces a limitation 
of this study because our IOP burden is an ‘estimated’ IOP burden, due to the discrete IOP 
measurements taken throughout the study. These IOP measurements did not include the 
daily IOP fluctuations which are known to be variable, especially in OHT eyes (Jia et al. 
2000b; Kwong et al. 2013; Agnifili et al. 2015). The analysis might have led to different 
conclusions if we were able to continuously monitor the IOP to obtain the ‘true’ IOP burden 
for each animal. 
Finally, we observe that even if the findings from Kimball et al. and our current 
study agreed, there would still be limitations regarding the chosen rodent model of 
glaucoma. In contrast to primates, rodents do not have a collagenous lamina cribrosa. This 
is an important anatomical difference, since the lamina cribrosa is known to be the main 
structural component in the ONH which resists IOP-induced strain. Therefore, future 
studies should evaluate how scleral stiffening affects RGC damage when there is more 
structural support in the ONH from the lamina cribrosa.  
 Future Directions 
Although our study provided promising results indicating a potential preservation 
of the retinal thickness from genipin treatment, there could be other factors which led to a 
lack of retinal thinning observed. For one, we did not analyze retinal health by using retinal 
histology. Further histological evaluation of the retina would allow us to better understand 
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whether genipin-treated eyes had signs of retinal edema or scarring, which would tend to 
increase retinal thickness.  
Further, we cannot conclude definitively that scleral stiffening is not efficacious 
due to experimental limitations described above. To more thoroughly assess the hypothesis 
of this thesis, an improved rat model of glaucoma is necessary. Future studies should use 
a model of OHT which induces a more moderate IOP elevation that more closely resembles 
the clinical presentation of the disease. Ideally, this model would continuously monitor 
IOP and induce a similar level of IOP burden to each animal.  
Bello et al. recently developed a “smart pump” to continuously monitor and adjust 
a rat’s IOP (Bello, Malavade, and Passaglia 2017b, 2017a). This method involves an 
extremely difficult and long surgery to install the pump “outlet” in the eye and thus requires 
a trained surgeon to implement. Additionally, the surgery can only be performed on a 
maximum of two rats per day. Although these limitations seem difficult to overcome, 
limitations with other models of OHT are also severe, and sometimes impossible to 
overcome. There are also several advantages of the Bello et al. model. Since IOP exposure 
would be similar across all animals tested, we expect the outcome parameters to have less 
variability which would decrease the number of animals necessary to reach significance. 
Continuous IOP monitoring would also allow for a more exact IOP burden measurement, 
which would lead to more accurate results in analyses which use IOP burden as a covariate 
(Huang et al. 2018; Frankfort et al. 2013; Mabuchi et al. 2003). Implementation of an OHT 
model resembling Bello et al. would be more efficacious for further studies evaluating 
scleral stiffness along with other treatments. Other models of OHT involving genetic 
modifications of the Brown Norway rat may also be of interest once they are developed. 
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Morrison et al. recently developed an acute model of OHT which uses a controlled 
elevation (CEI) of IOP at 60 mmHg (Morrison et al. 2016). The advantages of this 
technique are that the exact IOP history is known and that it presents a similar damage 
pattern to that seen in glaucoma. While these facts are attractive, there are also concerns, 
specifically that the model appears to have aspects of acute ischemic damage. For example, 
ERG measurements two days after CEI revealed functional deficits in all retinal layers 
including photoreceptors (a-wave amplitude), bipolar cells (b-wave amplitude), and RGCs 
(pSTR). Function in the photoreceptors and bipolar cells recovered to control levels at 14 
days after CEI, but there was a sustained deficit in RGC function. One might conclude that 
this is indicative of early glaucomatous damage. However, another conclusion is that RGCs 
are simply more prone to develop permanent damage after ischemia. Since there is a known 
preferential loss for inner retinal neurons compared to outer retinal neurons in ischemic 
conditions, this conclusion makes sense (Schmid et al. 2014). For these reasons, I believe 
that the CEI model is not the best option for future studies aiming to evaluate potential 
clinical treatments for RGC-specific, non-ischemic damage.  
 Final Thoughts 
This dissertation developed a safe and efficacious genipin-induced scleral 
stiffening treatment through ex vivo and in vivo experiments in healthy rat eyes. These 
findings support the clinical translatability of genipin-induced scleral stiffening treatments.  
When applied in a rat model of glaucoma, there is an absence of a strong protective effect 
of genipin-induced scleral stiffening on RGC function and structure, which may be due to 
significant limitations in our rat model of OHT. These findings caution researchers to 
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thoroughly assess their models of OHT to ensure they are modelling RGC-specific 
glaucomatous damage.  
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Abstract 
In this work, we develop a robust, extensible tool to automatically and accurately 
count retinal ganglion cell axons in optic nerve (ON) tissue images from various animal 
models of glaucoma. We adapted deep learning to regress pixelwise axon count density 
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estimates, which were then integrated over the image area to determine axon counts. The 
tool, termed AxoNet, was trained and evaluated using a dataset containing images of ON 
regions randomly selected from whole cross sections of both control and damaged rat ONs 
and manually annotated for axon count and location. This rat-trained network was then 
applied to a separate dataset of non-human primate (NHP) ON images. AxoNet was 
compared to two existing automated axon counting tools, AxonMaster and AxonJ, using 
both datasets. AxoNet outperformed the existing tools on both the rat and NHP ON datasets 
as judged by mean absolute error, R2 values when regressing automated vs. manual counts, 
and Bland-Altman analysis. AxoNet does not rely on hand-crafted image features for axon 
recognition and is robust to variations in the extent of ON tissue damage, image quality, 
and species of mammal. Therefore, AxoNet is not species-specific and can be extended to 
quantify additional ON characteristics in glaucoma and potentially other 
neurodegenerative diseases.  
Introduction 
Glaucoma is the leading cause of irreversible blindness worldwide (Greco et al. 
2016; Kwon et al. 2009), and thus is a significant research focus. This optic neuropathy is 
characterized by degeneration and loss of retinal ganglion cells (RGCs), which carry visual 
signals from the retina to the brain. Therefore, an important outcome measure in studying 
glaucomatous optic neuropathy, particularly in animal models of the disease, is the number 
and appearance of RGC axons comprising the optic nerve (Mikelberg et al. 1989; Morrison 
et al. 1998), usually evaluated from images of optic nerve cross sections. Using images 
obtained by light microscopy is known to result in an axon count underestimation of around 
30% relative to counts from images obtained by transmission electron microscopy (Marina, 
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Bull, and Martin 2010a; Cepurna et al. 2005). However, light microscopy is widely used 
to count optic nerve axons because of its lower cost and favorable time requirements for 
tissue preparation. Therefore, in this work we focus on axon counting in optic nerve images 
generated by light microscopy. 
Manual counting is the gold standard approach to quantify RGC axons, but it is 
extremely labor-intensive, since RGC axon numbers in healthy nerves range from the tens 
of thousands in mice to more than a million in humans (Sanchez, Dunkelberger, and 
Quigley 1986). Further complicating axon quantification is the fact that axon appearance 
can be highly variable. For example, in the healthy nerve, most axons are characterized by 
a clear central axoplasmic core and a darker myelin sheath; following previous work 
(Chauhan et al. 2006; Marina, Bull, and Martin 2010a), we will refer to such an appearance 
as “normal”. However, in damaged nerves (and even occasionally in ostensibly heathy 
nerves), other axon appearances occur, such as an incomplete myelin sheath and/or a darker 
axoplasmic region. Such variability further increases the time needed for axon counting, 
since the person doing the counting often needs to decide whether a given feature is (or is 
not) an axon. Here and throughout we place the term “normal” in quotes. An “abnormal” 
axon appearance does not necessarily imply non-functionality, and it is important to keep 
this distinction in mind. 
 To reduce the time-intensive counting process, various techniques have been 
developed for assessing axon counts and/or optic nerve damage, including: semi-
quantitative, sub-sampling, semi-automated counting, and automated counting. In the 
semi-quantitative approach, scores based on a damage grading scale are assigned to optic 
nerves by different trained observers, and then averaged (Chauhan et al. 2006; Jia et al. 
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2000b). While this method is capable of quickly capturing whole-nerve changes, and can 
identify subtle changes that may not be detectable by axon counting, it is subjective and 
requires scorers who have significant experience and training. Sub-sampling is the process 
of estimating axon loss by manually counting smaller regions of the nerve using either 
targeted or random sampling and then extrapolating to the whole nerve or providing an 
RGC axon count per area measurement (Marina, Bull, and Martin 2010a). Sub-sampling 
is faster than full manual counting, but it is still labor-intensive and can be poorly suited to 
analyzing nerves with regional patterns of axonal loss (Jia et al. 2000b). Koschade et al. 
have recently presented an elegant stereological sub-sampling method that eliminates the 
bias that can occur in sub-sampling, but still requires manual axon counting in 5-10% of 
the full nerve area (Koschade et al. 2019). While this is feasible in animals with fewer 
axons per optic nerve like the mouse, counting this proportion may be prohibitive for 
animals with more axons per optic nerve, as in primates. Semi-automated axon counting 
methods use algorithmic axon segmentation techniques involving hyperparameters, such 
as intensity thresholds which are manually tuned for individual sub-images (Cull et al. 
2003). These methods are faster than manual counting and more thorough than qualitative 
or sub-sampling methods, but still require extensive human direction and time. Because of 
these limitations, there has been a push to develop fully automated counting tools.  
Two of the most used automated counting tools are AxonMaster (Reynaud et al. 
2012) and AxonJ (Zarei et al. 2016). Both tools are designed to count “normal”-appearing 
axons, i.e. axons with a clear cytoplasmic core and a dark myelin sheath (Chauhan et al. 
2006; Marina, Bull, and Martin 2010a). They use dynamic thresholding techniques to 
segment axonal interiors from myelin and other optic nerve features. While these tools are 
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faster and provide more detail than sub-sampling methods, they also suffer limitations. For 
example, they are not easily extensible to counting features other than “normal”-appearing 
axons. Further, the two automated counting packages that currently exist were each 
developed for a specific animal species, and due to inter-species differences, it is not clear 
how accurate these approaches are for other species. Specifically, AxonMaster (Reynaud 
et al. 2012) and AxonJ (Zarei et al. 2016) were calibrated and validated for use in non-
human primate (NHP) and mouse models of glaucoma, respectively. Recently, 
AxonMaster has been applied to count RGCs in healthy and damaged tree shrew optic 
nerves (Samuels et al. 2018), but it has yet to be validated in this animal model. Our 
preliminary testing using these packages suggested that they are also sensitive to image 
quality, tissue staining intensity, and nerve damage extent in images of rat optic nerves (see 
Results). 
Our goal was thus to create axon-counting software to overcome the above 
limitations, i.e. software which was robust to image quality and staining intensity, which 
could be used in multiple animal models of glaucoma, and which was extensible to 
quantification of features other than “normal”-appearing axons. Our approach to building 
this software, which we refer to as AxoNet, is an adaptation of the U-Net convolutional 
neural network architecture developed by Ronnenberger et al. (Ronneberger, Fischer, and 
Brox 2015) applied to the count density learning approach of Lempitsky et al. (Lempitsky 
and Zisserman 2010). 
We used a dataset of manually annotated rat optic nerve images for developing and 
training AxoNet (detailed in 
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Annotated Dataset Construction). The rat is a widely used animal model for 
glaucoma research and elevation of IOP produces retinal structural changes and loss of 
RGC axons similar to those observed in the human pathology (Johnson and Tomarev 
2010). We then applied our software to the dataset of NHP optic nerve images which was 
used to validate AxonMaster by Reynaud et al. (Reynaud et al. 2012). Below we present 
the detailed methodology of the dataset and software construction used to develop AxoNet, 
as well as a comparison of AxoNet’s automated counting results to those of AxonMaster 
and AxonJ. We have packaged AxoNet into a user-friendly open source plugin for the 
widely-used ImageJ image processing platform (Schneider, Rasband, and Eliceiri 2012), 
as described in greater detail in the Discussion. 
Methods 
Rat Optic Nerve Dataset 
Animals 
This study used twenty-seven optic nerves from fourteen (12 male and 2 female) 
Brown Norway rats aged 3 to 13 months (Charles River Laboratories, Inc., Wilmington, 
MA). All procedures were approved by the Institutional Animal Care and Use Committee 
at the Atlanta Veterans Affairs Medical Center and Georgia Institute of Technology and 
conformed to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) 
guidelines. All experiments were performed in accordance with relevant guidelines and 
regulations. Rats used in this study had various degrees of optic nerve health. Each animal 
had one eye with experimental glaucoma induced unilaterally by either microbead injection 
(12 animals) (Samsel et al. 2011; Bunker et al. 2015; Hannon et al. 2018) or hypertonic 
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saline injection (2 animals) (Feola et al. 2019). Optic nerves in the resulting dataset ranged 
from ostensibly normal to severely damaged due to ocular hypertension. These 14 rats had 
been used in other studies and both optic nerves were used from each animal. One optic 
nerve was excluded from the study because it had suffered extreme damage secondary to 
abnormally high IOP elevation, which made it unsuitable for use in studying experimental 
models of chronic glaucoma. 
Tissue Processing and Imaging 
Animals were euthanized via CO2 and the eyes were enucleated. The optic nerves 
were transected with micro scissors close (<1 mm) to the posterior scleral surface. Optic 
nerves were then placed in Karnovsky’s fixative, post-fixed in osmium tetroxide, 
dehydrated in an ethanol series, infiltrated and embedded in Araldite 502/Embed 812 resin 
(EMS, Hatfield, PA). Semithin sections of 0.5 µm thickness were cut on a Leica UC7 
Ultramicrotome (Leica Microsystems, Buffalo Grove, IL) and stained with 1% toluidine 
blue (Sigma-Aldrich, St. Louis, MO). They were imaged with a Leica DM6 B microscope 
(Leica Microsystems, Buffalo Grove, IL) using a 63x lens and 1.6x multiplier for a total 
magnification of 100x. A z-stack tile scan of the entire nerve was taken and the optimally 
focused image within each z-stack tile was selected using the “find best focus” feature in 
the LAS-X software (Leica Microsystems, Buffalo Grove, IL). Contrast was then adjusted 
for each tile by maximizing grey-value variance.  
Annotated Dataset Construction 
To train the AxoNet algorithm, it was necessary to create a dataset of rat optic nerve 
images in which axons had been identified. For this purpose, 12 x 12 µm sub-images were 
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randomly selected from the full 27 nerves, producing a dataset of 1514 partial optic nerve 
images, with a minimum of 20 sub-images selected from each nerve, as follows:  
• 200 images were taken from each nerve from the two female rats. These images 
were initially 48 x 48 µm, but were subdivided into 16 images, so that each sub-
image matched the 12 x 12 µm standard image size.  
• 50 images were taken from each nerve from an early cohort of four microbead 
model rats. The images from this source were initially 24 x 24 µm, and were 
similarly subdivided to yield 12 x 12 µm standard sub-images.   
• 20 to 50 images, each of which was 12 x 12 µm, were selected from each nerve 
from a later cohort of eight microbead model rats.   
All sub-images were 187 x 187 pixels, i.e. image resolution was 15.7 pixels per μm. 
However, during training and processing, the U-net architecture’s four max pooling layers 
each reduced the image side lengths by half, so all images used by AxoNet were required 
to have dimensions evenly divisible by 24. To comply with this restriction, we used bilinear 
pixelwise interpolation to resize all dataset images to 192 x 192 pixels, i.e. to the 
dimensions closest to the images’ original size which were divisible by 16.  
Selected sub-images varied in image quality and contrast, and were from optic 
nerve sections that varied in tissue staining intensity and degree of nerve damage (Figure 
38). The images in our dataset can be viewed using the code found at github.com/ethier-
lab/AxoNet. Four trained counters manually annotated “normal”-appearing axons in 1184 
sub-images, where a “normal” axon was defined as a structure with an intact and 
continuous myelin sheath, a homogenous light interior, and absence of obvious swelling or 
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shrinkage (Marina, Bull, and Martin 2010a; Chauhan et al. 2006). Each counter annotated 
one point per axon at the axon’s approximate center. The remaining 290 sub-images were 
annotated by two counters, who annotated one point per axon at the approximate center by 
consensus. Axons with abnormal morphology were not annotated. Counters were 
instructed to count axons which lay fully inside the frame of the image or which intersected 
either the left or top image border and lay more than halfway within the image borders. 
Manual annotations were made using Fiji’s Cell Counter plugin (Schindelin et al. 2012) 
which recorded the spatial location of each axon marked within the image. There was good 
agreement between manual counts for most sub-images (Error! Reference source not f
ound.). 
 
Figure 38: Rat Dataset Image Variety. A representative set of images from the rat optic nerve 
image dataset is shown. These images include a range of nerve health, variations in sample 
processing quality, and in image acquisition contrast and quality. 
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These manual annotations were then used to create a “ground truth” axon count 










                    where 
𝑐𝑘(𝑖, 𝑗) = {
1,  if the (𝑖, 𝑗)th pixel was annotated by the kth counter
0,  otherwise
 
Figure 39: Histogram of Manual Count Variability for Rat Dataset. Variability between counters 
is expressed as the coefficient of variation (standard deviation of the manual count divided by the 
mean of the manual count for each image). The median coefficient of variation was 0.12, indicating 
good general agreement between manual counters. 
 180 
and 𝐾 was the number of counters for the sub-image in question. Note that the dimensions 
of 𝑫 equaled the dimensions (in pixels) of the corresponding sub-image. Entries in 𝑫 were 
then distributed (“blurred”) according to 𝑫𝒅𝒊𝒔𝒕 = 𝒢(𝑫), where 𝒢 is an isotropic Gaussian 
blur operator with 𝜎 = 8 and filter size of 33 pixels, chosen empirically to distribute the 
annotated density values 𝐷(𝑖, 𝑗) over the full axon. This operation resulted in some of the 
annotated density values lying outside the edges of the original sub-image. This is a desired 
effect as an object which lies partially on an image’s boundary should not be counted as a 
full object (Lempitsky and Zisserman 2010). The resulting ground truth matrix 𝑫𝒅𝒊𝒔𝒕 
provided the spatial distribution of axon count density over the full sub-image, which when 
summed over all entries, produced the ground truth axon count for the full sub-image or 
the average count from all experts for that sub-image. All density map values were stored 
as double-precision floating-point numbers. 
Dataset Subdivisions 
The dataset was randomly divided into training, validation, and testing image 
subsets following a 60%-20%-20% split (Ripley 1996). Images selected from each 
animal’s optic nerves were used exclusively for either the training, validation, or testing 
subsets. AxoNet was trained using the training subset. The validation subset was used to 
optimize AxoNet’s architecture and hyperparameters as well as to construct axon count 
correction equations, as was done using the calibration set in Reynaud et al. (Reynaud et 
al. 2012) and as described in the Correction Equations section. Finally, the testing subset 
was used for final evaluation of tool performance. 
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NHP Optic Nerve Dataset 
We then evaluated the performance of AxoNet on optic nerve sub-images from 
NHPs with experimental glaucoma. This dataset had been previously annotated using a 
semi-automated manual method and used to develop one of the existing automated axon 
counting tools, AxonMaster, as described in Reynaud et al. (Reynaud et al. 2012). 
NHP dataset images were randomly divided into validation and testing subsets 
following a 50%-50% split to match the even proportion of images in the validation and 
testing subsets of our rat dataset. Each subset contained 247 images.  The validation subset 
was used to construct axon count correction equations, as was done using the calibration 
set in Reynaud et al. (Reynaud et al. 2012) and as described in the Correction Equations 
section. The testing subset was used for final evaluation of performance for each tool. 
AxoNet Development 
Implementation and Network Architecture  
We implemented a U-Net based encoder/decoder architecture similar to the original 
architecture developed by Ronnenberger et al. (Ronneberger, Fischer, and Brox 2015). 
Specifically, we reduced the number of filters in our convolutional layers by a factor of 
two, resulting in a feature depth at each layer half of that in the original architecture. This 
reduction by a factor of two was chosen to reduce the number of parameters in the network, 
decreasing training time and reducing the danger of overfitting, while retaining the base-
two relationship between the feature depths of the encoding and decoding paths of the U-
Net. We also tried reducing the feature numbers by a factor of four, but this reduction 
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decreased network performance. We used a rectified linear unit (ReLU) instead of a 
sigmoid activation for the final layer, indicated by the red arrow in Figure 40. The change 
in the final layer allowed us to regress the ground truth pixelwise count density function 
instead of predicting cell segmentation. A ReLU activation layer is better suited for this 
task because it produces a linear range of output pixelwise density map values, while a 
sigmoid activation biases its outputs towards either 0 or 1. We also included padding on 
all convolutional layers so that feature arrays would not shrink after each convolution. This 
network was implemented in Python (Version 3.7.3, Python Software Foundation) using 
Keras (Chollet 2015) and Tensorflow (Ramsundar and Zadeh 2018). The images were 
normalized by subtracting the mean pixel value for the entire image from the pixelwise 
values and dividing the resulting pixel values by twice the standard deviation of the image 
pixel values. This ensured that all pixels with intensities within ±2 standard deviations of 
the mean fell within the range [-1.0, +1.0]. Finally, outlier pixels were set to either -1.0 or 
1.0.  
The network was trained for 25 epochs with a batch size of 1 image per step and a 
learning rate of 10-4. Our modified architecture was developed iteratively by training on 
the training subset of the rat dataset and evaluating on the validation subset of the rat 
dataset. Validation performance was used to compare architectures until performance 




Figure 40: U-Net Architecture. A visual representation of our adapted U-Net convolutional neural 
network architecture, with the encoding branch on the left and the decoding branch on the right. 
Each box represents the output array of one of the convolutional network’s layer operations, which 
are represented by colored arrows. The bold numbers to the left of the boxes indicate the row and 
column sizes of the feature array at those layers. The numbers above the boxes indicate the feature 
depth of each layer, which is the third dimension of the feature array at that layer. Numbers in the 
layer operations key indicate the size of that operation’s sliding window. Products of feature 
concatenation are indicated by two boxes sharing a border with the concatenated box in grey. The 
asterisk indicates dropout with rate = 0.5 applied after convolution. ReLU is an abbreviation for 




We used the Adam optimizer (Kingma and Ba 2014) to minimize a mean squared 
error loss function evaluated between ground truth and predicted count density function 
estimates for each image as follows:  
 
𝐿(𝑋, 𝛽) =  
1
𝑁





where 𝛽 is the learned network parameter set, 𝑁 is the number of pixels in the image, ?̂? is 
the predicted pixelwise axon count density function, 𝑋𝑛 is the n
th pixel in image 𝑋, and 𝑚 
is a density scaling factor. The density scaling factor was used to increase the magnitude 
of the predicted pixelwise density values, allowing better regression convergence. Its value 
was determined during hyperparameter optimization, resulting in a final value of 𝑚 = 1000. 
Since a density scaling factor was used, the trained network overestimated the density 
predictions by a factor of 𝑚. Thus, all density maps predicted during network application 
were divided by 𝑚 to accurately reflect ground truth. After density map prediction, we 
estimated total axon count within an image as follows: 
 
𝐴𝑥𝑜𝑛 𝐶𝑜𝑢𝑛𝑡(𝑋, 𝛽) =  
1
𝑚




Because dataset sub-images were randomly selected from larger full optic nerve images, 
their edges could contain cropping artifacts such as axons that intersected the edge. Dataset 
images and ground truth arrays were thus padded during training and evaluation through 
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the edge-mirroring process recommended in (Ronneberger, Fischer, and Brox 2015) to 
prevent the propagation of influence from these edge artifacts and any resulting biases in 
cell count. When computing the mean squared error loss function (Equation 6), we did not 
include mirrored pixels. Training images were resized from 187 x 187 pixels to 192 x 192 
pixels and extended to 224 x 224 pixels by this edge mirroring, as this size provided the 
optimum balance between training speed and output accuracy. Extensive data 
augmentation was used during training. This included image mirroring and rotation at 
intervals of 90° as well as random multiplicative pixel value scaling. The random 
multiplicative pixel value scaling was applied by taking the elementwise product of the 
training image matrix with a matrix of the same shape containing uniformly distributed 
values between .85 and 1.15. 
As expected, our dataset contained only a few images with extreme numbers of 
axons per image, i.e. very low or very high axon counts. Training with this dataset would 
therefore lead to higher error in such cases, which we wished to avoid since having few 
axons per image or many axons per image can be a significant experimental outcome. If 
we denote the number of manually counted axons per image by manual counts (MC), then 
we reasoned that we could reduce counting error in extreme cases by creating a data set 
which had a more uniform distribution of MC over all the images, which we achieved by 
resampling, as follows. A 10 bin histogram of MC over all images in the training set was 
created, and we augmented the number of images in any bin that had less than the 
maximum number of images. This augmentation consisted of replicating all of the images 
within that bin until the number of images within each bin was approximately the same. 
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The model did not show signs of overfitting, as shown by the similar loss values for the 




The three automated counting tools, AxoNet, AxonMaster, and AxonJ, cannot 
precisely replicate ground truth. However, empirical observation shows that each tool 
demonstrated a relatively consistent bias, which could be corrected for. We therefore first 
used the validation subsets to perform the following linear bias correction, following the 
method established in Reynaud et al. (Reynaud et al. 2012). In brief, MC and automated 
Figure 41: AxoNet Training Loss. Average training and validation set loss for each epoch vs. epoch 
number. Training and validation set losses do not diverge, indicating that our network did not 
overfit during training. 
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counts (AC) of axons in the validation subset were plotted against one another and fit using 
a linear least squares regression for each tool, 
   𝐴𝐶 = 𝑎 𝑀𝐶 + 𝑏, (8) 
where coefficients 𝑎 and 𝑏 reflect any systematic linear bias in the estimation of MC by 
AC for the automated counting tool being considered. We then account for this linear bias 






Ideally, our automated counting methods would not demonstrate any systematic bias, i.e. 
our network would learn to correct any such biases during training. However, all automated 
counting schemes that we are aware of either show some bias, and thus use linear bias 
correction equations, or do not report results in a manner that allows one to determine 
whether the scheme shows bias, e.g. by reporting only mean absolute error between ground 
truth and object counts. We have chosen to use correction equations.  
We conducted a series of tests to determine the cause of this systematic linear bias. 
Specifically, we first intentionally overfit models to determine whether there was a bug in 
our code causing systematic bias, reasoning that if we could eliminate bias by overfitting, 
then bias would not be due to a programming error and instead would be related to other 
factors. We thus trained on downsampled training sets with and without resampling and 
augmentation and evaluated the bias when the algorithm was applied to the same 
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downsampled training sets. Second, we tested for underfitting by training our network with 
randomized initial parameters and for more epochs and comparing the results to our initial 
results. We also considered differences between the training and testing sets and dataset 
imbalance as potential sources of bias. 
Statistical Analysis of Tool Performance on the Rat Image Dataset 
To evaluate the three automated counting tools on the rat image dataset, we applied 
all three tools to the validation subsets, created correction equations as described above in 
Equation 9, and applied the relevant correction equation to the automated counting results 
from the testing subset. Differences in sub-image manual counts and the automated counts 
produced by each automated axon counting tool were quantified for both datasets through 
linear regressions, Kruskal-Wallis tests comparing the mean absolute error for each tool, 
and a comparison of the limits of agreement as defined by the Bland-Altman methodology 
(Bland and Altman 1999). 
In more detail, after linear regression between manual and automated counts, we 
examined the residual distributions from the regressions, and discovered they were not 
normally distributed (Shapiro-Wilk test, all p < 0.05). However, inspection of the data by 
histogram and Q-Q plot showed approximate normality with the exception of a small 
number of outliers and a slight heteroscedasticity for each distribution. In addition, linear 
regression is known to be robust to such slight deviations from normality, particularly in 
larger data sets like ours (Williams, Grajales, and Kurkiewicz 2013; Osborne and Waters 
2002). We therefore judged these deviations from normality to be minor, and continued to 
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use simple linear regression to compare model performance, taking a larger R2 value to 
indicate a more consistent agreement between manual and automated counts.  
We also calculated the mean absolute error between each automated counting tool’s 
axon count and the gold-standard manual axon counts to quantify the accuracy for that tool. 
None of the mean absolute error distributions for each tool’s results were normally 
distributed (Shapiro-Wilk: all p < 0.001), so we compared the tools’ mean absolute errors 
using the Kruskal-Wallis test with Dunn’s post hoc test.  
Finally, we used Bland-Altman plots (Bland and Altman 1999) to compare the 
limits of agreement calculated for each method. Ideally, the errors from the automated tools 
would lie within the range of inter-observer variability. Thus, we aimed for the limits of 
agreement of these Bland-Altman plots (mean count error ± 1.96•SD of count error) to be 
within the limits of agreement calculated for individual counters’ MC relative to the mean 
MC. Using this definition, we computed the limits of agreement for our rat dataset as ± 
14.3 axons. Additionally, for each image with four manual counters (1184 of 1514 images), 
corrected ACs were compared to a 95% confidence interval constructed from the four MCs. 
We defined a success rate as the proportion of images for which the corrected AC fell 
within this 95% confidence interval. This approach evaluated both automated counting 
accuracy and precision in the same measurement. 
Statistical Analysis of Tool Performance on the NHP Image Dataset  
We also evaluated our rat-trained AxoNet algorithm and the two existing axon 
counting tools on the NHP dataset. To do so, we applied all three tools to the validation 
subset, created correction equations as stated above, and then applied the correction 
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equations to the automated counting results from the testing subset. Relationships between 
semi-automated manual (SAM) and corrected automated counts were assessed in the same 
manner as they were in the rat image dataset. Since only mean axon counts were available, 
we were unable to compute the proportion of the automated counts that fell within the 95% 
confidence interval for the SAM counts or define a desired range for the limits of agreement 
as we did for the rat optic nerve image dataset. However, we were able to compare the 
limits of agreement between the corrected ACs and the SAM counts.  
Results 
Rat Model Dataset Results 
We first applied the three automated counting tools to the validation subset of the rat 
dataset to determine correction equations that accounted for linear bias, as described above (Figure 
42). We then applied the automated tools to the testing subset. Before compensating for 
linear bias using the correction equations, the relationship between AxoNet automated and 
manual counts (AC and MC) in the testing subset was AC = 0.826*(MC) + 5.36 (R2 = 
0.938), indicating a comparable bias to that seen when our model was applied to the 
validation subset. For all three automated tools, the corrected linear fit between 𝑀𝐶 and 
𝐴𝐶corrected resulted in regression slopes and intercepts that were mostly significantly 
different from 1 and 0, respectively (t-test for slope, all p<.05; t-test for intercept, p = 
0.0319, p = 0.059, p <.001; all p-values presented in the order: AxoNet, AxonMaster, and 
AxonJ; Figure 42). These findings indicate that the correction equation method did not 




Figure 42: Comparison between automated and manual axon counts for the rat validation and 
testing subsets. Validation subset results are shown for AxoNet (a), AxonMaster (b) and AxonJ (c). 
The regression relationships between MC and AC counts were: AxoNet: AC = 0.801*(MC) + 4.8; 
AxonMaster: AC = 0.731*(MC) – 0.633; and AxonJ AC = 0.508*(MC) + 26.2. These relationships 
were used as correction equations when counting axons in the testing subset. Testing subset results 
are shown for AxoNet (d), AxonMaster (e) and AxonJ (f). Testing subset mean absolute errors are 
4.4, 12.8, and 9.5 axons for AxoNet, AxonMaster, and AxonJ respectively. AC values are shown 
after applying the correction equations from the validation subset results. Each data point is 
obtained from a single sub-image from the corresponding subset. 
Figure 43: Comparison of error distribution for the rat testing subset. Differences between rat 
testing subset MC and corrected AC are plotted against manual counts for AxoNet (A), AxonMaster 
(B) and AxonJ (C) as Bland-Altman plots. Each data point is a single sub-image from the rat testing 
dataset. Red lines represent the upper and lower bounds for the limits of agreement, calculated as 
mean error ± 1.96*(standard deviation of error). Limits of agreement are [-8.3, 12.6], [-14.59, 
25.8], and [-27.7, 39.4] axons for AxoNet, AxonMaster, and AxonJ, respectively. 
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Of the three tools, AxoNet achieved the highest correlation between its corrected 
AC and the MC (R2 = 0.938) as well as the smallest mean absolute error (Kruskal-Wallis: 
Chi-square = 169.7 and p < 0.001; Dunn’s post-hoc: all p < 0.001, Figure 42). Only AxoNet 
demonstrated limits of agreement within the threshold determined by the manual count 
agreement (Figure 43). For the images annotated by four counters, the percentage of 
corrected ACs that fell within the 95% confidence interval of the manual counts was 83%, 
48%, and 58% for AxoNet, AxonMaster, and AxonJ respectively. Taken together, we 
observe that AxoNet performed the best (i.e. the closest to manual annotations) on the 
testing subset of the rat dataset. 
 
 
Figure 44: Visualization of AxoNet Performance. The images from the rat testing subset which 
produced the smallest (top) and greatest (bottom) difference between AxoNet predicted and ground 
truth manual axon count are shown in the left column. The corresponding manually annotated 
ground truth axon count density maps are shown in the middle column, and the automatically 
detected axon count density maps are shown in the right column. The scale bar on the right shows 
the map used to visualize axon count density as greyscale intensity. 
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We also visualized the output of AxoNet by determining whether AxoNet was 
accurately replicating the density maps used during its training by comparing its predicted 
spatial axon count densities to ground truth (Figure 44). Generally, the density maps 
produced by AxoNet matched those produced by the manual annotators.  
NHP Dataset Results 
We then applied these three automated counting tools to the NHP dataset. We first assessed 
the performance of the three tools using the validation subset of the NHP dataset in order to 
construct bias correction equations relating each tool’s AC to the SAM count. When applied to 
the validation subset of the NHP dataset, AxoNet achieved a higher correlation between 
SAM count and AC than the other two tools, although AxonMaster needed less bias 
correction (Figure 45), likely because it had been optimized for the NHP dataset.  
The automated counting methods and their correction equations were then applied 
to the testing subset of the NHP dataset to directly compare their ability to accurately 
quantify the number of axons present in each image. For all three automated tools, the 
corrected linear fit between SAM count and 𝐴𝐶corrected resulted in regression slopes and 
intercepts that were not significantly different from 1 and 0, respectively (t-test for slope, 
p = 0.77, p = 0.47, p = 0.81; t-test for intercept, p = 0.77, p = 0.82, p = 0.71; all p-values 
presented in order: AxoNet, AxonMaster, and AxonJ; Figure 45). Of the three tools, 
AxoNet achieved the highest correlation between its corrected automated and manual 




Figure 45: Comparison between automated and manual axon counts for the NHP validation and 
testing subsets. Validation subset results are shown for AxoNet (a), AxonMaster (b) and AxonJ (c). 
The regression relationships between SAM and AC counts were: AxoNet: AC = 1.11*(SAM) + 
69.0; AxonMaster: AC = 0.9849*(SAM) + 17.4; and AxonJ AC = 1.01*(SAM) + 139.2. These 
relationships were used as correction equations when counting axons in the testing subset. Testing 
subset results are shown for AxoNet (d), AxonMaster (e) and AxonJ (f). Testing subset mean 
absolute errors are 17.7, 18.2, and 35.0 axons for AxoNet, AxonMaster, and AxonJ respectively. 
AC values are shown after applying the correction equations from the validation subset results. 
Each data point is obtained from a single sub-image from the corresponding subset. 
Figure 46: Comparison of error distribution for the NHP testing subset. Differences between NHP 
testing subset semi-automated manual count and corrected AC are plotted against semi-automated 
manual count for AxoNet (A), AxonMaster (B) and AxonJ (C) as Bland-Altman plots. Each data 
point is a single sub-image from the rat testing subset. Red lines represent the upper and lower 
bounds for the limits of agreement, calculated as mean error ± 1.96*(standard deviation of error). 
Limits of agreement are [-43.9, 42.8], [-48.9, 47.5], and [-91.0, 93.4] axons for AxoNet, 
AxonMaster, and AxonJ respectively. 
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AxoNet and AxonMaster both had lower mean absolute error when compared to AxonJ 
(Kruskal-Wallis: Chi-square = 62.57 and p < 0.001; Dunn’s post-hoc: both p < 0.001, 
Figure 45), while AxoNet and AxonMaster had similar mean absolute error values to one 
another (p > 0.9). AxoNet and AxonMaster produced comparable limits of agreement, 
whereas AxonJ’s limits of agreement were larger (Figure 46). 
We packaged AxoNet into a user-friendly plugin for Fiji and ImageJ. This plugin 
is capable of counting full rat optic nerve images in about 15 minutes (Figure 47). We 
typically count c. 80,000 “normal”-appearing axons in a healthy nerve, consistent with 
previous reports (Levkovitch-Verbin et al. 2002; Marina, Bull, and Martin 2010a; Cepurna 
et al. 2005). 
  
Figure 47: AxoNet Plugin Results. After using the AxoNet plugin for ImageJ and Fiji on an image 
of a full rat optic nerve (a), the output axon density map (b) and the combination of these two 
images (c) are displayed. The combination of these two images is shown with the input image (a) 
in greyscale and the axon density map (b) overlaid in pink. Axon density scale is not provided here 
because these full images are scaled down significantly for inclusion in the manuscript and color 
scale is indistinguishable at this resolution. A grid of dark lines is visible in panel a; these lines 
correspond to tile edges from the microscopy imaging and are an artifact of visualization only 
since counts are carried out on much smaller portions of the full image. 
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Bias  
To investigate the source of the small bias seen in AxoNet, i.e. the fact that there 
was a difference between the unity line and the best fit regression lines in Figure 42 and 
Figure 45, we conducted several experiments. In constructing these experiments, we 
considered the following possible sources of error: (1) a bug in the algorithm; (2) poor 
convergence of our parameter values during the training phase, i.e. underfitting; (3) 
inherent differences between the training and testing data sets; and (4) tendency of the 
algorithm to be biased towards the majority group, which in our case was images with axon 
counts close to the dataset mean axon count (Johnson and Khoshgoftaar 2019). We 
consider each of these in turn.  
1. Bug in the algorithm: We conducted experiments in which we intentionally overfit the 
network, as follows. We first trained AxoNet on subsets of the full training set of 
different sizes, and then evaluated the algorithm on those same images. Within this 
framework, training was conducted using three variations of the training image sets: 
images that were neither augmented nor resampled, images that were augmented but 
not resampled, and images that were resampled but not augmented. As data set size 
decreased, bias decreased; indeed, training on a single repeated image and testing on 
the same image produced essentially zero error (less than one axon; Figure 48). 
Because we were able to essentially eliminate bias by overfitting, we concluded that a 
bug in the code used to train or assess our network was unlikely. 
2. Underfitting. Our numerical experiments suggested that the parameter optimization 
process had converged. Specifically, we found that increasing the number of epochs 
during training did not improve convergence, as measured by the loss function’s final 
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value. Further, using different initial parameter values yielded essentially the same loss 
function values at the end of training. Thus, we do not believe that bias was due to 
underfitting. 
3. Inherent differences between data sets: Error can arise if the training, validation and 
testing data sets have systematic differences. Such an error source is inherent in 
supervised machine learning approaches (Neyshabur et al. 2017). In our case, we saw 
that the bias differed between validation and testing data sets (compare Figure 42 and 
Figure 45), suggesting subtle systematic differences between image sets. Consistent 
with this suggestion, the bias was reduced if we trained and tested on the same data set, 
while image augmentation increased bias if testing was conducted on the training data 
set (Figure 48; compare red with black symbols). It is interesting to note that training 
set resampling slightly increased the mean absolute error (compare red with green 
symbols in Figure 48). We suggest that this occurs because resampling increases the 
proportion of “hard to count” images, i.e. those with extensive damage or many small 
axons. However, resampling also reduces error when evaluating different testing and 
training data sets, and thus is still recommended.  
4. Bias towards the mean: We note that the algorithm consistently overcounted images 
with small numbers of axons, and undercounted images with large numbers of axons, 
suggesting bias towards the mean. Research on evaluating the effects of class 
imbalances on neural network training for classification and regression shows a similar 
effect (Johnson and Khoshgoftaar 2019; Krawczyk 2016; Anand et al. 1993) here in 
our case, images with counts closer to the dataset mean are analogous to the “majority 
class”. To reduce the magnitude of this effect, we resampled our training set images to 
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produce a uniform distribution of axon counts (see Methods). Even when doing so, a 
small systematic bias remained, which perhaps reflects a tendency of bias towards the 
mean even when training occurs on a uniformly sampled image set. Nonetheless, this 
bias was small and considered acceptable in this application.  
 
Figure 48: Training Set Subsampling. The full training data set was sub-sampled to produce 
training data sets of different sizes (N). AxoNet was then trained with these sub-sampled sets, and 
subsequently used to count axons in the same data set, i.e. for purposes of generating this figure, 
the testing and training data set were the same for each realization. We computed a mean absolute 
error (MAE) over the data set and repeated this process 3 times for each training set size (i.e. 3 
replicates) to obtain a mean and standard deviation of the MAE. This full analysis was completed 
for three training set conditions: training augmentation without resampling (blue symbols), 
resampling without training augmentation (green symbols), and no training augmentation or 
resampling (red symbols). The respective fitted relationships for these three conditions were MAE 
= 0.1 + 1.8*log(N), MAE = -0.4 + 1.5*log(N), and MAE = -0.2 + 1.2*log(N). Note that the 
horizontal axis is logarithmic and that plotted values at the same training set size are offset slightly 




The purpose of this study was to develop and evaluate a new approach to 
automatically count “normal”-appearing RGC axons in a diverse dataset of healthy and 
damaged optic nerve cross sections. Such an automated axon counting tool is a useful tool 
in studying glaucoma and potentially other neurodegenerative disorders. We designed this 
new approach to work well over a range of image qualities and for multiple mammalian 
species. AxoNet’s predicted axon counts proved to be highly correlated to manual axon 
counts in both the rat and NHP datasets, indicating that it met our requirements for an 
automated axon counting tool. As judged by the uniform error over the range of manual 
axon counts (Figure 43 and Figure 46), AxoNet performed equally well on images of 
damaged vs. healthy optic nerves. This is significant because axon counting is more 
difficult in diseased tissue, and suggests promise for the use of AxoNet as a tool for nerve 
damage analysis in experimental glaucoma. 
Prior to building AxoNet, we explored the methodologies previously used to create 
existing automated axon counting tools. AxonMaster uses a fuzzy c-means classifier as an 
adaptive thresholding method to segment axon interiors from the darker myelin sheath. 
These clusters are then filtered by size and circularity before counting axons. AxonJ uses 
a Hessian operator to identify the darker myelin sheath and then performs similar adaptive 
thresholding and connected region size filtering region before counting the connected 
regions as axons. When applied to the rat dataset, these two tools produced adequate 
segmentation of total axon area in optic nerve images, but often did not produce accurate 
segmentation of individual axons, leading to inaccurate counts. We also attempted to apply 
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two other segmentation techniques, ilastik (Sommer et al. 2011) and the basic pixel 
segmentation U-Net (Ronneberger, Fischer, and Brox 2015). These approaches also 
resulted in inaccurate counts, especially when applied to damaged tissue; therefore, we 
adapted an alternate cell counting framework introduced by Lempitsky et al. (Lempitsky 
and Zisserman 2010). This approach avoids the difficult task of semantic segmentation and 
instead predicts a pixelwise cell count density estimate. The authors accomplished this 
through using machine learning with hand-crafted pixelwise features (Lempitsky and 
Zisserman 2010). More recently, attempts have been made to perform similar count density 
function estimations using convolutional neural networks (Wang et al. 2018) and adapted 
U-Net architectures (Valloli and Mehta 2019) for crowd counting, which is a technically 
similar problem to cell counting. Convolutional neural networks have also been used 
recently for axon segmentation in scanning and transmission electron microscopy images 
of mammal and human spinal cord (Zaimi et al. 2018). The tool produced in this work is 
the result of this synthesis between a convolutional neural network architecture designed 
for cell segmentation, the U-Net, and a count density prediction strategy. This method 
avoids the hard problem of axon segmentation in lower-resolution light microscopy, 
trading the ability to analyze single-axon morphology for the most accurate axon count. 
This study was limited by several factors. First, and most important, to date AxoNet 
has been trained to count only “normal”-appearing axons, similar to existing axon-counting 
software. The classification of an axon as “abnormal” in appearance does not necessarily 
imply that the axon is non-functional, and thus our tool may not count axons that are in fact 
conducting visual information. However, due to AxoNet’s generalizability and lack of 
reliance on hand-crafted features specific to “normal”-appearing axons, it can be extended 
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to count or even segment other features of both healthy and glaucomatous optic nerves, 
such as glial processes, nuclei, “abnormal” axons, large vacuoles, and extracellular matrix. 
We are currently extending AxoNet to quantify these features. Such analysis of features 
beyond “normal”-appearing axons may provide new insight into the pathophysiological 
processes of glaucomatous nerve degeneration. 
Second, we were unable to fully eliminate systematic biases in the network’s 
predictions. We investigated the source of this systematic prediction bias and found that it 
did not originate from errors within the training or prediction code or from underfitting. 
We posit that some bias may be unavoidable due to subtle differences in the training and 
testing sets, which can be mitigated by increasing the variability within the training data 
set. Based on the literature, we also posit that training set imbalance may cause training 
bias towards common training cases. This source of bias can be mitigated by resampling 
rarer cases to increase their influence during network training. By doing so, we were able 
to reduce bias to only a few axons per image.  Considering the complexity of our images 
and the variability from animal to animal in glaucoma models, we judged this level of bias 
to be acceptable.  
Third, the linear bias correction equations determined in this study were suitable 
for countering systematic bias in our data set, but may not necessarily be accurate for other 
data sets, since the conditions which create these systematic biases may vary with 
experimental treatment, imaging protocols, or tissue processing protocols. However, we do 
not expect such effects to be severe, since we intentionally included these sources of 
variability within the two image datasets used in this study and AxoNet still performed 
well. Nonetheless, it would be prudent to calibrate AxoNet for each new application, which 
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can be done through using correction equations like those created with our validation 
subsets or network retraining with a new dataset according to the training protocol detailed 
above.  
A fourth limitation is that all manual counts were conducted by members of one 
lab, and it is possible that manual counts generated in different research groups could be 
slightly different from ours since manual counting itself is not entirely unambiguous. This 
uncertainty is inherent in axon quantification and cannot be avoided, although to enhance 
repeatability we have explicitly described our definition of “normal”-appearing axons and 
have made the training data publicly available. 
Presently, AxoNet regresses a pixelwise count density function which is integrated 
over the full image to return a count. Fitting the density function is accomplished through 
the minimization of a mean squared error loss function evaluated at each pixel (Equation 
6). This loss function may be overly sensitive to zero-mean noise and other variations in 
training images. Lempitsky et al. (Lempitsky and Zisserman 2010) originally solved this 
problem through the Mesa loss function, which used a maximum subarray algorithm to 
find the image region with the largest difference between automated and manual counts 
and minimized count error over this region instead of at every pixel. When we attempted 
to use this loss function during our training, the resulting method was far too 
computationally expensive and resulted in a prohibitively long training time (on the order 
of hours per training step). However, developing a new loss function which avoids 
computing the mean square error at every pixel per iteration but does so without the 
computational expense may improve AxoNet’s performance in terms of accurate axon 
count insensitive to image noise. 
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The successful use of the rat-trained AxoNet to count NHP images is indicative of 
the versatility of our method, even without re-training. However, the network can be easily 
re-trained on a new counting case if needed. If there is adequate training data in the new 
set, the deep learning framework can adapt itself to new applications without requiring any 
changes in handcrafted features. Data augmentations like those described in the methods 
can be applied to improve network learning from limited datasets, as was done in the first 
published application of the U-net architecture (Ronneberger, Fischer, and Brox 2015).  
We can also use AxoNet to count axons in full rat optic nerve images by 
subdividing the full image into tiles for individual processing. This tile-based processing 
was necessary because of the prohibitive computational expense involved in applying the 
U-net architecture to large images. However, tile-based processing has the potential to 
create edge artifacts by cutting off portions of cells on the borders of each tile. We correct 
for this potential error by padding the edges of each processing tile with bordering pixels 
from adjacent processing tiles. Including this information from bordering tiles meant that 
the resulting density map prediction was not affected by these potential tile cropping 
artifacts. Once processed, the resulting density map was cropped back to its original tile 
size. This padding was not done when it would have required pixels from beyond the image 
boundaries. These padded tiles were then also mirrored, as described for model training 
above.  
When running on the system used for this study (Windows Desktop, Intel i7-3770 
CPU at 3.40 GHz, 16 GB RAM; Dell, Round Rock, TX), AxoNet counts the axons within 
a full rat optic nerve image in approximately 15 minutes. For comparison, it took AxonJ 
and AxonMaster approximately 30 minutes and 1 hour, respectively, to count the axons 
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within a full rat optic nerve image. Therefore, our tool can be applied to analyze full optic 
nerve images with runtimes comparable to, or better than, those of the existing automated 
tools. 
Conclusion 
We have successfully applied a deep learning method to accurately count “normal” 
axons in both rat and non-human primates, and in both healthy and experimentally 
glaucomatous optic nerve sections. Additionally, we have compared AxoNet to two 
previously published automated counting tools and shown that AxoNet performs as well 
as or better than these two tools in counting healthy axons in these two datasets. Our tool 
is available online as an ImageJ plugin and can be installed by following the instructions 
at https://github.com/ethier-lab/AxoNet-fiji. The code and data we used to train the model 
can be found at https://github.com/ethier-lab/AxoNet. 
Data Availability 
The rat optic nerve image dataset generated and analyzed during the current study 
are available in the Github repository, https://github.com/ethier-lab/AxoNet. A spreadsheet 
containing the count data for each image in both the NHP and rat datasets is available on 
the same repository. The NHP optic nerve image dataset and AxonMaster software are the 




Relative Stiffness in Terms of Strain Derivation 
The outputs from our DIC inflation tests were strain values on the scleral surface for 
different IOP levels, as set by a hydrostatic pressure reservoir. Our goal was to use these 
strain measurements to estimate the stiffness of the experimental region of an eye relative 
to the control region. Relative stiffness was defined as the stiffness of the experimental 
material (here sclera) relative to the control material: 
 




where Eexp is the effective modulus of the experimental material and  Econ is the effective 
modulus of the control material. Since the sclera is not a linearly elastic material and 
therefore has an elastic modulus that varies as a function of applied stress (or in our case, 
IOP) we defined the effective modulus as the tangent modulus at a certain point (or IOP) 
on the stress-strain curve. 
By modeling the eye as a thin-walled sphere and assuming a spatially uniform radius and 






where σ is the hoop stress in the wall of the sphere, P is the internal pressure, R is the 
radius, and t is the wall thickness of the sphere (see Figure 49). 
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Since the internal pressure, 𝑃, is spatially uniform within the eye, the hoop stresses in the 
experimental and control regions of the eye, σexp and σcon , are the same: 
 𝜎 = 𝜎𝑐𝑜𝑛 =  𝜎𝑒𝑥𝑝 (12) 
We approximate the tissue behavior as incrementally linear elastic within the loading 
regime of interest to write: 
 𝜎𝑐𝑜𝑛
𝜀𝑐𝑜𝑛
= 𝐸𝑐𝑜𝑛 , 
𝜎𝑒𝑥𝑝
𝜀𝑒𝑥𝑝
= 𝐸𝑒𝑥𝑝 (13) 
where 𝜀𝑐𝑜𝑛 and 𝜀𝑒𝑥𝑝 are the control and experimental first principal (hoop) strains, 
respectively. 

























Algebraic simplification yields an expression for the relative stiffness in terms of strains at 
a given pressure step: 
 









































Myosin_ heavy polypeptide 9_ non-
muscle 
Actin binding and motor activity 32 283.4 0.248 0.401 
RCG55135_ isoform CRA_b Cell adhesion 24 210.8 0.374 0.454 
Complement C3 Immune Response 22 195.6 0.432 0.489 
Vimentin Cytoskeleton structural support 31 335.2 0.331 0.441 
Collagen type VI alpha 2 chain Extracellular matrix structural support 23 236.8 0.189 0.398 
Heat shock cognate 71 kDa protein Protein binding 24 265.0 0.091 0.372 
Spectrin alpha chain_ non-erythrocytic 1 Calcium binding 22 148.5 0.199 0.398 
Collagen type VI alpha 1 chain Extracellular matrix structural support 34 361.8 0.299 0.430 
Actin_ cytoplasmic 1 Cell adhesion 23 303.0 0.760 0.638 
Lamin A_ isoform CRA_b Cytoskeleton structural support 40 371.7 0.510 0.534 
AHNAK 1 (Fragment) Protein binding 25 195.5 0.094 0.372 
Filamin A Protein binding 37 283.8 0.853 0.677 
Collagen type XIV alpha 1 chain Extracellular matrix structural support 44 401.0 0.030 0.372 
Collagen alpha-1(XII) chain Extracellular matrix structural support 134 1368.9 0.244 0.401 
Collagen alpha-2(I) chain Extracellular matrix structural support 43 370.0 0.413 0.477 
Spectrin beta chain Actin binding and motor activity 29 214.4 0.133 0.372 
Myosin heavy chain 1 Actin binding and motor activity 95 1011.0 0.675 0.604 
 
Table 7: RT-PCR genes analyzed and corresponding primers. 
Gene name Symbol Gene ID Forward 5'-3' Reverse 5'-3' Length 
matrix metallopeptidase 
1 
Mmp1 ID: 300339 CACTCCCTTGGACTCACTCA GTTGGCTGGATGGGATTTGG 149 bp 
matrix metallopeptidase 
2 
Mmp2 ID: 81686 ACAGTGGATGATGCCTTTGC TCCATCTCCATGCTCCCATC 129 bp 
matrix metallopeptidase 
3 
Mmp3 ID: 171045 ACCTATTCCTGGTTGCTGCT TGGGAGGTCCATAGAGGGAT 168 bp 
TIMP metallopeptidase 
inhibitor 1  
Timp1 ID: 116510 GTGCACAGTGTTTCCCTGTT GGTATTGCCAGGTGCACAAA 158 bp 
TIMP metallopeptidase 
inhibitor 2  
Timp2 ID: 29543 ATCCAAGTGGGTTCACGCTA GCTCTACTCCTGCTGTACCA 172 bp 
TIMP metallopeptidase 
inhibitor 3  
Timp3 ID: 25358 CCCTTTGGCACTCTGGTCTA CAGCCCTGTGTACATCTTGC 186 bp 
tumor necrosis factor Tnf ID: 24835 GGTCCCAACAAGGAGGAGAA GCTTGGTGGTTTGCTACGAC 134 bp 
interleukin 1 beta Il1b ID: 24494 CACTCATTGTGGCTGTGGAG AGGACGGGCTCTTCTTCAAA 115 bp 
Cd68 molecule Cd68 ID: 287435 ACGGACAGCTTACCTTTGGA AATGTCCACTGTGCTGCTTG 118 bp 
glyceraldehyde-3-
phosphate  
Gapdh ID: 24383 AAGATGGTGAAGGTCGGTGT GCTTCCCATTCTCAGCCTTG 196 bp 
actin, beta Actb ID: 81822 TCCTCCCTGGAGAAGAGCTA ACGGATGTCAACGTCACACT 171 bp 
Table 8: Proteomic expression levels in the sclera, computed as the fold change of scleral protein 





Figure 50: Genipin treatment did not significantly affect message abundance for genes involved in 
extracellular matrix turnover in the sclera, nor for pro-inflammatory genes in the retina. Plotted is 
the fold change of message for MMPs (A and C) and TIMPs (B and D) at one week (A and B) and 
four weeks (C and D) post-injection in the sclera for HBSS/Naïve and Genipin/HBSS rats. In 
HBSS/Naïve rats, the HBSS-injected eye was normalized to the contralateral Naïve eye, and in 
Genipin/HBSS rats, the genipin-treated eye was normalized to the contralateral HBSS-injected eye. 
Values are missing for Mmp3 in (C) and Timp1 in (D) due to lack of data after outlier removal. E 
and F show fold change of message levels for inflammatory cytokines (Cd68, Tnf, and Il1b) at one 
week (E) and four weeks (F) post-injection in the retina for HBSS/Naïve and Genipin/HBSS rats. 
No significant differences were found between contralateral eyes in any tissue at any timepoint. 




Figure 51: Whole nerve axon counts in hypertensive eyes are plotted vs IOP burden included (solid) 
and excluded (hollow) based on IOP Criterion (A) and ERG Criterion (B). Axon counts of all 
hypertensive eyes (black dashed in A and B) and hypertensive eyes included based on both IOP 
Criterion (A) and ERG Criterion (B) were significantly correlated with IOP burden (all p < 
0.0001). C) Axon counts of hypertensive eyes from all rats (black), included based on IOP Criterion 
(blue), and included based on ERG Criterion (red) were not different from one another (One-way 












Normotensive Eye Sample Size Hypertensive Eye Sample Size 
HBSS GP MB Total HBSS GP MB Total 
Peripapillary Strain 218 15 11 15 41 16 10 13 39 
Peripheral Strain 220 15 11 15 41 16 11 14 41 
Equatorial Diameter 224 17 12 13 42 17 11 14 42 
Axial Length 224 17 12 13 42 17 11 14 42 
Anterior Chamber Depth 223 17 12 12 41 17 11 13 41 
Nerve Cross-sectional Area 225 19 16 16 51 20 18 19 57 
Axon Count 229 19 16 14 49 20 17 19 56 
Axon Density 226 18 16 15 49 19 17 19 55 
Retinal Thickness at 0.5 mm 222 19 18 16 53 20 18 18 56 
Retinal Thickness at 1.2 mm 218 20 18 17 55 19 18 18 55 
Contrast Sensitivity 226 21 20 19 60 20 18 18 56 
Spatial Frequency 226 21 20 19 60 20 18 18 56 
pSTR Amplitude 224 21 20 18 59 21 20 19 60 
nSTR Amplitude 225 21 20 19 60 21 20 19 60 
b-wave Amplitude 227 21 20 19 60 20 20 19 59 
OP3 Amplitude 225 21 19 19 59 21 20 19 60 
Figure 52: Chemical crosslinker genipin (left inset) or photocrosslinker methylene blue (right 
inset) were injected by retrobulbar injection to induce scleral crosslinking. Genipin induced non-
targeted crosslinking. Methylene blue was activated with a transpupillary light beam to selectively 
crosslink peripapillary sclera. 
Table 9: Tabulated average IOP burden of rats included in each outcome parameter group with 






Figure 53: Correlations of baseline control and experimental eye values prior to treatments. 
“Control” indicates eyes designated to be normotensive. “Experimental” indicates eyes 
designated to be normotensive (microbead injection). A) pSTR amplitude, B) nSTR amplitude, C) 
b-wave amplitude, D) oscillatory potential 3 amplitude, E) retinal thickness at 0.5 mm from the 
ON, F) retinal thickness at 1.2 mm from the ON, G) spatial frequency, and H) contrast sensitivity, 
showed no significant correlation at baseline between eyes of the same rat. 
Figure 54: A) Image of BN rat fundus viewed through refraction-negating corneal contact lens 
showing optic nerve head and retinal vasculature. The lens created a clear optical path facilitating 
B) projection of an annular beam (measuring 2 mm outer diameter, 1 mm inner diameter) of 660 
nm incoherent light from a custom-designed microscope to the peripapillary sclera following 
retrobulbar injection of MB. The inset shows an image of the beam projected onto a BN rat fundus 







Figure 55: A) Peripapillary and B) peripheral strain as a function of IOP burden. Dashed line 
represents mean values from normotensive controls and their corresponding standard deviations 
(grey band).  
Table 10: Table of experimental variables investigated in this study compared with those of the 
Kimball et al. 2014 study which investigated effects of scleral crosslinking on visual/morphological 






Table 11: Two-way ANCOVA outcomes for measured parameters including main effects of crosslinking treatment (HBSS, GP, MB) and microbead 




Figure 56: OCT retinal thickness measurements as a function of IOP burden at A) 0.5 mm from the 
ONH and B) 1.2 mm from the ONH. Dashed line represents mean values from normotensive 
controls and their corresponding standard deviations (grey band). 
Figure 57: Representative experimental eye optic nerve/retina OCT images from each treatment 
in specified range of IOP burden. Damage qualitatively increases with increasing IOP burden. “*” 
indicates choroid, “†” indicates optic nerve head. Vertical yellow lines on each image indicate 
(from left to right), -1.2 mm, -0.5 mm, 0 mm, 0.5 mm, 1.2 mm distances from center of optic nerve 
head at which retinal thickness measurements were taken. Scale bar = 0.5 mm. Specifically, 






Figure 58: A) Axon count, B) axon density, and C) optic nerve cross-sectional area as functions of 
IOP burden. Dashed line represents mean values from normotensive controls and their 
corresponding standard deviations (grey band). 
Figure 59: No qualitative differences were found in optic nerve cross-sections of hypertensive eyes 
between crosslinking treatment groups. Representative images from each treatment in specified 
range of IOP burden are shown. Images were taken from the central region of each nerve. Scale 






Figure 60: Eye size parameters vs IOP burden including A) anterior chamber depth, B) equatorial 
width, and C) axial length. Dashed line represents mean values from normotensive controls and 
their corresponding standard deviations (grey band). 
Figure 61: ERG outcomes vs IOP burden for A) pSTR amplitude, B) nSTR amplitude, C) b-wave 
amplitude, and D) oscillatory potential 3 amplitude. Dashed line represents mean values from 






Figure 62: Resolved A) spatial frequency and B) contrast sensitivity of normotensive control eyes 
at Days -7, 0, 7, and 14 with respect to induction of hypertension at Day 0. Significant differences 
were found at Day 7 and Day 14 compared to Day -7 (baseline) for spatial frequency and for 
contrast sensitivity in all crosslinking treatment groups. These findings suggest the presence of a 
hyperacuity effect in the normotensive eye after induction of hypertension in the contralateral eye 
C) Spatial frequency differed between Day -7 (baseline) and Day 0 (after stiffening treatment) for 
GP (p < 0.01) and MB (p < 0.0001). D) Contrast Sensitivity differed between Day -7 (baseline) 
and Day 0 (after stiffening treatment) for GP (p < 0.05) and MB (p < 0.05). 
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